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Abstract 
 
Diagnostic criteria for schizophrenia are based on signs and symptoms and do not 
take into account biological abnormalities. Therefore, current diagnoses are subjective 
and unspecific, promoting enormous differences in clinical presentations among 
patients with the same diagnosis. On the other hand, lots of biological processes have 
been studied in relation to schizophrenia. Some of the findings support 
neurotransmitters alterations, neuroanatomical changes, connectivity disruptions, 
immune dysregulation, genetic or environmental risk factors. Nevertheless, research 
findings are inconclusive, very heterogeneous and difficult to replicate. Thus, 
schizophrenia aetiology is not well understood in spite of the huge efforts made by 
researches.  
Different evidence suggests that schizophrenia is not a homogeneous disease but a 
syndrome comprising patients with different biological disruptions. In order to cope 
with this heterogeneity, the low replication rate of research findings and the lack of 
biological validity of current diagnosis is necessary to incorporate new research 
approaches that can eventually translate in a change in psychiatric diagnosis. 
In the present thesis, we aimed to explore the existence of biological subgroups 
within schizophrenia patients by using data from structural and functional brain 
connectivity as well as a genetic information. It includes five articles with sample sizes 
from 27 to 121 schizophrenia patients and 27 to 144 healthy controls. All patients were 
diagnosed according to DSM-IV or V criteria and their symptoms were scored using the 
Positive and Negative Syndrome Scale (PANSS).  
Structural connectivity was assessed in two different ways. Firstly, using structural 
magnetic resonance imaging (MRI) we extracted measures of cortical curvature. 
Secondly, diffusion magnetic resonance imaging (dMRI)  was used to obtain values of 
streamline count and fractional anisotropy in white matter tracts connecting a priori 
selected regions. Functional connectivity was calculated using electroencephalography 
(EEG) recordings during the performance of an auditive odd-ball task, in which 
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participants were instructed to respond to infrequent targets while ignoring other 
stimuli. Then, small-worldness (SWn) index, which quantifies the efficiency of the global 
electrical network, was calculated at two temporal windows: before and after the target 
stimulus onset (baseline/pre-stimulus and response window, respectively). We focused 
our study on the SWn difference between pre-stimulus and response windows as a 
measure of modulation efficiency.  
Regarding genetics, single nucleotide polymorphisms (SNP), related to the risk of 
schizophrenia and involved in important functions of connectivity such as myelination, 
excitatory/inhibitory balance or signal transduction, were genotyped. In particular, we 
studied three SNPs in neuregulin 1 gene (NRG1; rs6468119, rs6994992 and rs7005606), 
one in calcium voltage-gated channel subunit alpha1C gene (CACNA1C; rs1006737) and 
another in potassium voltage-gated channel subfamily H member 2 gene (KCNH2, 
rs3800779). Individuals were classified as risk-allele carriers or non-carriers for each 
SNP.  
In an initial study, we used a data-driven method to explore the potential of 
neuroanatomical MRI data for patients classification. Larger cortical curvature identified 
a subgroup of 20% schizophrenia patients. This subgroup also showed decreased 
metabolic rates in the thalamus and cingulate, a lack of the expected increase in 
metabolic rates in the putamen with antipsychotics and no improvement of negative 
symptoms.  
In a subsequent study, we demonstrated that prefrontal cortical curvature was 
related to prefrontal white matter connections with anterior cingulate and superior 
frontal cortex. Finally, in the following study, we found structural connectivity 
disruptions between the prefrontal cortex and the anterior cingulate, thalamus, caudate 
and hippocampus in schizophrenia patients. 
On the other hand, in a first study relating functional connectivity and genetics, NRG1 
polymorphisms were associated with impaired SWn modulation in healthy controls. 
Subsequently, in a second study, CACNA1C polymorphism was not associated with SWn 
modulation either in patients or in controls and KHCN2 risk allele (A) was related to 
abnormal SWn modulation in patients. Noteworthy, patients carrying the KCNH2 
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rs3800779 risk allele was characterised by an opposite SWn modulation in comparison 
to patients not carrying the risk allele and healthy controls.  
In summary, this thesis analyses the existence of biological distinguishable subgroups 
among schizophrenia patients. Our result supports the utility of data-driven 
neuroimaging and genetic-based approaches looking for biological valid subgroups in 
the study of mental diseases. Our findings do not seem to be an artefact of the classifying 
method selected and they appear to be closer to clinically relevant groups. We suggest 
that similar methods will be useful in the future to reframe psychiatric diagnoses and to 
lead to new and more productive research strategies. 
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Introduction  
 
Schizophrenia is characterised by positive and negative symptoms as well as cognitive 
disturbances and presents an estimated lifetime prevalence of 0.3-0.7% and an 
incidence of 10.2-22.0 per 100,000 person-year 1,2. Schizophrenia is one of the leading 
factors of global disease burden 3 and it is largely associated with expenditure and 
economic losses. In Spain, the total cost of schizophrenia was estimated in 1,970 million 
euros in 2002, 53% of which were direct costs, implying a 2.7% of the annual public 
health budget 4. 
Different theories aimed to explain the biological mechanisms underlying 
schizophrenia, however, they have managed to do so with a limited degree of success 5. 
It seems likely that different processes such as genetic risk, neurodevelopmental 
alterations and environment hazards might, independently or not, contribute to the 
syndrome known as schizophrenia. Despite many decades of research in schizophrenia, 
huge efforts and investments, a perplexing lack of replication still exist across biological 
research results in this syndrome. This very low replication rate hampers our 
understanding of schizophrenia and, correspondingly, the development of better 
treatments. Therefore, some reframing may be needed in the research approach for this 
syndrome 6.  
The present thesis aims to study the possible heterogeneous biological underpinnings 
of schizophrenia by using structural and functional brain connectivity data in 
combination with genetic data. Overall, here we propose two different classification 
approaches to test the hypothesis that patients sharing a schizophrenia diagnosis would 
have different biological alterations. First, assessing the existence of subgroups of 
patients using anatomical data and data-driven classification analysis; and second, 
studying subgroups by using functional connectivity and genetical architecture data. 
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This kind of approaches eventually allows classification of patients with schizophrenia 
into different biologically defined subgroups.  
Taken as a whole, our results support the possibility of improving our understanding 
of the schizophrenia underpinnings through measurable biological impairments close to 
the mental functions altered in this syndrome (thoughts, emotions and behaviour). This 
thesis is supported by five articles, four of them already published in journals indexed in 
the Journal Citation Reports (JCR) and one recently submitted.  
In the following sections, in order to justify the purpose of this thesis, we briefly 
summarize the main characteristics of schizophrenia, some of the biological 
mechanisms involved and the large heterogeneity observed among patients. 
1.1. Schizophrenia signs and symptoms  
The onset of schizophrenia usually happens in late adolescence or early adulthood 
(20-26 years old in males and 26-30 in females), preceded by a prodromal period with 
cognitive and behavioural alterations 1. Life expectancy is 10-20 years lower in 
schizophrenia patients in comparison with the general population 7, usually due to 
unhealthy lifestyles, treatment side effects, suicide, pulmonary and cardiovascular 
diseases 8. 
Schizophrenia signs and symptoms are usually grouped into three core types 1,9,10: 
-Positive symptoms: mental and behavioural phenomena that should not be present 
in normal conditions, such as delusions, hallucinations and thought disturbances. 
-Negative symptoms: lack of mental and behavioural phenomena that are expected 
to be present in normal conditions, such as a minimal amount of verbal interaction, 
impaired emotional reactivity, low social involvement or a lack of interest and 
enjoyment of activities.   
-Cognitive symptoms: alterations in cognitive functions such as impaired memory, 
executive functioning, problem-solving or attention.  
Although the alterations described above are common in schizophrenia, a large 
comorbidity of symptoms exists across psychiatric diagnostics 1,11. For example, core 
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symptoms of schizophrenia, such as hallucinations and delusions, can also be present in 
other psychiatric pathologies such as bipolar disorder, major depression or substance-
induced psychosis. On the other hand, characteristic symptoms of other mental 
disorders, such as apathy or sleep disturbances associated with major depression, are 
frequently found in schizophrenia patients. Additionally, it is worth noting that affective 
symptoms, which are characteristic of affective psychosis, are not included in current 
schizophrenia diagnostic criteria, even though they are present in a significant 
percentage of schizophrenia patients.  
In conclusion, the large variability in symptoms within schizophrenia and, on the 
other hand, the similarities between this and other mental diseases make the 
characterisation of these clinical entities rather unspecific 6.  
1.2. Schizophrenia diagnosis and treatment  
Two systems are worldwide used to diagnose schizophrenia: the Diagnostic and 
Statistical Manual of Mental Disorders (DSM) and the International Classification of 
Diseases (ICD). The former is published by the American Psychiatric Association (APA), 
currently under its 5th edition (DSM-V) 9, and the latter by the World Health 
Organization, now under its 10th edition (the 11th is underway) 10.  
This diagnosis is based on signs and symptoms according to self-reported 
experiences, clinical interviews and observations by the clinician. Nowadays, no reliable 
biological measurement is included in the schizophrenia diagnostic process due to the 
fact that results in the field have been repeatedly inconsistent so far, not reaching 
enough degree of sensitivity and specificity for that purpose.  
According to DSM-V criteria, schizophrenia diagnosis could be reached if the patient 
has suffered at least two of the following symptoms for a month or longer: delusions, 
hallucinations, disorganized speech, catatonic or grossly disorganized behaviour, or 
negative symptoms like diminished emotional expression. One of them, at least, must 
be one of the first three. Moreover, the person should show a total period of 
disturbances of six months or longer, including possible residual and prodromal 
symptoms. Consequently, patient’s work, social, or/and self-care functioning should be 
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impaired for a diagnosis of schizophrenia. Finally, other types of psychosis such as mood 
disorders, psychosis induced by drugs or medical disorders should be ruled out.  
Due to these broad criteria, patients sharing the schizophrenia diagnosis could largely 
differ in their clinical presentations. For example, one schizophrenia patient could show 
bizarre delusions causing distress and impairment for a period longer than 6 months, 
while another one could show negative symptoms and persistent disorganized speech 
and behaviour 12 
Furthermore, as it has been pointed out, core symptoms are shared to a large extent 
with other mental syndromes. Therefore, boundaries between diagnoses become 
blurred, hampering the diagnostic procedure.  
Current treatments are mainly based on antipsychotic drugs, principally antagonists 
of dopamine D2 receptors although other approaches such as psychological therapies 
are also clinically useful 1. Unfortunately, the response to antipsychotics varies 
enormously among patients. One-third of patients are estimated to be treatment-
resistant 13, associated with worst functioning and prognosis. Indeed, specific biological 
differences have been reported in non-responder patients, for example, more 
remarkable neuroanatomical alterations 14–16. Furthermore, higher glutamate 
abnormalities but normal dopamine levels have been found in these patients 17,18, which 
may explain why D2 antagonists are not useful for them. Clozapine is the gold-standard 
antipsychotic for those treatment-resistant patients which, interestingly, has a relatively 
weak affinity and short-term occupation of dopamine receptors 19,20.  
Treatment strategies go beyond the current diagnosis. Antipsychotics and other 
drugs like antidepressants, anxiolytics or anticonvulsants are used for patients with 
psychotic features across psychiatric entities such as schizophrenia, bipolar disorder, 
substance-induced psychosis, major depression or, even Alzheimer’s disease and other 
dementias (National Institute of mental health). 
Prognosis is also largely variable among patients 21. Some cases show a favourable 
outcome with long periods of remission or even no relapses and a good general function, 
while other patients have a devastating scenario with no complete remission and 
spending large periods in psychiatric wards 9,22,23. Different research studies have tried 
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to understand the causes of prognosis differences by analysing divergences in 
underlying mechanisms 24,25, neuroanatomy or drug abuse 26without clear results. 
Among the more replicated predictors of good outcome are the presence of affective 
symptoms, shorter duration of untreated psychosis, rapid response to treatment, less 
negative symptom severity, or being female and employed 27. 
1.3. Biological substrates of schizophrenia 
1.3.1. Overview: the heterogeneity issue 
The aetiology of schizophrenia is largely unknown, without any concrete alterations 
known to underly the disorder. Previous efforts in search of the biological underpinnings 
of schizophrenia have yielded inconsistent results. Even the relatively more replicated 
findings, such as hyperdopaminergia or larger ventricular volumes, are insufficiently 
replicated to be accepted as schizophrenia substrates. A recent review analysed the 
possibility of using the most relevant research findings as potential biomarkers for the 
diagnosis of schizophrenia without success 5.  
Several biological mechanisms studied in relation to schizophrenia, such as the 
dopaminergic system or brain connectivity, have been found to be altered (figure 1.1). 
Nevertheless, research findings in this respect are largely heterogeneous and most have 
not been replicated in different samples. Indeed, meta-analyses and reviews highlight 
the large variability observed in all kinds of biological factors, making it difficult, or 
impossible, to reach global conclusions 28–32Importantly, although for certain variables 
patients show significant differences in comparison to controls, there is usually a large 
overlap in values between both samples.  
Heterogeneity is accepted in terms of symptoms, response to treatment or outcome. 
Even in first-episodes, one of the most homogeneous samples (they share 
approximately the same age, illness duration and a low exposition to antipsychotics), a 
clear heterogeneity has been noted in both clinical manifestations and biological 
findings 25,33–35. In addition, the biological mechanisms likely involved in schizophrenia 
are shared with other psychiatric conditions, which underscores their lack of clinical 
validity and specificity 29,36–39. For example, genetic variants associated with the risk of 
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schizophrenia are also implicated in an increased risk of suffering bipolar disorder, 
autism or major depression 40–43. 
Figure 1.1. A scheme which integrates some of the risk factors and biological 
processes studied in relation to schizophrenia.  
 
Different explanations could account for those heterogeneous research findings. 
First, one possibility could be that there are no biological processes underlying 
schizophrenia symptoms. However, this is implausible, since many findings have been 
partially replicated and drugs targeting specific neurotransmitter receptors are useful 
for a group of patients. Second, other option could be that all the disrupted systems 
studied in relation to schizophrenia, which would implicate many biological processes 
and brain regions, could converge to cause schizophrenia. This is an unlikely option, as 
it is not possible that so many alterations take place in a single person. Third, another 
explanation could be that the specific biological disruption explaining schizophrenia has 
not been found yet. This seems also a remote possibility since many different biological 
systems have been explored in large patient samples. Moreover, modern techniques, 
allowing a better examination of the central nervous system (CNS), add more complexity 
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to the global picture rather than shedding light on the alterations. Fourth, the last 
possibility could be that schizophrenia is a syndrome encapsulating different 
abnormalities. This option seems to be more plausible, as heterogeneous results would 
be due to the intrinsic patients’ biological variability, different patients’ samples and 
recruiting strategies. Similar situations occur in other diseases where diagnostic 
procedures are complicated due to diverse clinical manifestations and trajectories, as in 
some types of cancer, for instance 44.  
Diagnostic manuals and research approaches comparing schizophrenia patients and 
controls contribute to the heterogeneity, since patients are classified exclusively based 
on symptoms and clinical signs. These manuals do not consider sources of patients’ 
differences such as symptoms severity, outcome or response to treatment. 
Classification in terms of clinical differences has failed to lead us to the underlying neural 
pathologies. Moreover, clinical-based classification is unstable over time 45. Therefore, 
regarding schizophrenia, current diagnostic tools may cluster together different 
syndromes, which precludes the possibility of finding disrupted mechanisms 
characterising them 6.  
Consequently, it seems plausible that schizophrenia diagnosis includes patients with 
different biological alterations contributing to interindividual variability in clinical 
manifestations. Classifying together different patients can lead to draw misleading 
conclusions. For instance, supposing no abnormalities in one biological process when 
patients’ global mean for a variable is not significantly different from the mean in 
controls, although this variable is truly different in a subgroup of patients. On the other 
hand, assuming an altered process in all patients when patients’ mean significantly 
differs from controls although the alteration is limited to one subgroup that strongly 
drives the differences in mean values.  
Therefore, the typical research approach (i.e. comparing schizophrenia patients as a 
homogeneous group and healthy controls) could hamper the possibility of identifying 
reliable markers for some biologically plausible subgroups within this syndrome. Thus, a 
different approach is necessary for a real progress in identifying the underpinnings of 
schizophrenia. A good start point could be to take an example from another field of 
Medicine: 
- 8 -  Chapter 1 
Heart failure is a syndrome manifested by a group of symptoms. Each individual has 
a set of those possible clinical symptoms, meaning that each patient suffering heart 
failure syndrome could have a particular profile of symptoms. Nevertheless, despite 
sharing a heart failure syndrome diagnosis, the underlying causes can be diverse, such 
as myocarditis, myocardial ischemia or hypertension. Therefore, diagnosis cannot be 
reached based only on symptoms, rather auxiliary techniques are needed to identify the 
underlying causes. If these techniques are not available, we could wrongly group 
together patients with different aetiologies leading to inconclusive research results.  
Similar to the heart failure syndrome, psychosis could be the common endpoint of 
different aetiologies. The current state of the art does not allow to diagnose 
schizophrenia patients based on their biological causes, but classifies all patients 
together, possibly hiding their biological differences. Thus, from a research perspective, 
it seems necessary to “deconstruct schizophrenia” in its multiple components 11. 
Approaching clinical manifestations from a biological perspective will help in finding new 
biological valid diagnosis which, in the end, could implement more efficient treatment 
strategies directed towards the real underlying causes.  
As a summary, several biological alterations are likely involved in the pathogenesis of 
schizophrenia syndrome and some of them may be distinctly involved in different 
subgroups of patients. This thesis explores this idea by searching distinct subgroups of 
patients based on anatomical and genetic data. In the following paragraphs, the main 
biological systems which seem to be altered in the schizophrenia syndrome are briefly 
revised, emphasizing the evidence of results heterogeneity.  
1.3.2. Genetic architecture  
The estimated schizophrenia heritability varies from 33% to 67% in family studies 46–
48. Twins studies yield concordance rates for the heritability of liability to schizophrenia 
to approximately an 80% 49. Therefore, genetics has an important role in the disease, 
but non-genetic factors should also play an important role in this syndrome. Indeed, a 
study suggested that only 25% of the risk of schizophrenia is explained by genetic 
variants identified in massive analysis 50. Thus, interactions between genetic 
architecture and environment are key to understand the disorder 51.  
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Large efforts have been devoted to understanding the genetic background of 
schizophrenia with rather disappointing results. Thousands of genetic variants, not 
pathogenic per se, seem to be involved and interacting in complex ways. Each of those 
variants has a small effect increasing the risk of schizophrenia and they are also present 
in the normal population 48,52. Therefore, a combination of risk genes, with thousands of 
different possible combinations within each patient, seems to mediate the genetic effect 
on the disease phenotype. 
Genome-wide association studies (GWAS) are hypothesis-free approaches that can 
shed light on the understanding of genetic contribution to diseases. GWAS consists in a 
massive genotyping technique able to analyse thousands of single nucleotide 
polymorphism (SNPs) along the whole genome. SNPs are genetic variants differing in 
only one nitrogenous base which is present in at least 1% of the population. They are 
the most common genetic variation among humans, there can be up to 10 million SNPs 
in one person’s genome 53. The SNPs effect varies depending on its location on coding 
or noncoding regions. For those SNPs located in coding regions, depending on the 
genetic variation position, it may or may not produce a significant change in the protein 
expression or function.  
The largest GWAS in schizophrenia so far 48 estimated that around 6,300-10,200 
independent and mostly common SNPs with small effect contributed to schizophrenia, 
accounting for around a 32% of liability variance. The SNPs most robustly associated  
with schizophrenia risk belong to dopamine regulation (DRD2), glutamatergic 
neurotransmission (GRM3, GRIN2A, SRR, CLCN3, and GRIA1), neuronal calcium signalling 
(CACNA1C, CACNB2, and CACNA1I), immune pathways (major histocompatibility 
complex (MHC)), transcriptional regulatory proteins (ZNF804A), non-coding regulatory 
RNAs (miRNA-137), synaptic plasticity and functionality (KCTD13, CNTN4, PAK6) and 
other SNPs located on inter-genetic non-coding regions that could relate to gene 
expression regulation. 
The genetic risk of schizophrenia not explained by SNPs could be related to other 
types of genetic variants such as copy number variants (CNV), rare variants of strong 
effect, de novo variants or epigenetics (briefly revised in section 1.3.6) 54. Copy number 
variants are common or rare deletions or duplications of DNA fragments (longer than 50 
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base-pairs) that can affect various genes. For example, a deletion in the chromosome 3 
(3q29) of approximately 1.6 megabases, including genes related to synapsis, dendritic 
spines or glutamate transmission, was related to a 40-fold increase of schizophrenia risk 
55–57.  
Although genetic studies have expanded the knowledge about possible genetic risk 
factors in schizophrenia, some of the results are inconsistent. Some polymorphisms 
associated with schizophrenia in GWAS have not been replicated in smaller samples and, 
inversely, some candidate gene studies have not been replicated in GWAS. It seems 
impossible that the large amount of risk genetic variants, between six and ten thousand, 
combine in a similar way in all patients 6,58. To complicate even more the genetic 
perspective, bipolar disorder, depression or intellectual disabilities share a large number 
of risk variants with schizophrenia, emphasizing the lack of genetic specificity and the 
similarities across categorical disorders 40–43. The Brainstorm Consortium has recently 
published an interesting article based on GWAS meta-analysis showing the high genetic 
overlapping among many psychiatric diseases, including attention deficit, hyperactivity 
disorder, anorexia, anxiety disorders, autism, bipolar disorder, major depressive 
disorder, obsessive-compulsive disorder, post-traumatic stress, Tourette syndrome and 
schizophrenia 59.  
Interestingly, Arnedo and colleagues described different genetic networks (groups of 
interacting SNPs) associated with 70% of the risk of schizophrenia that might specifically 
lead to diverse phenotypes within “the schizophrenias” 58. They propose that 
schizophrenia includes different clinical syndromes related to specific sets of interacting 
risk genes and argue for assessing the genotype in a context of phenotypes described in 
detail, beyond the clinical diagnosis.  
Thus, an alternative genetic approach, starting from genetical differences within 
patients to reach phenotype syndrome, may be useful instead of the classical genetic 
one (from diagnosis to genetics). Some brain dysfunctions or molecular abnormalities 
can be considered endophenotypes, defined as quantitative parameters within 
biological systems associated with diseases and more closely related to genetics than 
the clinical manifestation 60. Therefore, studying the genetic contribution to 
endophenotypes may help in identifying subgroups with biological and clinical validity. 
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As an example, a risk variant close to microRNA-137 gene (codifies a key protein in gene 
expression regulation which is associated with the risk of schizophrenia) can predict an 
earlier age-at-onset of schizophrenia and was associated with disrupted white matter 
integrity, smaller hippocampus and larger ventricles in patients 61. 
In this line, the present thesis studied the effect of selected polymorphisms on 
functional connectivity in controls and patients. The corresponding articles can be found 
in chapter six and seven of this manuscript. We selected polymorphisms related to 
myelinisation, neuron electrical properties regulation and excitatory/inhibitory (E/I) 
balance. In particular, three SNPs in neuregulin 1 gene (NRG1; a pleiotropic protein that 
participates in neuron development, migration and plasticity, myelination and NMDA 
receptor signalling) 62, one SNP in a gene which encodes a pore protein, alpha1C, of L-
type voltage-gated calcium channel (CACNA1C), and another SNP in a gene which 
encodes a pore-forming subunit of voltage-gated potassium channel subfamily H 
member 2 (KCNH2), were genotyped. Then, controls and patients (in the second article) 
were classified as carriers or non-carriers of each risk allele, and the genetic effects on 
functional connectivity modulation during an electroencephalographic (EEG) odd-ball 
task were analysed.  
1.3.3. Neuroanatomical abnormalities 
Brain anatomical abnormalities have been identified in schizophrenia both in vivo 
using neuroimaging techniques, and in post-mortem samples using histological 
techniques. Enlarged ventricles 63, grey matter (GM) deficits at prefrontal, anterior 
cingulate, thalamus and temporal regions, as well as white matter (WM) reductions are 
among the most replicated anatomical findings, but inconsistencies are very common 
30,31,64–67.   
Anatomical alterations appear to be already present at initial stages of the disease or 
before the illness onset 25,68,69. Meta-analyses on longitudinal studies concluded that 
structural abnormalities occur already in prodromal stages, progressively worsening 
along the illness course, although it is likely some effect of treatment in this declining 70–
72.  
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The brain’s macroanatomical changes could be partially explained at a microscale 
level by cellular and histological disruptions like altered neuropil density 73, glial cells 
abnormalities, changes in neuron number, synaptic loss, abnormal axonal arborisation 
or altered neuronal pruning 74–79. 
Brain structural patterns in schizophrenia are very heterogeneous and even 
contradictory 30,31. A recent meta-analysis 28 analysed the variability in brain volume data 
(data dispersion) in first-episode schizophrenia (FES) patients and healthy controls. The 
authors collected regional brain volumetric measures from previous studies and 
calculated the inter-individual variability of that measures in each group. Subsequently, 
they compared the variability rates between groups. They observed that most 
measurements, except for the anterior cingulate cortex (ACC), showed greater 
variability (more dispersion) in first-episode patients than in controls; that is, patients’ 
volumetric data seemed to differ significantly between samples. Moreover, anatomical 
values in some patients were in the same range than controls. 
Based on heterogeneous literature findings, it has been suggested that distinctive 
patient subgroups within schizophrenia could differ on severity and extent of anatomical 
abnormalities, and that some alterations could even be specific of one particular 
subgroup of patients 14. Indeed, the same research group observed brain structural 
differences within schizophrenia depending on genetics and symptoms. First, patients 
homozygous for rs1344706 polymorphism (AA) at ZNF804 gene, which codifies for a 
transcription factor, showed higher grey matter volumes mainly at the prefrontal cortex 
(PFC) and temporal cortex than heterozygous patients (AC) 80. Interestingly, the opposite 
genetic effect was found in healthy controls, being the homozygous genotype (AA) 
associated with lower grey matter volumes than heterozygous genotype (AC). Secondly, 
they observed a widespread cortical thinning in a subgroup of schizophrenia patients 
with predominant negative symptoms, differing from the disorganised and paranoid 
symptoms subgroups81.  
Other studies have identified brain anatomical differences among patients depending 
on their outcome or treatment response. Worse outcome schizophrenia patients 
presented GM deficits in subcortical areas particularly in thalamus and striatum in 
comparison to better outcome patients 24. Another study in first-episode patients 
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related prefrontal and medial-temporal alterations with worse one-year outcome 25. 
Furthermore, treatment-resistant patients have been related to higher GM loss 15,16,82. 
In schizophrenia patients with predominant negative symptoms, response to 
transcranial magnetic stimulation was predicted based on brain anatomical patterns. 
Specifically, marked GM reductions in prefrontal, temporal and cerebellar cortex and 
increases in parietal regions and thalamus were associated with non-response to active 
transcranial magnetic neurostimulation 83. 
As with other biological alterations, brain structural impairments associated with 
schizophrenia have also been identified in other psychiatric pathologies. Grey matter 
deficits in the dorsal anterior cingulate and anterior insula, related to executive function 
impairment, were concordant between schizophrenia, bipolar disorder, depression, 
addiction, obsessive-compulsive disorder and anxiety 84. Moreover, other meta-analysis 
identified two trans-diagnostic subgroups based on GM alterations including 
schizophrenia, autism and obsessive-compulsive patients39. The first subgroup showed 
abnormalities in the insula, ventromedial PFC and thalamus, which were associated 
mainly with alterations in the self, introspection, emotions and salience. The second 
subgroup showed cortical abnormalities in the four lobes, middle insula and lingual 
areas which were related to alterations in motion, visual perception, face recognition, 
mentalizing and theory of mind 39.  
In general, anatomical findings support the idea that patients with schizophrenia do 
not share the same alterations and that some of these abnormalities are common to 
several psychiatric syndromes. 
1.3.4. Structural and functional dysconnectivity 
Higher mental functions are supported by the coordinated work of different brain 
areas 85,86. Therefore, efficient communication between close and distant areas, also 
known as connectivity, is essential for proper mental functioning 87. Cerebral 
connectivity allows integration of information between distant regions and 
communication between close regions in a specialized and segregated manner. 
Three types of connectivity have been proposed 87: 
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-Structural connectivity, defined as the anatomical connections formed by neuron 
synapsis, axons projections and myelin fibres. It can be assessed in post-mortem brains 
or in vivo using neuroimaging technics such as diffusion magnetic resonance (dMRI).  
-Functional connectivity, defined as the statistical dependency or synchronization 
between neurophysiological signals in different brain locations. It could be measured in 
vivo using: i) electroencephalography (EEG), by measuring electrical oscillations created 
by groups of synchronously firing pyramidal neurons; ii) magnetoencephalography 
(MEG), by recording magnetic fields created by brain electrical currents, or ii) functional 
magnetic resonance (fMRI), which quantifies blood oxygen level dependent signal 
(BOLD), assuming that perfusion and oxygen consumption rise in active cerebral areas. 
EEG and MEG have a largest temporal resolution, but fMRI has a better spatial 
resolution.  
-Effective connectivity, defined as the causal connections between areas or units, 
calculated with complex statistical models assessing the directionality and causality of 
connections 88.  
In 1998, Karl J. Friston formulated the disconnection hypothesis of schizophrenia 89, 
proposing that impaired functional integration between neurons and brain areas is the 
central problem of schizophrenia. Nevertheless, not only functional but also structural 
connectivity seems to be disrupted. Olaf Sporns described schizophrenia as an altered 
structural connectivity disorder accompanied by disrupted functional communication 
between brain areas 87. Therefore, assessing altered global connectivity (structural and 
functional) could help in elucidating pathogenic mechanisms within schizophrenia 
syndrome.  
White matter connectivity deficits have been reported in schizophrenia in all disease 
stages, trending to worsen with illness duration. However, these findings are largely 
heterogeneous and inconclusive as it is highlighted in different reports 66,90–92. Indeed, 
meta-analyses differ in localizing WM alterations 30,31,64,93. The largest meta-analysis, as 
far as I know, including data from both volumetric WM (using volumetric brain 
morphology technique, VBM) and tractography (assessed with Diffusion Tensor Imaging, 
DTI),  located these alterations mainly in fronto-temporal-limbic, callosal-commissural 
and motor descending projections 30. 
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Regarding functional connectivity, both decreased and increased connectivity have 
been reported in schizophrenia at resting state and during task performance 90,94–96. The 
default mode network (DMN) is a functional network more active in absence of specific 
cognitive tasks and likely associated with mind-wandering which includes the cingulate, 
medial PFC, medial temporal and inferior parietal cortex. This is one of the most studied 
functional networks at resting state in schizophrenia, with findings indicating both 
decreased 97,98 and increased connectivity 99–101 in first episode, chronic patients and 
their relatives. Also, a recent meta-analysis of resting state 94 supports a lower 
connectivity in patients among areas of the following networks: affective, ventral 
attention, thalamus, somatosensory and DMN. These alterations seem to be already 
present in first-episode patients involving mostly language areas which may extend with 
illness progression 102. During the performance of a P300 task (an event-related brain 
potential elicited by an infrequent target stimulus during an odd-ball paradigm), 
dysconnectivity was observed in first-episode and chronic patients involving mainly 
frontal, parietal, occipital, cingulate, and hippocampus regions 103–105. 
Interestingly, overlapping patterns of structural and functional connectivity have 
been found with other diseases. One meta-analysis described no WM integrity 
differences between schizophrenia and bipolar disorder 106. Furthermore, both shared 
with major depression abnormal WM in the corpus callosum 37. Also, similarities in 
functional disruptions were found between schizophrenia and autism 107 and between 
schizophrenia, bipolar disorder and depression, especially in local functional 
connectivity during resting state 108.  
Graph theory 87,109,110 is a useful method for assessing complex networks based on 
nodes and its connections, called edges. The application of graph theory to brain 
connectivity is useful to study global brain functions. According to available data, global 
brain connectivity, both structural and functional, has a small-world (SW) topology 111–
113. This type of network is characterised by the efficient transmission of information by 
means of balanced integration (long-distance communication) and segregation (local 
areas communication). SW organization has been found abnormal in patients with 
schizophrenia 114–117. 
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The structural connectome of patients with schizophrenia, in terms of graph theory, 
has been studied with different results. Structural connectivity has been described as 
less integrated, more segregated, with increased modularity and decreased global 
efficiency (usually measured using SW parameters) 96,118–120. Moreover, rich-club nodes 
(key nodes for information transmission, highly connected between them and with the 
rest of the graph) organization and their connections seemed to be especially impaired 
in this syndrome 121, likely affecting brain global communication 122.  
Functional networks in schizophrenia have also been studied using graph theory. 
Although again, discrepancies exist, the main findings during resting state pointed 
towards a functional network closer to random networks 123 with decreased small-
network architecture. This implies a decreased network efficiency, normal or decreased 
integration and a tendency towards decreased segregation 95,123,124. During the 
performance of working memory tasks, patients also show worse , or even absent, small-
network architecture 125, including heterogeneous results: decreased or increased 
clustering coefficient (CLC, a measure of segregation), and normal or longer path lengths 
(PL, a measure of integration) 115,117,126. Functional SW disruptions have been found to 
be already present in high-risk individuals and first-episode patients 117,127 and, 
interestingly, they have also been observed in high functioning patients 128. Moreover, 
similar to structural findings, functional connectivity in patients shows abnormalities in 
rich club hubs 129 and lower connectivity among them 95,122. 
An unresolved question is how structural disconnectivity determines functional 
connectivity 130. Based on research results, the direction of the alterations is not the 
same in both types of connectivity since main findings support both increased and 
decreased functional connectivity but only decreased structural connectivity. There are 
data supporting coupling 122,131,132 and decoupling 90,133 between structural and 
functional connectivity. Also, a recent meta-analysis found that, in drug-free patients, 
structural and functional abnormalities partially overlap within the default mode 
network and auditory networks 134. On the contrary, we reported that both types of 
connectivity disruptions were not related, maybe because each type of alteration could 
be present in different subgroups of patients 120.  
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Connectivity differences have been observed within schizophrenia depending on 
clinical manifestations, supporting that connectivity alterations are not homogeneous 
among patients. Connections between the prefrontal and medial-temporal cortex to 
subcortical structures have been associated with patients outcome 25, for example, 
patients with poor outcome showed decrease volume of the interior limb of the internal 
capsule (which was interpreted as decrease frontothalamic connectivity) in comparison 
with patients with good outcome. Also, first-episode patients who did not respond to 
treatment in the first year, had lower fractional anisotropy (FA), a measure of WM 
connections integrity (higher FA values is generally interpreted as better integrity), 
mainly at uncinate, cingulum and corpus callosum than responders patients and controls 
135. In terms of functional connectivity, patients with verbal hallucinations, compared 
with patients without them, showed increased functional connectivity within DMN, but 
decreased connectivity within areas of the salience network136 (a functional network 
active when the individual is paying attention to salient stimuli, it is involved in detecting 
relevant stimuli and includes the dorsal ACC and insular cortex 137) . Treatment-resistant 
patients showed decreased connectivity in striato-nigro-striatal network in comparison 
to treatment-responders 138. Unexpectedly, deficit schizophrenia patients (patients with 
primary and enduring negative symptoms139) showed increased functional integration 
(shorter connections between distant regions) and higher functional global efficiency in 
comparison to non-deficit patients 140  
The effect of treatment on connectivity is not clear. Some antipsychotics seem to 
improve WM connectivity since increased FA (better WM integrity) was observed after 
one year of treatment 135. Functional connectivity changes, mainly in cortico-striatal 
network, were described after treatment with risperidone or aripiprazole and increased 
connectivity was related to psychotic symptoms improvement 141. Moreover, decreases 
of functional connectivity after 6 weeks of treatment with atypical antipsychotics 142 or 
improved effective connectivity after 1 week of treatment 143 were reported.  
The above-mentioned evidence supports connectivity alterations, but the directions 
and localizations vary across studies. It could be possible that connectivity changes in 
different networks are caused by particular biological impairments, such as 
hypofunction of NMDA receptor, altered pruning or disrupted myelinisation in fibres 
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with later maturation, and are related to different clinical manifestations 111. Therefore, 
subgroups of patients within the same diagnosis may show different connectivity 
patterns related to specific disruptions of higher mental functions. However, all of them 
could fit into the current, biologically unspecific, schizophrenia criteria 144.   
In the present thesis, both structural and functional connectivity have been studied 
in schizophrenia in order to find patient subgroups with specific patrons of connectivity. 
First, brain cortical curvature was calculated as an indirect measure of structural 
connectivity. Second, DTI was included to understand the relation between cortical 
curvature and structural connectivity, measured by means of FA, as well as to assessed 
structural connectivity alterations in patients. Finally, EEG signals and graph-theory were 
used to assess functional connectivity in terms of small-world and its possible relation 
to genetic polymorphisms. 
1.3.5. Other biological alterations 
1.3.5.1. Neurotransmission: 
Available evidence supports dopaminergic, glutamatergic and GABAergic signalling 
impairments in schizophrenia. Alterations in those systems are not mutually exclusive, 
since glutamate release is partially controlled by presynaptic dopamine receptors 145, 
and GABA release is controlled by glutamate receptors in inhibitory neurons 146,147. 
Moreover, genetic variants related to neurotransmission are associated with that 
syndrome 48. 
Dopamine transmission alterations have been related to schizophrenia 41,146,148 on 
the basis of: i) the effectiveness of dopamine receptor D2 antagonists, ii) psychosis 
induced by dopamine agonists, and ii) higher dopamine receptor concentration in post-
mortem brain samples of schizophrenia patients. In its initial formulation, this theory 
proposed that positive symptoms would be caused by mesolimbic hyperdopaminergia, 
while negative and cognitive symptoms could be secondary to dopamine deficits in the 
frontal cortex. Antipsychotics would restore mesolimbic dopamine activity but would 
induce a further decrease in other dopamine pathways. Therefore, side effects would 
emerge as a consequence of the decreasing dopamine levels in nigrostriatal, 
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mesocortical and tuberoinfundibular dopaminergic pathways 145. Moreover, the altered 
dopamine levels could partially be due to impaired neurons phasic dopamine release to 
relevant and irrelevant stimuli 149. 
More recently, the dopamine hypothesis has been questioned, since recent studies 
showed that hyperdopaminergia is not present in all schizophrenia patients. Treatment-
resistant patients may not show dysfunctional dopaminergic transmission 15,17. 
Interestingly, long-term treatment with antipsychotics has been related to up-regulation 
of the density of dopamine D2 receptors, associated with treatment resistance and 
psychotic exacerbation, i.e. dopamine super-sensitivity psychosis 150. Thus, dopamine 
abnormalities do not seem to be homogeneous in schizophrenia patients but might 
characterize a subgroup of patients which respond to dopamine receptors blockers 
(current antipsychotics) 145. Indeed, Howes and Kapur proposed a classification of 
patients based on dopaminergic levels, one group called “hyperdopaminergic” with 
elevated dopamine synthesis and release in the striatum, and another group called 
“normadopaminergic” without dopamine abnormalites151. Moreover, such dopamine 
level increase is not specific to schizophrenia as it has also been described in bipolar 
disorder or autism 152. 
Glutamate is the major excitatory neurotransmitter in the brain. The glutamatergic 
hypothesis proposed a hypofunction of the glutamate NMDA receptor in patients with 
schizophrenia 153. NMDA receptor antagonists as ketamine or phencyclidine transiently 
mimic key psychotic symptoms of schizophrenia. Similarly, mouse models not 
expressing different NMDA receptor subunits (knockout models) exhibit schizophrenia-
like symptoms 154,155. Different therapeutics approaches tried to study the beneficial 
effect of glutamate agonist but, unfortunately, with no conclusive results 156. 
Inhibitory interneurons releasing GABA (gamma-aminobutyric acid, the major 
inhibitory neurotransmitter) are key to control the neuronal firing tuning that supports 
complex cognitive processes. At the same time, interneurons firing is controlled by 
excitatory neurons, so a complex interaction between GABA and glutamate is necessary 
for a correct brain electrical tuning.  
The NMDA receptor (NMDAr) hypofunction leads to a decreased activation of GABA 
inhibitory interneurons, creating an excitatory/inhibitory imbalance that disrupts the 
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correct brain electrical synchrony. Thus, interneurons inefficiency might underlie 
gamma-frequency synchronization alterations 157, higher electrical noise likely related 
to aberrant salience 158,159, or alterations in functional connectivity 160,161. More direct 
evidence of altered GABAergic signalling has been found in schizophrenia patients 
mainly supported by a decrease of glutamate decarboxylase 67 (GAD67) expression 
162,163, an important enzyme involved in the GABA synthesizing pathway.  
As in the case of dopamine, glutamate and GABA dysfunction might differ in 
subgroups of patients with schizophrenia. Glutamatergic neurotransmission seems to 
be particularly dysfunctional in treatment-resistant patients 15,18,164,165with higher 
glutamatergic abnormalities apparently accompanied by normal striatal dopamine 
release 18. In the same direction, mouse models of dopamine supersensitivity psychosis 
have shown a glutamatergic signalling decrease accompanied by an increase in 
GABAergic signalling in the striatum 166. 
1.3.5.2. Immune alterations  
In recent years, the immune-inflammatory hypothesis of schizophrenia has gained 
relevance and visibility. This framework proposes that low-grade chronic inflammation 
could contribute to schizophrenia based on the following findings: 
First, epidemiological studies have detected a high comorbidity between 
schizophrenia, autoimmune diseases and chronic inflammation 167. Moreover, some 
autoimmune diseases produce schizophrenia-like symptoms or even could be initially 
confused with psychiatric diseases, as in the case of autoimmune encephalitis caused by 
anti-NMDA receptors antibodies 168.  
Second, prenatal or early childhood infections have been related to higher risk of 
schizophrenia and overactive inflammatory response in the adulthood 169–171. 
Nevertheless, most individuals exposed to infections during prenatal or early postnatal 
periods do not develop schizophrenia and most of the patients with schizophrenia did 
not suffer infections in that period 171.  
Third, some post-mortem studies have observed an increased microglial (the primary 
immune cells in the brain) density. Moreover, an increased microglial activation has 
been described both in vivo and in post-mortem samples 172,173. Nevertheless, only half 
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of the studies have replicated the findings in post-mortem studies 32. In addition, in vivo 
PET studies to detect active microglia have yielded mainly negative results using second-
generation radiotracers in spite of the positive findings observed with first-generation 
tracers 32. 
Fourth, elevated pro-inflammatory markers have been found both in the blood and 
the cerebrospinal fluid (CSF) of patients with schizophrenia. Intriguingly, meta-analyses 
reported contradictory results in the direction and type of cytokines abnormalities 
(figure 1.2) 34,38,174. 
 
Figure 1.2. Resume of cytokines concentration in the serum of schizophrenia patients 
from meta-analytic studies. Different colours indicate different findings: Red = higher 
concentration in schizophrenia patients; Green = no difference between patients and 
controls; Blue = lower concentration in patients; White = not analysed. FEP=first episode 
patients, CHR= chronic patients. 
 
Finally, GWAS studies have found that genetic areas related to immunity are strongly 
associated with the increased risk of schizophrenia, mainly the MHC region 48. In 
particular, the strongest genetic association with schizophrenia was in component 4 of 
complement (C4) gene 48,74.  
- 22 -  Chapter 1 
Inflammatory abnormalities have been related to processes deemed to be altered in 
schizophrenia 169,175. Hyperactive microglia could produce an excess of neuronal pruning 
that could, in turn, lead to a decreased grey matter density. Indeed, Sekar and colleagues 
showed that schizophrenia-related polymorphisms in the C4 gene could raise C4A 
expression and also that higher C4A concentrations were associated with increased 
synaptic pruning in mouse models 74. Overactive inflammatory responses could also 
damage oligodendrocytes and myelin, contributing to white matter impairments and 
therefore to structural connectivity alteration 176. Finally, excessive chronic cytokines 
release and immune induction of tryptophan catabolites, such as kynurenine or 
kynurenic acid, may be related to NMDAr hypofunction and GABA release 177.  
However, as expected, immune abnormalities are not specific to schizophrenia. One 
meta-analysis observed similarities between schizophrenia, bipolar disorder and major 
depressive disorder in abnormal cytokine levels in CSF 29. Some authors argued that 
antipsychotics can affect microglial activity and cytokines secretion 42,178. In this sense, 
randomised controlled trials on the effects of anti-inflammatory drugs in co-treatment 
with antipsychotics described a large variety of results, from significant beneficial effects 
to irrelevant differences. These discrepancies could be due to inflammation changes 
through the illness course, or to immune abnormalities present only in a subgroup of 
patients. Therefore, immunomodulators may only have beneficial effects for a certain 
group of patients during a given stage of the disease 174.  
The described inconsistencies and some studies point out immune disturbances 
restricted to a subgroup of patients across diagnosis. Shannon Weickert and her group 
analysed inflammatory and stress-signalling markers in post-mortem brain tissues of 
schizophrenia, bipolar disorder patients and healthy controls 179. They observed a 
distinguishable subgroup of patients, including cases with both diagnoses, characterised 
by higher levels of inflammatory and stress biomarkers. Besides, they also reported that 
those schizophrenia patients with higher inflammation markers also showed astrogliosis 
(increase in the number of astrocytes) 180 and cortical grey matter reductions 181. In a 
posterior work, including a different sample of patients with schizophrenia, the same 
group found a subgroup with increased inflammation, higher cytokines mRNA levels, 
lower verbal fluency scores and decreased Broca’s area volume 182. In the same 
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direction, a subgroup of schizophrenia patients with an increase in either immune 
molecules or growth factors in serum, but not hormones, was also reported 183.  
1.3.6. Environmental factors 
Some environmental variables have been associated with the increased risk of 
schizophrenia 184,185. These factors might interact with genetic architecture, triggering 
the illness onset 51. Environmental factors are especially relevant during sensitive time 
frames when the brain is under development and maturation, making prenatal, 
childhood and adolescence environments crucial for the individual health. Obstetric 
complications, migratory status to a racial or cultural minority, living in urban areas, 
birth in the winter season, drug abuse, trauma and stress are among the more replicated 
environmental risk factors for schizophrenia 185–187. A meta-analysis in ultra high-risk 
individuals concluded that childhood trauma, adverse life events and affective 
impairments are those factors most associated with increased vulnerability to psychosis 
184.  
In general, early traumatic experiences are one of the leading environmental factors 
associated with an increase of schizophrenia risk, which could underlie migration and 
urbanicity risk factors. Migration status or belonging to a minority group has been 
related to discrimination, social adversities and isolation 188,189. Moreover, people living 
in urban areas could suffer tougher social maladjustment, although it was also 
hypothesized that higher pollution or infection rates could mediate this relation to 
schizophrenia risk 190–192. Interestingly, urbanicity was associated with a lower cortical 
thickness in healthy individuals 193. 
Early traumatic experiences, such as emotional, physical and sexual neglect or abuse, 
are more prevalent in people with schizophrenia 194–196. Furthermore, childhood trauma 
has been related to more hospitalizations, worse functioning, lower quality of life and 
emotional distress in schizophrenia patients 197. A recent meta-analysis supported the 
relationship between childhood trauma and severity of positive symptoms 198. Trauma 
may lead to permanent changes during brain neurodevelopment, such as changes in the 
hypothalamic-pituitary-adrenal axis that sensitise individuals to posterior stressors and 
can even disrupt dopamine balance 186,195. The interaction between childhood trauma 
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and genetic variation could be the key to understanding its relation to schizophrenia. As 
an example, suffering childhood trauma plus carrying the risk allele of Val66Met 
polymorphisms in brain-derived neurotrophic factor (BDNF) gene had an additive effect, 
reducing BDNF mRNA levels and decreasing hippocampal volume 51. Nevertheless, 
contradictory results can be found in the literature, for instance, no BDNF by childhood 
trauma interaction was observed on hippocampus volume and cognition 199. 
Another relevant environmental factor is drug consumption. Cannabis consumption, 
especially during adolescence, has a strong correlation with increased risk of 
schizophrenia and with an earlier age-at-onset 200–202. Patients who consume cannabis 
have shown higher positive symptoms scores, worst psychosocial functioning, shorter 
time to relapse and worst general prognosis 26,197,203,204. It has been suggested that 
cannabis could also be used by these patients as self-medication, in order to relieve 
primary psychotic symptoms or medication side-effects, improve self-esteem or 
overcome social isolation 204,205. Risk polymorphism in dopamine transporter 1 gene 
(DAT1) may mediate cannabis effects on abnormal hippocampal volumes 206. 
Furthermore, the modulation of the interaction between cannabis consumption and the 
risk of schizophrenia by the COMT gene has been widely studied. This gene codifies for 
an enzyme that degrades catecholamines such as dopamine. Val/Val genotype in the 
COMT Val158Met polymorphism could mediate the increased risk of schizophrenia 
associated with cannabis 207 and be related to an earlier psychosis onset 208. 
Nevertheless, there are also contradictory and negative findings in the interaction 
between cannabis and COMT polymorphisms 209–211.  
Furthermore, dietary factors may also have a role in the disease, low levels of vitamin 
D or polyunsaturated fatty acids have been related to an increased schizophrenia risk 
212,213. Some studies pointed out that a diet supplementation with vitamin D and 
polyunsaturated fatty acids could be beneficial on preventing and treating schizophrenia 
214,215. 
The majority of the studies trying to understand environmental risk factors in 
schizophrenia are observational and epidemiological, hence it is not possible to infer the 
true causation of environmental factors. However, epigenetics could link environmental 
adversities to changes in gene expression and, therefore, to phenotypes 187,216,217. 
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Epigenetic effects include: i) changes in DNA methylation profile, higher methylation 
rates of cytosines in CpG islands located on promoters which repress gene expression; 
ii) post-translational modifications of histones changing the chromatin status 
(heterochromatin, compacted chromatin and not accessible to transcriptional 
machinery; and euchromatin: less compacted chromatin and accessible for 
transcription); and iii) other regulatory mechanisms such as micro RNAs 218. 
Interestingly, some epigenetic marks are also heritable in a process called imprinting 
185,187. Therefore, it is not only relevant how a child was raised but also the life events of 
their parents. The link between environmental situations and epigenetic changes can be 
addressed using animal models. Factors such as stress, hormones, maternal care or early 
infections have been associated with changes in epigenetic fingerprints 216–218. 
Finally, it is also important to consider that not all patients have been exposed to risk 
environmental situations. In addition, patients are exposed to different types of risk 
environmental factors, and most people exposed to similar situations do not develop 
schizophrenia. It seems likely that environmental factors exert their effect only when 
certain genetic risk is present 209. Therefore, any environmental risk factor is not 
sufficient nor necessary by itself to develop schizophrenia.  
1.4. The need for a new research strategy 
As discussed above, the variety of aetiological factors associated with schizophrenia 
plausibly interact in a complex way leading to the clinical signs and symptoms of this 
syndrome 51,146,219. It is not possible to know whether certain alterations are a 
consequence of other abnormalities or whether all of them are secondary to the same 
underlying disturbance or genetic background. Moreover, multiple biological processes 
and environmental hazards have been associated with increased schizophrenia risk (set 
of risk genes, different neurodevelopmental abnormalities, infections, trauma, stress, 
drug use, living style, etc.). This scenario creates thousands of possible combinations 
between genes, environment and biological processes. Thus, the probability that all 
possible scenarios occur in one’s individual life is very low (figure 1.3, b), hence it is very 
unlikely that all patients suffer from the same process. It is then plausible that different 
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combinations of genetic risk plus environmental factors lead to specific neural 
dysfunctions which take place in different groups of patients (figure 1.3, d). Despite the 
complexity of the possible scenarios and interactions between environmental and 
biological factors, current research approaches fail to take into account this complexity. 
Typical research strategies follow the idea that alterations converge in individuals with 
schizophrenia being the cause of the disease (figure 1.3, b). Nevertheless, the large 
clinical heterogeneity and the lack of research findings replication support that different 
and more complex scenarios are more likely (figure 1.3, c and d). 
 
Figure 1.3. Diagram of the possible disease scenarios from pathological processes to 
clinical manifestations: a) one pathological process produces one specific clinical 
manifestation; b) various pathological processes interact creating one clinical 
manifestation; c) different pathological processes produce specific clinical 
manifestations, although all clinical manifestations are grouped together as if they were 
only one specific manifestation; d) various pathological processes interact in different 
ways generating diverse clinical manifestations that, again, are grouped together as if 
they were one specific manifestation. 
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As a hypothetical example of the possibility presented in figure 1.3d, a group of 
patients with risk polymorphisms in genes involved in myelinisation and exposed to 
childhood trauma could show impaired myelinisation of fibres mainly connecting 
prefrontal cortex (which maturate later in life) and could be diagnosed with 
schizophrenia with predominant negative symptoms. Another group carrying risk 
polymorphisms involved in immune regulation and glutamate transmission and exposed 
to infectious processes or immune activation in early periods of life could show 
abnormalities in pruning processes. This would lead to impaired synaptic connections 
affecting functional networks integration and excessive microglial activations, damaging 
oligodendrocytes. These individuals might be diagnosed with schizophrenia with 
marked disorganization and cognitive deficits. A third group with a genetic background 
including risk polymorphisms related to dopaminergic signalling and exposed to 
obstetric complications might be diagnosed with schizophrenia with predominant 
positive symptoms and would respond to antipsychotic treatments. Currently, these 
three speculative scenarios with different aetiologies would produce symptoms 
according to current schizophrenia diagnostic criteria, and hence patients would be 
diagnosed and treated in a similar way. Also, if they participated in a research project, 
they would be included in the same group despite the fact that their aetiologies and 
symptoms were completely different (figure 1.3, d)). 
It is important to note that the biological processes assessed so far are distant from 
the psychological functions known to be altered in schizophrenia such as thinking, 
behaviour and emotions. Thus, we may wonder: are we correctly designing research 
approaches? Given the lack of replicated findings, the answer may be negative. One 
potentially useful alternative to test is the hypothesis that groups of patients could be 
identified based on their common biological alterations, regardless of their clinical 
diagnosis. Therefore, new research strategies with techniques close to altered mental 
functions (i.e. connectivity is close to brain global functioning) are necessary to resolve 
this complex scenario.  
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Figure 1.4. Comparison between typical research approaches in schizophrenia 
research and our suggested approach, which is useful to identify biologically significant 
subgroups within patients. 
 
In this direction, some research programs have been launched aiming to explore 
different approaches, deal with the conundrum of schizophrenia cerebral underpinnings 
and find more accurate diagnostic tools. The Research Domain Criteria Initiative (RdoC), 
from the National Institute of Mental Health 220,221, is·”a research framework for new 
approaches to investigating mental disorders”. This aims to collect a broad set of 
experimental data (i.e. genetical, psychological and neuroimaging) in large samples of 
patients with mental disorders to undercover valid behavioural and neurobiological 
dimensions. This would eventually help reframing the current diagnostic classifications 
of schizophrenia. A similar project is held by The Bipolar-Schizophrenia Network for 
Intermediate Phenotypes, a consortium built to identify psychosis subgroups by means 
of neurobiological biomarkers. In this line, our suggestions in this thesis are an unbiased 
data-driven research approach (figure 1.4) and genetic-based classification using 
connectivity measures.  
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1.5. Thesis overview 
The main purpose of this thesis is the search for subgroups of patients within 
schizophrenia based on structural/functional connectivity and genetic polymorphisms. 
The publications included addressed two classifying options, data-driven and genetic-
based, and additionally aimed to understand the implications of the traits (gene 
polymorphisms and functional and structural connectivity) that characterise the 
different subgroups.  
The thesis includes five articles, four of them already published and one recently 
submitted. The first one describes a data-driven approach defining a subgroup of 
patients based on structural data (mainly cortical curvature). The second article aimed 
to describe the relations between cortical gyrification and structural connectivity. In the 
third article, structural connectivity alterations in schizophrenia were described. The 
fourth and fifth studies analysed functional connectivity differences according to genetic 
polymorphism in controls and schizophrenia patients. 
The thesis is organised into 9 chapters. This introduction is followed by the aims and 
hypotheses of the thesis, the five articles, a general discussion and conclusions. 
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Chapter 2  
 
Aims and Hypotheses 
2.1. Aims  
Following the ideas put forward in the introduction and based on the existing 
heterogeneity within schizophrenia and the importance of dysconnectivity to normal 
mental functioning, the following general and specific aims are proposed in this thesis: 
General aims:  
To use biological data in order to explore the existence of patient subgroups within 
schizophrenia, characterising the possible subgroups with other clinical and biological 
variables. 
Specific aims: 
1. To explore the existence of patient subgroups based on neuroanatomical data 
(cortical thickness, curvature, area and subcortical volume) using a statistical data-
driven approach.  
2. To validate subgroup of patients using clinical data (symptoms) and brain 
function measurements (electroencephalography and brain glucose metabolic rate). 
3. To assess the relationship between frontal cortical curvature and structural 
connectivity quantified as fractional anisotropy from diffusion tensor imaging.  
4. To evaluate frontal structural alterations in schizophrenia patients in comparison 
with healthy controls.  
5. To assess whether genetic polymorphisms related to increased schizophrenia 
risk and involved in white matter development and excitatory/inhibitory balance 
contribute to differences in functional connectivity in healthy controls.  
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6. To evaluate the possible influence of polymorphisms associated with 
schizophrenia risk, synaptic transmission and excitatory/inhibitory balance on functional 
connectivity in patients and healthy controls.  
2.2. Hypotheses 
General hypothesis:  
Biological data and data-driven approaches would be useful to identify patient 
subgroups with common biological underpinnings within schizophrenia.  
Specific hypotheses: 
1. Subgroup of patients would be identified based on neuroanatomical data: 
cortical thickness, curvature, cortical surface area and subcortical volume. 
2. Previously defined subgroups of patients would have differentiated clinical 
outcome and biological characteristics. 
3. Frontal cortical curvature would be related to frontal structural connectivity. 
4. Structural connectivity would be altered in schizophrenia in comparison to 
healthy controls.  
5. Polymorphisms related to an increased risk of schizophrenia and implicated in 
white matter development and excitatory/inhibitory balance would have an effect on 
functional connectivity in healthy controls. 
6. Polymorphisms associated with increased schizophrenia risk and implicated in 
synaptic transmission and excitatory/inhibitory balance would have a relevant effect on 
functional connectivity principally in patients. 
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Chapter 3 
 
Identification of two clusters within 
schizophrenia with different structural, 
functional and clinical characteristics 
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Abstract 
Several biologically distinct subgroups may coexist within schizophrenia, which may 
hamper the necessary replicability to translate research findings into clinical practice. 
Cortical thickness, curvature and area values and subcortical volumes of 203 subjects 
(121 schizophrenia patients, out of which 64 were first episodes), 60 healthy controls 
and 22 bipolar patients were used to identify clusters using principal components and 
canonical discriminant analyses. Regional glucose metabolism using positron emission 
tomography, P300 event related potential, baseline clinical data and percentage of 
improvement with treatment were used to validate possible clusters based on MRI data. 
All the controls, the bipolar patients and most of the schizophrenia patients were 
grouped in a cluster (cluster A). A group of 24 schizophrenia patients (12 first episodes), 
characterized by large intrinsic curvature values, was identified (cluster B). These 
patients, but not those in cluster A, showed reduced thalamic and cingulate glucose 
metabolism in comparison to controls, as well as a worsening of negative symptoms at 
follow-up. Patients in cluster A showed a significant putaminal metabolic increase, 
which was not observed for those in cluster B. P300 amplitude was reduced in patients 
of both clusters, in comparison to controls.  
Results of this study support the existence of a biologically distinct group within the 
schizophrenia syndrome, characterized by increased cortical curvature values, reduced 
thalamic and cingulate metabolism, a lack of the expected increased putaminal 
metabolism with antipsychotics and persistent negative symptoms.  
3.1. Introduction 
More than 8000 genetic variants may contribute to the risk of suffering from 
schizophrenia 48 and recent research supports schizophrenia subtypes characterized by 
both specific clinical presentation and clusters of genetic variants 58. Considering the 
likely effect of genetic variation upon brain structure 222, distinct groups within 
schizophrenia might be characterized by specific patterns of cerebral alterations. 
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A possible approach to identify such groups is data-driven (a priori independently of 
diagnosis) cluster segregation, starting from plausible cerebral variables: i) previously 
associated with schizophrenia as a group but not unanimously replicated across 
samples, ii) not primarily related to confounders, such as treatment or chronicity, iii) 
with likely genetic influence, iv) associated with neurodevelopment and v) likely related 
to relevant clinical and biological variables.  
Cortical thickness may prove useful to this purpose, since cortical thinning has been 
reported in first-episode (FE) and chronic schizophrenia patients 223 (although not 
unanimously 224) and in antipsychotic naïve patients 225. It is highly heritable 226, with a 
complex relation to genetic background in schizophrenia 227 and early experiences 228. 
Moreover, cortical thickness increases during normal neurodevelopment 229 and has 
been associated with treatment response 230 and cognition 231 in FE patients.  
Cortical curvature measures cortical folding and may reflect different neurobiological 
underpinnings 232. It may contribute to the proposed clustering since higher 233 , normal 
234 and reduced 235 gyrification indexes have been reported in schizophrenia and FE 
patients have also shown altered gyrification 236. Furthermore, gyrification has genetic 
underpinnings 237 and cerebral gyrification takes place largely in the third trimester 238, 
thus, altered gyrification may result from developmental events in this period. Finally, 
gyrification is associated with formation of proper cortico-cortical connections 239. 
The present study has reanalysed data from previous samples assessing cortical 
thickness and curvature in order to blindly investigate clustering of schizophrenia 
patients. Regional cortical area was also included in analyses, since it may convey 
different information than other structural data in schizophrenia 240. In addition, 
subcortical volumes were included, given the caudate and thalamic volume association 
with poor-prognosis schizophrenia 24. Regional cortical volumes were not included since 
they are largely explained by the corresponding area and thickness. In order to validate 
clusters, other data were collected, including clinical (baseline symptoms and variation 
with treatment) and biological (glucose metabolic rate, P300 amplitude and latency) 
parameters. Chronic bipolar subjects were introduced into the analyses to discard 
clusters being primarily related to chronicity and/or treatment. Therefore, rather than 
directly comparing anatomical values depending on clinical diagnosis (schizophrenia, 
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bipolar and healthy controls), our approach was looking for biologically distinct clusters, 
not considering diagnosis a priori as the primary classifying factor. According to our 
hypothesis, clusters identified on the basis of structural alteration would be expected to 
be treatment-independent, associated with clinical outcome and/or presentation and 
associated with other relevant biological markers in order to be considered as valid. 
3.2. Methods and materials 
3.2.1. Sample description 
Sample included 203 subjects: 121 schizophrenia (DSM-IV criteria), patients (64 
patients were FE), 22 chronic bipolar patients and 60 healthy controls. Patients were 
recruited during a psychotic relapse (chronic patients) or first psychotic episode (FE), 
following their admission to a psychiatric short-term unit. After release they were 
treated and followed in an outpatient clinic.  
MRI data were collected over a 15-year period, in the context of several research 
projects ( identification of cerebral correlates of treatment-resistance 241, early stages242 
of schizophrenia, differences between major psychoses 243 and effects of antipsychotics 
on brain structure 244.  
18 chronic schizophrenia patients had been treated prior to inclusion with typical 
antipsychotics, and 39 with atypical antipsychotics. They were included at the time of 
psychotic relapse. 18 bipolar patients were receiving atypical antipsychotics. FE patients 
had received antipsychotic treatment for less than three days prior to MRI.  
Additional data used to validate the hypothesized clusters included: 
- Resting metabolic glucose rates in dorsolateral prefrontal cortex (DLPFC), orbital, 
parietal, occipital and temporal lobes, cingulate, hippocampus, caudate, thalamus and 
pallidum were measured with F18-FDG PET during an attention test, in 64 schizophrenia 
patients (41 FE) and 34 healthy controls. 
- P300 amplitude and latency were measured in 52 schizophrenia patients and 24 
healthy controls. 
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- Clinical status at inclusion was assessed using Positive/Negative Symptoms scale 
in schizophrenia (PANSS) 245. 
- Improvement percentage in 91 schizophrenia patients (40 FE) after 6 months 
follow-up. 
Exclusion criteria included history of substance dependence, any current comorbid 
Axis I diagnosis or psychoactive treatment, serious head trauma or any neurological or 
systemic disorder with known effects on CNS.  
After complete description of the study to the subjects, written informed consent 
was obtained. Full comprehension of the procedures was checked during the consent 
procedure. The research boards of the Hospitals of Salamanca and Doce de Octubre 
endorsed the study. The hospital ethical committee approved the study. All technics and 
procedures were conducted in accordance with the ethical standards of the Helsinki 
Declaration. 
3.2.2. Imaging data collection 
3.2.2.1.MRI 
Description of MRI acquisition is available elsewhere 241,243,244. In summary, 3D SPGR 
T1 MRI studies were acquired using a 1.5 system (159 cases using Philips Gyroscan and 
44 using General Electrics 1.5 scanner). For each subject, a 3D T1 acquisition was 
obtained with following parameters: TR=7.5 ms, TE = 3.5 ms, flip angle= 8º, 0.78 x 0.78, 
FOV = 240 mm × 240 mm, matrix size = 256 × 256, in 70-150 slices (thickness between 
1.5 mm and 3 mm). 
Given their relevance in schizophrenia, the following regions were included in the 
initial clustering analysis (left and right separately): caudal anterior cingulate, caudal 
middle frontal, cuneus, inferior parietal, medial orbitofrontal, parahippocampal, pars 
orbitalis, pars triangularis, precentral, rostral anterior cingulate, rostral middle frontal, 
superior frontal, superior temporal and insula. For each of these regions, thickness, area 
and curvature were calculated using FreeSurfer (http://surfer.nmr.mgh.harvard.edu). In 
addition, subcortical volumes (pallidum, thalamus, caudate and hippocampus) were 
assessed. 
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3.2.2.2. PET acquisition and analyses  
Detailed description of acquisition and quantification is available elsewhere 239,240. In 
summary, PET studies were obtained in SIEMENS Exact 47 tomography, 20 minutes after 
injecting 370 MBq of 18FDG in resting condition. Image values were proportionally 
normalized to global count rate for each PET. To perform metabolic measurements of 
different brain structures, a two step procedure was adopted to co-register MRI and 
PET, hence, defining regions of interest (ROI) onto each subject's Talairach co-ordinate 
system. ROI activity was calculated as the portion of tissue mask contained in the set of 
grid-cells defining the ROI. 
3.2.2.3. P300 
Details are given elsewhere 246. A standard odd-ball paradigm was used and subjects 
were instructed to mentally count the number of target tones. Electroencephalograms 
were recorded from 16 scalp sites, according to 10/20 International System and analyses 
on P300 were performed on Pz site after correction of electrooculogram artifacts. The 
reference was algebraically-linked earlobes. The sampling rate was 250 Hz. 
3.2.3. Statistics  
The analysis followed several stages in order to reduce data noise for the cluster 
search, since not all of MRI variables are useful to generate clusters and clusters may 
not differ in these data. In a first step, Principal Component Analysis (PCA) was 
repeatedly used to summarize information and to obtain simple graphical displays. The 
scores of the first principal components were used to identify outliers, to generate three 
initial groups, one with doubtful cases, and to describe the final clusters. The two initial 
components from this PCA for area, curvature, thickness and subcortical volumes were 
selected, yielding explained variability percentages: 55%(PC1AREA)+4%(PC2AREA) for 
area, 48%(PC1CURV)+7%(PC2CURV) for curvature, 54%(PC1THICK)+7%(PC2THICK) for 
thickness and 57%(PC1SCVOL)+15%(PC2SCVOL) for subcortical volume. 
An algorithm based on canonical discriminant analysis was designed to classify 
doubtful cases. Once these cases were allocated to one of the two clusters, a linear 
discriminant function (LDF) was derived using the whole set of variables as a 
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discrimination index for the clusters. A leave-one-out procedure was used to cross-
validate the classifier function.  
Besides, a PCA for the glucose metabolic rate values was also carried out and the first 
principal component, PC1GLMCR (with percentages of explained variability of 34%) was 
used to summarize metabolism information. 
After having ascribed each subject to a given cluster, we looked for characterizing the 
schizophrenia groups included in these clusters. In order to do so, we compared 
anatomical, metabolic and electrophysiological values between patients in each cluster 
and healthy controls as well as between patients belonging to different clusters. 
Therefore, the differences in parameters used for cluster definition between patients in 
each cluster and healthy controls were assessed and other biological and clinical 
characteristics between patients in each cluster and patients in other cluster(s) and 
healthy controls were compared. Comparision were carried out using the Wilcoxon test 
(significance set at p<0.005).  
Finally, it was considered interesting to evaluate possible relationships between 
structural cluster characteristics and other biological and clinical dimensions. Thus, if a 
given set of structural variables was found to describe a distinct cluster of subjects, its 
relation to other variables significantly different in this cluster as compared to other 
patients was assessed using Pearson´s rho coefficients. 
3.3. Results  
3.3.1. Cluster identification  
The PCA analysis summary and the plots of the first two components for the four 
structural variables are shown in figure 3.1. Scatterplots in figure 3.1 clearly show two 
outliers, which were subsequently eliminated from remaining analyses. Also, from these 
graphs, the PC1CURV (PCA scores in the first factor for curvature) was selected as initial 
index for generating separate clusters. 
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Figure 3.1. Scatter plots of the distribution of the values of the first two principal 
components for curvature, thickness, area and subcortical volume, respectively. Subjects 
are identified by color code. Outliers are marked in red. In the lower row, Scatter plots 
for the three PCs of the total set of MRI markers, showing different symbols for the final 
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cluster and the type of observation. In the three dimensions scatter plot for these PCs, in 
figure 3.1e, the two clusters have been identified with different symbols, showing that 
patients identified primarily on the basis of higher mean curvature also showed globally 
smaller thickness and area. Moreover, in figure 3.1f, the observations have also been 
represented with different symbols for healthy controls, schizophrenia and bipolar 
disorder cases. 
 
In the next step, PC1CURV was used to define three initial clusters: the first included 
19 subjects with very large curvature values (G1: PC1CURV >4.5), the second included 
30 subjects with high to moderate values (G2: 2.0 PC1CURV 4.5) and the third included 
154 subjects with moderate to low values (G3: PC1CURV <2.0). In order to determine 
robust final clusters, an iterative process to allocate, one by one, individuals in G2 was 
designed. For each iteration, a LDF was derived using data from individuals in groups G1 
and G3 and the whole data set. This function was then applied to individuals in G2, 
providing distance measurements to G1 and to G3. Then, the individual in G2 who was 
closest to G1 or G3, using these distances, was incorporated into the closest group for 
subsequent iterations. This process finished when all individuals in G2 were allocated 
into the other two groups (figure 3.2). The final LDF was a combination of standardized 
MRI data, as follows:  
LDF=left superior frontal curvature*0.696+ left inferior parietal curvature*0.486-
right precentral thickness *.468-right caudal middle frontal area *0.269+right caudal 
middle frontal curvature*.346+right inferior parietal curvature*0.616-right caudal 
anterior cingulate curvature*0.324+left pallidum volume*0.238-left parahippocampal 
thickness*0.184-left caudal middle frontal area*0.223. 
At the end of the process, two clusters were determined: 
- Cluster A, including 97 Schizophrenia (52 FE) and all bipolar patients and healthy 
controls (figures 3.1 and 3.3).  
- Cluster B, including 24 Schizophrenia, 12 of them FE patients. 
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The LDF correctly classified, using cross-validation, 100% of the sample individuals in 
clusters A or B. 
 
 
Figure 3.2. Distribution of factor scores for the PCA for curvature (PC1CURV), thickness 
(PC1THICK), and glucose metabolism (PC1GLMCR) in healthy controls (C), cluster A 
schizophrenia patients (SzA) and cluster B schizophrenia patients (SzB). 
 
There were no significant differences in sex distribution between subjects in clusters 
A and B (χ2=0.537, df=1, p=0.463), age (Z=0.470, p=0.639), previous typical or atypical 
treatment (χ2=0.133 p, df=1, p=0.989) or illness duration (Z=-0.68, p=0.946) (Table 3.1). 
Cluster A included 136 subjects assessed with Philips scanner, 43 with 1.5 General 
Electrics, while cluster B included 16 assessed with Philips and 8 with 1.5 GE (χ2=0.84, 
df=1, p=0.24). 
However, there were weakly significant differences in slice thickness between cluster 
A (47: 1.5 mm; 17: 2 mm; 30: 2.20 mm; 87: 3 mm) and cluster B (8: 1.5 mm; 4: 2 mm; 8: 
2.20 mm; 3: 3 mm) (χ2=8.54, df=3, p=0.036). 
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Table 3.1. Demographic, clinical, electrophysiological, and principal component 
values. Values are shown as means with standard deviation, SD, in brackets. Significance 
differences are shown with two types of symbols: *p=0.08, *p=0.05, **p=0.01 and 
***p=0.001 in comparison between schizophrenia clusters; °p=0.05, °°p=0.01, 
°°°p=0.001 in comparison to healthy controls. 
  
Schizophrenia A  Schizophrenia B Bipolar disorder  Healthy controls  
(n=97)  (n=24)  (n=22) (n=60) 
Mean Mean Mean Mean 
Age (years) 31.05 (9.90) 29.79 (15.52) 45.41 (9.89)°°° 29.30 (10.97) 
Sex distribution (F:M) 37:60 11:13 10:12 27:33 
FE/chronic 52:45 12:12 - - 
Typical/atypical treatment (chronic) 12:33 4:08 - - 
Illness duration (months) 54.87 (74.34) 55.87 (106.87) 143.46 (84.96) - 
Area factor scores 0.03 (3.60) -1.76 (6.46)° 0.60 (2.95) 0.44 (3.52) 
Curvature factor scores -0.53 (2.44) 7.20 (3.19)***°°° -2.02 (2.49) -1.28 (1.92) 
Thickness factor scores 0.40 (3.75) -1.12 (3.60)*° -2.90 (2.74)° 0.86 (3.39) 
Subcortical volumen  factor scores 0.17 (2.27) -0.21  (2.96) -0.86 (2.07) 0.12 (2.39) 
  
Schizophrenia A 
n= 48 
Schizophrenia B 
n=16 
- 
Healthy controls  
n=34 
Metabolism factor scores 0.54 (2.76) -1.07 (2.44)***°   0.03 (2.12) 
  
Schizophrenia A 
n=73 
Schizophrenia B 
n=18 
- - 
PANSS-positive 23.69 (6.48) 24.82 (6.90) - - 
PANSS-negative 22.53 (8.97) 20.78 (8.91) - - 
PANSS-general 42.86 (11.34) 44.61 (11.18) - - 
PANSS-p (% improvement) 40.59 (25.30) 44.15 (28.76) - - 
PANSS-n (% improvement) 16.51 (22.86) -9.26 (61.59)* - - 
PANSS-g (% improvement) 27.38 (23.32) 26.67 (30.44) - - 
  
Schizophrenia A 
n=40 
Schizophrenia B 
n=12 
- 
Healthy controls  
n=24 
P300 amplitude in µV 6.17 (4.61)°°° 8.42 (5.02)° - 11.72 (2.72) 
P300 latency in ms 310.40 (100.95) 302.00 (106.99) - 324.00 (30.55) 
 
Thus, to test if slice thickness played a major role in cluster definition two issues were 
addressed: i) It was verified that after withdrawing cases with 3 mm slice thickness, PCA 
yields quite similar outputs to those obtained using the whole sample. In particular, both 
clusters are clearly separated in the new 3-dimensional PCA scatterplot (figure S3.1) and 
ii) It was shown that there were not significant differences between means across the 
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slice thickness groups using the LDF, an index that completely separates the clusters, 
(figure S3.2). Therefore, slice thickness can be discarded as a factor in cluster formation 
A final PCA from area, thickness and curvature was conducted to represent the most 
relevant information (figure 3.1). The first three principal components accounted for 
22%, 16%, and 14% of the variance, respectively. From this graphical representation, the 
same cluster of cases may be identified, underlining the robustness of the results. 
3.3.2. Cluster validation 
3.3.2.1. Comparison of MRI parameters between patient clusters and healthy 
controls 
3.3.2.1.1. Curvature 
Mean curvature was larger in Cluster B schizophrenia patients compared to healthy 
controls in most regions included in analysis (table 3.2): right caudal anterior cingulate 
(Z=2.97, p=0.003), bilateral caudal middle frontal (left Z=5.97, p<0.0001; right Z=6.32, 
p<0.0001), cuneus (left Z=5.50, p<0.0001; right Z=5.51, p<0.0001), inferior parietal (left 
Z=6.84, p<0.0001; right Z=6.77, p<0.0001), medial orbitofrontal (left Z=4.92, p<0.0001; 
right Z=5.09, p<0.0001),  parahippocampal (left Z=4.98, p<0.0001; right Z=3.43, 
p=0.0006), pars orbitalis (left Z=5.81, p<0.0001; right Z=4.99, p<0.0001), pars triangularis 
(left Z=5.89, p<0.0001; right Z=6.49, p<0.0001), precentral (left Z=6.13 , p<0.0001; right 
Z=6.31, p<0.0001), rostral anterior cingulate (left Z=3.66, p=0.0002; right Z=3.66, 
p=0.0002), rostral middle frontal (left Z=6.64, p<0.0001; right Z=6.80, p<0.0001), 
superior frontal (left Z=6.98, p<0.0001; right Z=6.90, p<0.0001), superior temporal (left 
Z=6.25, p<0.0001; right Z=6.07, p<0.0001) and insula (left Z=3.22, p=0.001; right Z=3.91, 
p<0.0001).  
Cluster A schizophrenia patients only showed larger curvature values in comparison 
to healthy controls in right rostral anterior cingulate (Z= -2.92, p= 0.003) (table 3.2, figure 
3.2). 
3.3.2.1.2. Thickness 
Cluster B schizophrenia patients showed a modest thinning in comparison to healthy 
controls at left caudal anterior cingulate (Z=-3.46, p=0.0005, right superior frontal (Z= -
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3.28, p=0.001), precentral (Z=-3.05 p=0.002) and right caudal middle frontal (Z=-2.83, 
p=0.0046). 
Cluster A schizophrenia patients showed no thickness differences in comparison to 
healthy controls. 
3.3.2.1.3. Area 
In comparison to healthy controls, neither cluster B nor cluster A schizophrenia 
patients showed a significant difference in area values.  
3.3.2.1.4. Subcortical volumes 
Neither type A nor type B patients showed significant subcortical volume differences 
in comparison to healthy controls (Supplementary table 3.1). 
3.3.2.2. Comparison of other parameters between clusters of schizophrenia 
patients  
3.3.2.2.1. Resting metabolism 
Cluster B patients had significantly smaller glucose metabolism than cluster A 
schizophrenia patients in left thalamus (Z=-3.03. p=0.002) and left caudate (Z=-2.87. 
p=0.004) (figure 3.2. table 3.3).  
3.3.2.2.2. P300 parameters 
There was no significant effect of cluster on P300 parameters (table 3.1). 
3.3.2.2.3. Clinical data 
Baseline scores did not differ between patient clusters (table 3.1). However, cluster 
A schizophrenia patients showed a modest improvement in negative symptoms, while 
cluster B schizophrenia patients exhibited a modest worsening at follow-up (Z=-1.74. 
p=0.08). 
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Table 3.2. Cortical curvature, thickness and area values for every cluster. The data are shown as means and standard deviation in 
brackets. Significance differences are shown with two types of symbols, each one with three categories: *p=0.005, **p=0.001 and 
***p=0.0001 in comparison between schizophrenia clusters; °p=0.005, °°p=0.001, and °°°p=0.0001 in comparison to healthy controls  
  Schizophrenia A (n= 97) Schizophrenia B (n=24) Bipolar disorder (n=22) Controls (n=60) 
  Left Right Left Right Left Right Left Right 
  Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
Cortical curvature (1/mm)                                 
Caudal anterior cingulate  0.15 0.02 0.16 0.01 0.16 0.02 0.17° 0.02 0.15 0.02 0.15 0.01 0.15 0.01 0.15 0.01 
Caudal middle frontal 0.15 0.01 0.15 0.01 0.17***°°° 0.02 0.18***°°° 0.01 0.15 0.01 0.14 0.01 0.15 0.01 0.15 0.01 
Cuneus 0.17 0.02 0.17 0.01 0.19***°°° 0.02 0.19***°°° 0.03 0.16 0.01 0.16 0.01 0.17 0.01 0.17 0.01 
Inferior parietal 0.15 0.01 0.15 0.01 0.17***°°° 0.01 0.17***°°° 0.01 0.14 0.01 0.14 0.01 0.15 0.01 0.15 0.01 
Medial orbitofrontal 0.17 0.01 0.17 0.02 0.18***°°° 0.02 0.18**°°° 0.02 0.16 0.01 0.15 0.01 0.16 0.01 0.16 0.01 
Para hippocampal 0.14 0.02 0.14 0.02 0.17***°°° 0.03 0.16**°° 0.03 0.14 0.02 0.14 0.02 0.14 0.02 0.14 0.02 
Pars orbitalis 0.18 0.02 0.18 0.02 0.21***°°° 0.02 0.22***°°° 0.04 0.19 0.03 0.18 0.03 0.18 0.02 0.18 0.01 
Pars triangularis 0.15 0.01 0.15 0.01 0.18***°°° 0.02 0.18***°°° 0.02 0.15 0.02 0.15 0.01 0.15 0.01 0.15 0.01 
Pre central 0.15 0.01 0.15 0.01 0.18***°°° 0.02 0.18***°°° 0.02 0.15 0.01 0.15 0.01 0.15 0.01 0.15 0.01 
Rostral anterior cingulate 0.15 0.01 0.15 0.02° 0.17**°° 0.02 0.16°° 0.02 0.15 0.01 0.15 0.02 0.15 0.01 0.15 0.01 
Rostral middle frontal 0.17 0.01 0.17 0.01 0.19***°°° 0.01 0.19***°°° 0.02 0.16 0.01 0.17 0.01 0.16 0.01 0.17 0.01 
Superior frontal 0.15 0.01 0.16 0.01 0.18***°°° 0.01 0.18***°°° 0.01 0.15 0.01 0.15 0.01 0.15 0.01 0.15 0.01 
Superior temporal 0.14 0.01 0.15 0.02 0.17***°°° 0.01 0.17***°°° 0.02 0.14 0.02 0.14 0.01 0.14 0.02 0.14 0.01 
Insula 0.14 0.02 0.16 0.02 0.16**° 0.02 0.18***°°° 0.02 0.15 0.03 0.16 0.01 0.15 0.02 0.16 0.02 
Cortical thickness (mm)                                 
Caudal anterior cingulate  2.77 0.32 2.78 0.30 2.57°° 0.28 2.65 0.28 2.72 0.40 2.69 0.34 2.87 0.35 2.79 0.29 
Caudal middle frontal 2.42 0.21 2.41 0.19 2.37 0.22 2.30° 0.19 2.25 0.20 2.26 0.16 2.44 0.21 2.45 0.20 
Cuneus 1.79 0.15 1.82 0.18 1.82 0.30 1.88 0.37 1.73 0.17 1.74 0.16 1.76 0.17 1.78 0.19 
Inferior parietal 2.30 0.15 2.36 0.15 2.24 0.20 2.29 0.21 2.24 0.13 2.28 0.17 2.30 0.17 2.36 0.17 
Medial orbitofrontal 2.52 0.24 2.50 0.22 2.52 0.26 2.52 0.33 2.42 0.18 2.46 0.24 2.56 0.23 2.52 0.25 
3.3. Results - 47 - 
Para hippocampal 2.49 0.39 2.45 0.31 2.22** 0.27 2.27 0.25 2.27 0.29 2.29 0.21 2.42 0.37 2.38 0.29 
Pars orbitalis 2.53 0.32 2.49 0.30 2.48 0.38 2.47 0.40 2.18 0.25 2.28 0.27 2.52 0.29 2.48 0.26 
Pars triangularis 2.39 0.21 2.38 0.18 2.37 0.26 2.35 0.27 2.26 0.23 2.24 0.17 2.40 0.22 2.41 0.19 
Pre central 2.36 0.21 2.34 0.21 2.26 0.21 2.22° 0.21 2.12 0.17 2.12 0.15 2.38 0.19 2.38 0.19 
Rostral anterior cingulate 2.92 0.27 2.92 0.31 2.79 0.33 2.81 0.27 2.70 0.25 2.73 0.27 2.98 0.29 2.98 0.28 
Rostral middle frontal 2.27 0.21 2.27 0.19 2.30 0.25 2.30 0.24 2.10 0.15 2.13 0.16 2.30 0.20 2.30 0.19 
Superior frontal 2.66 0.22 2.64 0.19 2.57 0.20 2.55° 0.19 2.47 0.17 2.48 0.19 2.71 0.21 2.72 0.17 
Superior temporal 2.51 0.23 2.51 0.24 2.38 0.23 2.40 0.23 2.42 0.14 2.38 0.16 2.53 0.21 2.54 0.21 
Insula 2.99 0.20 2.94 0.22 2.89 0.22 2.84 0.23 2.91 0.15 2.79 0.21 2.98 0.23 2.96 0.21 
Cortical área (mm2)                                 
Caudal anterior cingulate  632.62 139.79 729.54 142.59 571.29 157.54 687.79 244.84 628.77 128.40 748.68 150.36 626.67 114.51 739.75 145.81 
Caudal middle frontal 2.381.29 359.56 2.167.52 398.71 2.153.75 577.70 2.026.25 533.28 2.477.14 419.05 2.344.91 432.70 2.396.33 453.16 2.169.42 387.07 
Cuneus 1.387.10 219.80 1.472.12 231.63 1.265.58 311.53 1.334.46 319.46 1.374.59 195.19 1.404.32 157.84 1.379.72 175.41 1.486.77 208.20 
Inferior parietal 4.440.72 628.73 5.209.14 751.45 4.433.08 1.123.59 5.029.42 1.308.08 4.477.73 604.67 5.509.41 767.63 4.640.20 731.46 5.355.18 733.19 
Medial orbitofrontal 1.816.48 281.29 1.743.64 255.91 1.660.25 418.44 1.588.88 424.38 1.866.64 279.29 1.681.00 219.34 1.866.13 279.40 1.745.07 260.98 
Para hippocampal 683.45 89.71 662.40 102.73 740.58 269.44 644.04 163.61 693.45 88.07 680.18 64.93 705.28 145.30 693.97 105.60 
Pars orbitalis 637.27 100.65 784.49 126.28 583.21 138.21 733.67 183.66 667.50 128.40 796.09 145.89 654.53 77.70 797.40 108.49 
Pars triangularis 1.269.51 210.75 1.502.27 274.46 1.180.21 236.31 1.359.33 331.85 1.296.41 255.93 1.485.77 272.32 1.292.13 219.88 1.441.08 229.32 
Pre central 5.028.60 697.27 4.988.73 640.53 4.917.42 1.018.04 4.864.04 971.81 5.268.48 526.22 5.332.14 608.46 5.068.40 616.95 5.093.12 621.59 
Rostral anterior cingulate 773.69 151.86 630.25 133.77 677.50 224.54 560.88 210.02 804.48 166.56 617.23 130.69 791.17 148.86 601.90 140.65 
Rostral middle frontal 5.743.54 968.99 5.896.24 925.88 5.122.29 1.635.49 5.299.54 1.628.71 5.933.90 763.35 6.204.09 1.005.00 5.888.22 843.59 5.977.92 840.58 
Superior frontal 7.256.28 983.44 6.952.41 959.53 7.045.33 1.628.92 6.585.71 1.475.44 7.425.14 823.80 7.067.59 930.96 7.313.22 988.94 6.991.13 874.27 
Superior temporal 3.701.63 488.21 3.439.22 431.27 3.572.38 821.71 3.311.13 715.76 3.793.19 460.08 3.687.41 510.54 3.753.40 549.13 3.510.15 470.87 
Insula 2.103.54 280.38 2.204.28 311.98 2.134.92 382.14 2.171.50 390.55 2.192.67 232.70 2.371.50 347.38 2.140.32 244.24 2.231.53 322.35 
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Table 3.3. Metabolic activity values. The data are shown as means and standard 
deviation in brackets. Significance differences are shown with two types of symbols, each 
one with three categories: * p <0.005, ** p <0.001 and *** p <0.0001 in comparison 
between schizophrenia clusters; ° p< 0.005, °° p< 0.001, °°° p< 0.0001 in comparison to 
healthy controls 
 
3.3.2.3. Comparison of other parameters between clusters of schizophrenia 
patients and healthy controls. 
3.3.2.3.1. Glucose metabolism 
Cluster B patients showed significantly reduced left cingulate (Z=-2.98. p=0.003) and 
left thalamic (Z=-2.85, p=0.004) activity in comparison to healthy controls. 
Cluster A schizophrenia patients showed a significantly larger putaminal (Left Z= 3.78, 
p=0.0001; Right Z=4.14, p<0.0001) metabolism than healthy controls (figure 3.3).  
Both A and B clusters showed a significantly larger metabolic activity in right parietal 
grey matter (Cluster A Z=-3.05, p=0.002; Cluster B Z=2.98, p=0.003) in comparison to 
healthy controls (table 3.3). 
3.3.2.3.2. P300 parameters 
Patients in the two clusters showed significant decrease in P300 amplitude, but not 
in latency (Cluster A: Z=4.98, p<0.001; Cluster B: Z=-2.39, p=0.016) (table 3.1). 
Metabolic activity Schizophrenia A (n= 48) Schizophrenia B (n=16) Controls (n=34) 
 Left  Right   Left  Right   Left  Right  
  Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
Cingulus 101.68 6.05 101.50 6.22 97.49° 3.92 98.37 4.93 101.98 5.06 101.51 4.84 
Superior temporal gyrus 96.75 4.81 98.26 3.51 97.06 4.37 98.51 4.09 98.36 3.53 97.66 4.04 
Frontal grey matter 104.28 3.28 106.98 3.41 104.33 5.37 106.41 4.03 106.71 3.48 107.77 3.42 
Occipital grey matter 104.10 3.91 103.39 4.33 107.31 4.39 106.75 4.99 105.62 3.74 104.76 3.52 
Orbital grey matter 96.61 4.50 96.43 4.45 94.06 4.80 93.44 5.38 97.47 4.23 96.52 4.14 
Parietal grey matter 103.59 2.71 104.56° 3.39 103.65 3.45 105.42° 4.53 102.15 2.80 102.01 2.64 
Total temporal GM 91.61 2.81 92.16 2.29 91.62 3.47 91.74 3.25 91.59 3.13 91.42 3.13 
Pallidum putamen 117.78°° 9.49 118.39°°° 9.15 112.78 9.45 114.61 10.98 109.68 8.79 108.97 8.69 
Thalamus 102.25 8.56 103.04 9.05 95.16*° 6.50 97.00 6.41 101.63 7.57 101.36 7.13 
Caudate 108.95 11.82 109.91 11.12 99.69* 11.43 102.79 10.79 104.61 8.56 105.16 8.17 
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3.3.2.4. Association between curvature, metabolism and clinical variables 
There was a significant association between PC1CURV (explaining most of curvature 
variance) and PRINM1 (explaining most of metabolism variance). The relation was 
negative (rho= -0.326. p=0.001). Thus, larger curvature values were associated with 
lower metabolic activity in the regions included in the study.  
There was a weak association between PC1CURV and improvement on negative 
symptoms (more curvature, less improvement; rho=-0.245, n=64, p=0.05). Basal 
symptoms were unrelated to curvature. 
3.4. Discussion  
A function, mostly contributed by cortical curvature, segregated 20% of subjects 
within the schizophrenia group (cluster B), who also showed a more modest cortical 
thinning and hypometabolism in the left cingulate and thalamus, together with 
persistent negative symptoms. Cluster A schizophrenia patients showed normal 
structure but higher putaminal glucose metabolism than healthy controls. Metabolism 
and clinical improvement were negatively related to curvature. All bipolar and healthy 
controls subjects were grouped within schizophrenia cluster A. Therefore, clear, 
qualitative differences in potentially relevant biological parameters were observed 
between syndromically-similar patients. 
This study’s findings are in partial agreement with Crow´s theory of two syndromes 
in schizophrenia 247. Type B in the current study overlaps partly with Crow´s type II (poor 
treatment response, structural abnormalities). However, Type A and B patients within 
this study did not differ in basal symptoms and seemed to correspond to different 
patients. In Crow’s theory, structural abnormalities centred around ventricular volumes 
247, however, our study used MRI parameters less dependent on cranial size. This 
approach has the advantage of being data-driven, where all cases were introduced a 
priori into the clustering analyses, without taking into consideration patients’ diagnoses.  
A number of schizophrenia patients (schizophrenia cluster A) showed significantly 
increased curvature, which correlates with reports of high 233, normal 234 and reduced 
235 gyrification within this syndrome. The relevance of this structural alteration is 
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underlined by reduced subcortical metabolism within this group and its equal 
proportion within FE and chronic patients. An alteration in cortical gyrification in 
schizophrenia may reflect neurodevelopmentally-determined disturbed connectivity 
248. In particular, short-range connectivity secondary to under-developed expansion of 
upper cortical layers 249. This may warrant the interest of assessing cortical folding in 
relation to measures of functional connectivity found to be altered in schizophrenia 96. 
Increased curvature has been related to white matter pathology 250, and myelin 
alteration may be found in some schizophrenia patients 251, which, according to this 
study’s data, may be speculatively more characteristic of cluster B schizophrenia 
patients.  
Furthermore, only cluster A showed a significant increase of putaminal activity. Since 
antipsychotics induce putaminal metabolic increase 252, and their absence is reportedly 
related to bad prognosis in schizophrenia 253, as well as to resistance to clozapine 254, the 
lack of this expected putaminal hyperactivation may characterize a biologically-discrete 
schizophrenia subtype along with persistent negative symptoms and increased mean 
curvature, according to this study’s results. 
Other metabolic findings in cluster B were reduced metabolism in the left anterior 
cingulate and thalamus. Metabolic activity was negatively associated with curvature, 
suggesting a common underpinning for structural and metabolic abnormalities. 
Cingulate hypometabolism has also been reported in chronic 255 and unmedicated 256 
schizophrenia. Thalamic hypoactivity distinguishes between patients that have or have 
not responded to clozapine 254. 
Contrary to our hypothesis, cortical thickness was less efficient in cluster definition 
than curvature. Since most of the treatment-resistant patients were discarded because 
of poorer MR quality, it cannot be discarded that such cases may show larger thinning. 
Moreover, the classificatory power of cortical thickness might be blurred by 
antipsychotics, since these drugs may reduce grey matter volumes 257.  
Most schizophrenia patients, as well as all the bipolar ones, clustered together with 
healthy controls. This may have consequences upon the interpretation of research 
results in the field, since the joint consideration of (at least) clusters A and B may obscure 
their respective particular characteristics. This may lead to the erroneous conclusion 
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that abnormalities such as abnormal folding or thalamic and cingulate hypoactivity are 
uncharacteristic of schizophrenia, since they might only be found in a subtype within 
that syndrome. A recent report has shown disjoint associations between networks of 
SNPs sets and clinical phenotypes 58. Two of these SNPs clusters were associated with 
severe process (respectively with positive or with negative and positive symptoms), 
hence supporting the possibility of uncovering the genetic background of at least some 
of the subgroups here identified.  
The present study has several limitations. Sample size is low and perhaps larger 
samples may reveal further valid clusters in schizophrenia and bipolar patients. 
Metabolic and electrophysiological data were available only for a subset of cases, as well 
as clinical outcomes. Moreover, it would be of great interest to have collected cognitive 
assessments measurements of daily functioning and a larger sample, especially of never-
treated patients, as well as other biological parameters, such as neuronal and glial 
markers. Slice thickness differed between 1.5 and 3 mm, but its influence on cluster 
definition seemed negligible and this may facilitate the clinical usefulness of the found 
subtypes, since it may not depend on particular acquisition parameters. 
As a conclusion, the variability here described (patients with and without cortical 
thinning and/or mean curvature associated with other features) may contribute to 
explain the still insufficient replication of imaging findings in schizophrenia. We propose 
the segregation within the schizophrenia syndrome of patients with large cortical 
curvature, persistent negative symptoms, thalamic and cingulate hypoactivity and a lack 
of putaminal metabolic increase with antipsychotics, which may constitute a focus for 
genetic research. Biologically-based subtypes may, therefore, offer a new framework for 
the identification of substrates of the illnesses included in the schizophrenia syndrome. 
Although at the current stage the possibility that our findings may have clinical utility 
remains preliminary, similar classifications may be useful in the near future to identify 
novel therapeutic targets in some of the schizophrenia clusters. 
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3.5. Supplementary materials  
Supplementary table 3.1. Subcortical volumes values. The data are shown as mean and standard deviation in brackets. There were no 
significant differences in any comparison  
Subcortical  Schizophrenia A (n=97) Schizophrenia B (n=24) Bipolar disorder (n=22) Controls (n=60) 
volume  Left Right Left Right Left   Right Left Right 
(mm3) Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
Thalamus 7961,1 1052,6 7065,4 851,27 7752,8 1304,8 6914,5 1103,5 8492,1 1175,9 7110,3 730,8 8064,6 1097,1 7196,1 849,75 
Caudate 3573,3 459,73 3699,4 500,99 3592,5 656,1 3718,5 709,27 3159,3 466,63 3302 544,27 3525,7 562,13 3740,1 586,56 
Putamen 5518,9 843,82 5371,1 782,76 5413,5 919,98 5244,9 931,57 4919,4 813,02 4879,3 698,41 5349,6 801,08 5222,7 766,71 
Pallidum 1625,4 349,07 1700,5 316,32 1648,6 466,72 1615,1 382,65 1405,8 267,68 1505,1 241,84 1612,0 305,75 1672,3 305,31 
Hippocampus 4357,2 446,97 4216,2 444,46 4205,2 562,81 4152,6 520,95 4476,3 508,46 4350,1 422,96 4377,3 482,22 4277,4 468,58 
 Mean SD Mean SD Mean SD Mean SD 
Total intra cranial 1,464,170.66 163,422.41 1,425,946.68 208,747.12 1,473,039.08 171,538.27 1,477,008.32 157,357.41 
                 
.
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Supplementary figure 3.1. 
Scatterplot for the three PCs 
of the total set of MRI 
markers excluding those 
magnetic resonance whose 
slice thickness were 3mm. 
 
 
 
Slice thickness Mean Confidence 
comparison differences  interval 
2 - 2.2 0.08 -11.92 13.67 
2 - 1.5     0.19 -10.11 14.10 
2 -3 0.88 -0.26 20.29 
2.2 - 1.5  0.11 -0.88 11.09 
2.2 - 3  0.79 -0.12 17.13 
1.5 - 3 0.68 -0.13 15.02 
 
Supplementary figure 3.2. Distribution of the LDF in the groups defined by the slice 
thickness values: 1.5, 2, 2.2 and 3, and pairwise comparisons using Tukey test, no 
differences were found. 
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Abstract 
Mean cortical curvature may relate to cortico-cortical connections integrity. We 
explored the association between prefrontal (PFC) cortical curvature and fractional 
anisotropy (FA) values for tracts connecting PFC and relevant cortical regions. 
 In schizophrenia Anatomical and diffusion magnetic resonance images were 
obtained from 34 patients (16 of them first-episodes) and 32 healthy controls. We 
calculated curvature at rostral lateral prefrontal (RLPF) and superior medial prefrontal 
(SMPF) areas and mean FA for the tracts respectively connecting RLPF and SMPF areas 
with anterior caudal cingulate (ACC), superior temporal gyrus (STG) and superior parietal 
SP regions. Cognitive and clinical data were collected, including baseline symptoms, 
clinical global impression change scores from baseline to follow-up, illness duration and 
treatment dosage. 
Patients showed significantly lower FA values in the tracts linking right RLPF-ACC, 
right SMPF-SPG and bilaterally PFC-STG. FA values mainly in short-range cortico-cortical 
connections (linking PFC-ACC) were inversely associated with PFC curvature. In patients, 
cognitive performance was negatively associated with PFC curvature. Larger curvature 
values were associated with a lack of clinical improvement at follow-up.  
We conclude that cortical curvature is influenced by integrity in short cortico-cortical 
connections and relates to cognition and clinical outcome in schizophrenia patients.
4.1. Introduction  
The diversity of clinical manifestations of schizophrenia, together with the low 
replicability of biological findings and the diversity of genetic underpinnings in that 
syndrome has led to proposals to divide schizophrenia into biologically homogeneous 
clusters 247. Recently, hyperdopaminergia 151, white matter abnormalities 35 and genetic 
profiles 58  have been proposed as biological traits identifying distinct clusters of patients 
within the schizophrenia syndrome. Moreover, using network measurements and 
cortical thickness, deficit-type schizophrenia patients showed an increased density of 
connections relative to non-deficit patients 258. These findings support the relevance of 
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anatomical connectivity for disentangling the variability in biological abnormalities in 
schizophrenia, since a significant decrease in that parameter might characterize a cluster 
of patients with a relatively distinct clinical and/or cognitive profile. 
In this line, we recently reported the identification of a cluster of schizophrenia 
patients (including the same proportion of chronic and first episode cases) characterized 
by larger mean curvature values across most regions of the cortex 259. This cluster was 
also different form the rest of cases in other parameters, i.e: i) a lack of the expected 
increase in striatal glucose metabolism produced by antipsychotics, ii) reduced thalamic 
and cingulate metabolism and iii) worsening of negative symptoms in the follow-up.  
Cortical curvature has been considered a marker related to cortico-cortical 
connectivity, in particular short-range connections 249. Tracts connecting nearby areas 
on the cortical surface have U-fibers (short association fibres with a curve shape), while 
major tracts (such as inferior and superior longitudinal fascicles) have straight cores 260. 
Although this relationship is still a matter of discussion, from that hypothesis can be 
predicted that white matter deficits would be reflected in higher curvature values 232. 
Therefore, the cluster we identified could be also characterized by a deficit of short-
range structural connectivity among relevant cortical regions. It seems thus of interest 
to test the possible association between cortical curvature and structural connectivity 
in schizophrenia, which could contribute to further characterize a possible schizophrenia 
subtype. To do so, we investigated the correlates of cortical curvature in a new 
schizophrenia sample using diffusion magnetic resonance imaging (dMRI). Cognitive and 
clinical data were included, and we tested the possible influence of illness duration and 
antipsychotic treatment upon curvature. We focused on the prefrontal lobe and its more 
relevant connections, given the previous connectivity and folding alterations reported 
for this region in schizophrenia 66,261,262 and in particular the recent identification of 
white matter alterations in specific tracts connecting this region 142 and the larger 
gyrification 263 or curvature values reported for the same region in schizophrenia 259. 
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4.2. Subjects and methods 
4.2.1. Patients 
The sample included 34 schizophrenia patients (16 of them were first-episode (FE) 
and 33 healthy controls (table 4.1). Participants were fully informed about the study and 
provided written informed consent. None of these subjects was included in our former 
report on schizophrenia sub-classification 259 but they include the subjects that 
participated in a previous report on structural prefrontal connectivity assessed with 
dMRI 264. 
Inclusion criteria for patients were schizophrenia diagnosis made by an expert 
clinician (V.M.) according to the criteria in the Diagnostic and Statistical Manual of 
Mental Disorders, 5th edition; and for the FE patients, illness duration of less than one 
year. All patients were on stable doses of atypical antipsychotic treatment. Symptoms 
were scored using the Positive and Negative Syndrome Scale (PANSS) 245. Clinical Global 
Impression change was scored to assess the patient’s global improvement, from 1 (large 
improvement) to 7 (large worsening). Improvement by this method was scored by the 
treating psychiatrist, when available, after 3 to 6 months of follow-up. 
Exclusion criteria were: (i) intelligent quotient under 70; (ii) past or present substance 
abuse (except caffeine and nicotine); (ii) cranial trauma with loss of consciousness longer 
than one minute; (iv) for patients, any other mental or neurological diagnosis, and (v) 
for controls, any current neurological or psychiatric diagnosis or any treatment affecting 
central nervous system. 
The study complied with the ethical standards of the Helsinki Declaration and was 
approved by the ethical committee of the University Hospital of Valladolid. 
4.2.2. Cognitive assessment 
Global IQ was assessed using a Spanish brief version of the Wechsler Adult 
Intelligence Scale WAIS-III 265. We used the Spanish version of Brief Assessment in 
Cognition in Schizophrenia Scale (BACS) 266, to assess performance in verbal memory (list 
learning), working memory (digit span), motor speed (token motor task), verbal fluency 
(categories), attention and processing speed (symbol coding) and executive function and 
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problem solving (Tower of London), as well as the Wisconsing Card Sorting Test (WCST; 
percent of perseverative errors).  
4.2.3. Diffusion MRI acquisition and processing 
Acquisitions were carried out using a Philips Achieva 3 Tesla MRI unit (Philips 
Healthcare, Best, The Netherlands) in the MRI facility at Valladolid University, and 
consisted of T1-weighted and diffusion weighted images. 
For the anatomical T1-weighted images, acquisition parameters included: turbo field 
echo (TFE) sequence, 256 x 256 matrix size, 1 x 1 x 1 mm3 of spatial resolution and 160 
slices covering the whole brain. 
With regard to the diffusion weighted images, the parameters of the acquisition 
protocol were the following: 61 gradient directions, one baseline volume, b-value = 1000 
s/mm2, 2 × 2 × 2 mm3 of voxel size. 128 × 128 matrix and 66 slices covering the entire 
brain. Total acquisition time was 18 minutes. Both T1 and diffusion weighted images 
were obtained in the same session and in the same order (T1 followed by diffusion). The 
total acquisition time refers to the whole T1+DWI protocol. 
MRI were processed in order to obtain cortical curvature and connectivity matrices. 
From the anatomical images, non-brain structures were first removed using the brain 
extraction tool from FSL (http://fsl.fmrib.ox.ac.uk) 267. Next, automatic cortical 
reconstruction was performed using FreeSurfer (http://surfer.nmr.mgh.harvard.edu). 
From this cortical segmentation, mean radial curvature (defined as the inverse of the 
radius of the circumference inscribing each gyrus) was calculated, also using FreeSurfer, 
at superior frontal and rostral middle frontal regions (figure 4.1). 
Grey matter, white matter and CSF were also separated, and subcortical grey matter 
structures were obtained using “fast” and “first” utilities from FSL. respectively 268,269. 
These structures were combined to form a “five-tissue-type” image (5tt) using “5ttgen” 
from MRtrix (www.mrtrix.org). The cortical segmentations provided by Freesurfer were 
visually inspected. 
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Figure 4.1. Location of the areas selected for cortical curvature (rostral lateral 
prefrontal (RLPF, in red) and superior medial prefrontal (SMPF, in blue)) and fractional 
anisotropy (tracts: RLPF- Superior temporal gyrus (STG, in yellow). RLPF- Superior 
parietal cortex (SP, in green), RLPF-Anterior caudate cingulate cortex (ACC, in orange). 
SMPF-STG. SMPF-SP and RLPF-ACC) calculation. 
 
From the diffusion weighted images (DWIs), non-nervous tissue components (CSF, 
meninges, bone) were removed using “dwi2mask" tool from MRtrix 270. Afterwards, also 
employing MRtrix, orientation distribution functions were estimated from the diffusion 
data using spherical deconvolution 271, and anatomically-constrained tractography was 
carried out 272 using the diffusion data and the 5tt image obtained from the T1-weighted 
anatomical images (after registration), 2.000.000 streamlines per subject were obtained 
following this procedure. 
In parallel, diffusion tensors at each voxel were estimated using a least squares 
method 273, and scalar FA (fractional anisotropy) volumes were computed from the 
tensor volumes. FA is a well-known descriptor of brain diffusion that has been widely 
employed in the literature. It measures the amount of anisotropy in the diffusion tensor, 
that is, how much it deviates from a totally isotropic diffusion. 
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Connectome matrices were computed from the tractography output and the 
(registered) cortical segmentation volumes. 84x84 connectivity matrices were obtained 
using mean FA as a connectome metric. A diagram of the processing pipeline is shown 
in figure 4.2.  
Our primary hypothesis was that FA in short-range connections would show a 
significant association with frontal curvature values. To evaluate the specificity of this 
possible relationship we assessed FA in short- (to anterior cingulate) and long-range (to 
superior parietal and superior temporal gyrus). Thus, from the connectivity matrices, FA 
was analyzed only in a priori selected pairwise cortico-cortical bilateral connections 
between superior-medial prefrontal (SMPF) and rostral lateral prefrontal (RLPF) cortex 
and, on the other hand, caudal anterior cingulate cortex (ACC), superior temporal gyrus 
(STG) and superior parietal gyrus (SPG) cortex (figure 4.1).  
4.2.4. Statistics 
We compared socio-demographical data (age, sex, education years and parental 
education) between patients and controls (t-test or χ2 tests when appropriate). 
After testing the normality of data distribution using Kolmogorov-Smirnov and 
Levene tests, we compared FA and curvature between patients and controls using t-
tests.  
Our main hypothesis was that FA values in the short-range cortico-cortical 
connections (linking PFC and ACC) would significantly predict mean curvature in the 
prefrontal region (i.e. the characteristics of those connections would significantly 
contribute to individual variability in curvature). Therefore, assuming that connectivity 
would drive variation in curvature, this hypothesis was tested using stepwise 
multivariate linear regression models in all subjects as well as in patients group, where 
the independent variables were the FA data. In order to avoid collinearity effects on 
regression, a principal component analysis (PCA) was first performed using individual FA 
variables of all subjects for the selected tracts (SMPF and RLPF with ACC, STG and SPG). 
Eigenvalues higher than the unit plus a scree plot yielded the number of factors to be 
selected. The resulting individual factor scores were saved. 
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Figure 4.2. MRI processing pipeline applied to obtain cortical curvature and fractional 
anisotropy. 
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We introduced these scores as independent variables in stepwise multivariate linear 
regression models, where curvature values (SMPF and RLPF, left and right) were the 
dependent variables. We also tested this association in the FE patients alone to study 
the possible effects of chronicity. 
Furthermore, to summarize cognitive performance, we performed PCA again using 
cognitive variables from BACS and WCST. Again, individual factor scores were saved 
after using a scree plot to identify the relevant factors. In this case, since we could not 
assume a causal role for cognition upon curvature, we assessed the significance of the 
association between cognitive performance (i.e., individual factor scores) and curvature 
using Spearman´s rho coefficients. This analysis was performed only on patients, since 
we only expected a significant cognitive deficit in the patients’ group.  
The relation between duration, symptoms (PANSS scores), treatment dosage (mg/d 
in chlorpromazine (CPZ) equivalents) and curvature was explored using Spearman 
correlation coefficients.  
Finally, we tested the association between curvature and clinical outcome by 
comparing with U-Mann Whitney tests the curvature values between cases where 
Clinical Global Impression -change scores were lower than 4 (mild to large improvement) 
with those with scores equal or larger than 4 (no change or worsening). 
4.3. Results  
4.3.1. Demographic data 
There were no significant differences between patients and controls in sex (X2=0.16, 
df=1, p=0.68), and age (t=-0.51, df=65, p=0.61). Nevertheless, the controls had 
significantly more years of education than patients (t=-3.05, df=57, p=0.003), but the 
difference in parental education between groups was not statistically significant (t=-
1.28, df=56, p=0.21) (table 4.1). 
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Table 4.1. Demographic, clinic, cognitive, curvature and FA data are shown for 
patients, FE and controls. Significant differences with controls: *p<0.05, ** p<0.01, 
***p=0.001 
  
Schizophrenia 
(n=34) 
First-episode 
(n=16) 
Controls (n=33) 
  Mean (SD) Mean (SD) Mean (SD) 
Age 34.26 (9.98) 28.56 (7.77)* 35.61 (11.52) 
Sex (M:F) 21:14 11:05 22:11 
Education (years) 14.00 (3.52)** 15.25 (3.04) 16.62 (2.90) 
Parental education (years) 10.41 (4.50) 12.60 (4.37) 12.00 (4.87) 
Intelligence coefficient 94.18 (11.90)*** 90.58 (11.98)*** 115.93 (10.79) 
Illness duration (months) 93.59 (118.75) 8.62 (11.09) - 
CPZ equivalents (mg) 396.48 (236.55) 393.33 (265.33) - 
PANSS positive 11.47 (3.43) 10.44 (2.1) - 
PANSS negative 15.63 (5.072) 13.88 (3.14) - 
PANSS total 49.09 (12.70) 42.25 (6.7) - 
Verbal memory (L.L) 35.30 (12.12)*** 37.38 (13.74)*** 50.56 (8.98) 
Working memory (D.S) 16.76 (4.41)*** 18.08 (4.58)** 22.93 (2.67) 
Motor speed (M.T) 61.34 (13.45)*** 61.42 (9.44)*** 83.93 (11.02) 
Verbal fluency 19.30 (4.86)*** 18.56 (5.38)*** 29.24 (5.41) 
Attention and processing speed (S.C) 44.45 (15.78)*** 51.75 (12.63)*** 69.96 (15.13) 
Executive function/problem solving (T.L) 16.14 (16.81) 16.17 (2.76) 16.81 (2.7) 
WCST perseverative errors (%) 20.79 (17.58)*** 15.99 (9.94)** 9.46 (5.32) 
PCA-F1 -0.22 (0.92) 0.29 (0.61) 0.24 (1.06) 
PCA-F2 -0.17 (1.07) 0.06 (0.89) 0.16 (0.9) 
printCG1 -0.79 (0.72)*** -0.61 (0.55)*** 0.76 (0.51) 
Curvature left RLPF (mm-1) 0.15 (0.01) 0.15 (0.01) 0.15 (0.01) 
Curvature left SMPF (mm-1) 0.13 (0.01) 0.13 (0.01) 0.13 (0.00) 
Curvature right RLPF (mm-1) 0.15 (0.01) 0.15 (0.01) 0.15 (0.01) 
Curvature right SMPF (mm-1) 0.13 (0.01) 0.13 (0.01) 0.13 (0.00) 
FA left RLPF-ACC 0.41 (0.03) 0.42 (0.03) 0.42 (0.03) 
FA right RLPF-ACC 0.43 (0.04)* 0.44 (0.04) 0.45 (0.04) 
FA left SMPF-ACC 0.37 (0.04) 0.37 (0.04) 0.38 (0.04) 
FA right SMPF-ACC 0.40 (0.04) 0.41 (0.05) 0.39 (0.04) 
FA left RLPF-SP 0.42 (0.03) 0.43 (0.02) 0.44 (0.02) 
FA right RLPF-SP 0.43 (0.03) 0.44 (0.02) 0.44 (0.03) 
FA left SMPF-SP 0.46 (0.02) 0.47 (0.02) 0.47 (0.02) 
FA right SMPF-SP 0.47 (0.02)* 0.48 (0.02) 0.48 (0.02) 
FA left RLPF-STG 0.44 (0.03)* 0.45 (0.02) 0.45 (0.02) 
FA right RLPF-STG 0.45 (0.03)* 0.46 (0.03) 0.46 (0.02) 
FA left SMPF-STG 0.45 (0.02) 0.46 (0.02) 0.45 (0.02) 
FA right SMPF-STG 0.46 (0.02)* 0.46 (0.02) 0.47 (0.02) 
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4.3.2. Curvature and FA comparison 
FA and curvature variables were normally distributed in each group (0.39<Z<1.04, 
0.23<p<1.00). There were no differences in bilateral SMPF or RLPF curvature between 
patients and controls (table 4.1).  
Patients showed significantly lower FA values in right RLPF-ACC (t=-2.11, df=61, 
p=0.039); right SMPF-SPG (t=-2.01, df=62, p=0.048), bilateral RLPF-STG (left t=-2.21, 
df=62, p=0.031; right t=-2.12, df=62, p=0.038) and right SMPF-STG (t=-2.09, df=62, 
p=0.041) tracts (table 4.1). None of these differences would survive after correction for 
multiple comparisons. 
4.3.3. FA principal component analyses 
Two main components were selected based on the scree plot and eigenvalues higher 
than 1. The first component (PCA-F1) explained 55.56% of the variance and was directly 
contributed by long-range cortico-cortical connections (PFC-STG and PFC-SPG). The 
second component (PCA-F2) explained 10.70% of the variance and was directly 
contributed by both PFC-ACC and left PFC-STG connections (table 4.2). Thus, this 
component is contributed by both short-range and long-range cortico-cortical 
connections. 
 
Table 4.2. Rotated component matrix for fractional anisotropy PCA. Rotation method: 
Varimax and Kaiser normalization. Two main components were extracted. 
WM connections PCA-F1 PCA-F2 
FA left RLPF-ACC  0.235 0.814 
FA left SMPF-ACC  0.071 0.739 
FA right RLPF-ACC 0.281 0.721 
FA right SMPF-ACC 0.114 0.123 
FA left SMPF-SP  0.875 0.114 
FA left RLPF-SP 0.730 0.321 
FA right SMPF-SP 0.833 0.165 
FA right RLPF-SP 0.808 0.267 
FA left SMPF-STG 0.646 0.600 
FA left RLPF-STG 0.544 0.718 
FA right SMPF-STG 0.685 0.473 
FA right RLPF-STG 0.595 0.582 
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4.3.4. FA PCA prediction of curvature 
In all subjects as a whole, PCA-F2 (contributed by bilateral connections from RLPF and 
SMPF to anterior cingulate and left RLPF to STG) significantly and inversely predicted 
bilateral RLPF curvature (table 4.3; figure 4.3a) and right SMPF curvature (table 4.3; 
figure 4.3b). 
In patients, PCA-F2 significantly and inversely predicted bilateral RLPF curvature and 
right SMPF curvature (table 4.3). 
In the FE patients, similar associations were found, PCA-F1 (summarizing long-range 
connections) significantly and inversely predicted right RLPF curvature and left SMPF 
curvature (table 4.3). PCA-F2 predicted right SMPF curvature (table 4.3).  
In the Controls, PCA-F2 predicted bilateral RLPF curvature (table 4.3). 
Since the PCA-F2 component was contributed by FA values in both PFC-cingulate and 
left PFC-STG tracts, we performed a post-hoc analysis in order to assess the contribution 
of these tracts to frontal curvature in the patients. To do so, we calculated Pearson´s 
correlation coefficients between FA values in the tracts contributing to the PCA-F2 factor 
and, on the other side, homolateral RLPF and SMPF curvature values. There was a 
significant inverse association between left RLPF-STG FA and curvature at left RLPF (r=-
0.512, p=0.002) and SMPF (r=-0.448, p=0.008). Correlation coefficients were also 
significant for the association between FA in the right RLPF-ACC tract and right RLPF (r=-
0.424, p=0.014) and SMPF (r=-0.375, p=0.032) curvature values. Thus, values in both 
long-range (prefronto-temporal) and short-range (prefronto-cingulate) contribute to 
prefrontal curvature in patients. 
4.3.5. Cognitive principal component analyses 
Only one component was selected based on scree plot and eigenvalues higher than 
1. This component (printCG1) explained 51.36% of the variance and was directly 
contributed by all cognitive variables, except for WCST percentage of perseverative 
errors that contributed negatively (table 4.4). 
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Figure 4.3. Association graphs: a) associations between individual scores in the second 
factor of the principal component analysis of fractional anisotropy (PCA-F2; see text) and 
rostral lateral prefrontal (RLPF) curvature for all individuals, b) associations between 
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PCA-F2 and SMPF for all individuals, and c) association between individual factor scores 
in the first component of cognitive performance PCA (printCG1, see text) and RLPF 
curvature for patients.  
 
Table 4.3. Regression coefficients (R2) between curvature values for the right lateral 
(RLPF) and superior medial (SMPF) prefrontal regions and the factor scores summarizing 
FA values respectively for the fronto-parietal and right fronto-temporal tracts (PCA-F1) 
and for fronto-cingulate and left RLPF-superior temporal tract (PCA-F2). Beta coefficients 
and F values for the corresponding regression models are also shown. *p<0.05; 
**p<0.01; *** p<0.001; n.s: non-significant 
    RLPF-right RLPF-left SMPF-right SMPF-left 
PCA-F1 All subjects n.s. n.s. n.s. n.s. 
 Patients  n.s. n.s. n.s. n.s. 
 First- episode 
0.27* β=-0.55. 
F=4.72 
n.s. n.s. 
0.34* β=-0.59. 
F=6.78 
  Controls n.s. n.s n.s. n.s. 
PCA-F2 All subjects 
0.20*** β=-0.44. 
F=14.73 
0.23*** β=-0.48. 
F=17.70 
0.10* β=-0.32. 
F=6.83 
n.s. 
 Patients 
0.20** β=-0.45. 
F=7.97 
0.24** β=-0.49. 
F=9.72 
0.16* β=-0.40. 
F=5.97 
n.s. 
 First-episode n.s. n.s. 
0.48** β=-0.69. 
F=12.05 
n.s. 
  Controls 
0.17* β=-0.41. 
F=5.48 
0.21* β=-0.46. 
F=7.03 
n.s. n.s. 
 
Table 4.4. Rotated component matrix for cognitive PCA. Rotation method: Varimax 
and Kaiser normalization. One main component was extracted. 
  printCG1 
Verbal memory  0.814 
Working memory 0.812 
Motor speed 0.813 
Verbal fluency 0.763 
Attention and processing speed 0.849 
Executive function/ problem solving 0.316 
WCST % of perseverative errors -0.454 
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4.3.6. Cognitive PCA relation to curvature 
In the patients, printCG1 was a significantly and inversely associated with bilateral 
RLPF curvature (left: ρ=-0.455, p=0.020; right: ρ =-0.451, p=0.021; figure 4.3c) 
4.3.7. Clinical variables relation to curvature 
Illness duration, treatment dosage and PANSS scores were not significantly 
associated with frontal curvature. 
4.3.8. Clinical outcome and curvature 
Patients showing no improvement (n=7) showed larger values of left SMPF mean 
curvature (mean=0.137, sd=0.004) than those improving after follow-up (n=22, 
mean=0.130, sd=0.005; U=24.5, z=-1.98, p=0.04). The same was found for the right side, 
although only at trend level (no improvement: mean=0.136, sd=0.006; improvement: 
mean=0.132, sd=0.004; U=1.696, p=0.09). 
4.4. Discussion 
In our patients and controls, mean curvature indices in the frontal lobe were inversely 
associated with FA values in the tracts connecting this region to anterior cingulum (a 
nearby cortical area relevant for schizophrenia) and left superior temporal regions. 
Although our design is cross-sectional and therefore cannot identify causal 
relationships, this finding is coherent with the proposal that larger mean curvature 
values (equivalent to larger gyrification), when found in patients, may relate to 
connectivity deficits through an under-developed expansion of upper cortical layers 249. 
However, our data indicate that deficits in connectivity in long-range tracts may also 
contribute to gyrification alterations in schizophrenia patients. The gyrification process 
is associated with the formation of proper cortico-cortical connections 239. Thus, the 
larger curvature in our cases associated with lower FA values may indicate a 
developmental deficit. Cerebral cortex gyrification development takes place largely in 
the third trimester of foetal life 248, thus our data, in the context of neurodevelopmental 
theories of schizophrenia, may suggest that some neurodevelopmental arrest in cortico-
cortical connections can underlie cortical curvature increase in at least a subgroup of 
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patients. Histopathological data may be necessary to confirm the association between 
curvature and white matter connectivity deficits in schizophrenia.  
Previous data in multiple sclerosis support a similar association to that here found 
between increased cortical curvature and reduction of both white matter volumes and 
FA values 250. Nevertheless, the marked inflammation and scars in white matter usual in 
multiple sclerosis are absent in schizophrenia, indicating that the underpinnings of the 
association may differ between these two syndromes. Our results are discrepant with a 
recent report showing an inverse association between radial diffusivity (RD) and cortical 
folding (i.e. curvature) in 19 schizophrenia patients 274. RD increases with WM damage 
usually are in the opposite direction as FA. Relevant methodological differences may 
have contributed to the discrepancy since these authors calculated the association 
between RD at a single voxel located at superior temporal cortex and folding 
measurement of each vertex of the subjects’ surface. 
Cortical curvature has genetic underpinnings 237, therefore, some genetic factors may 
contribute to a schizophrenia subset where cortico-cortical connections are deficient. 
Since clinically diverse subgroups within schizophrenia have been proposed on the basis 
of different genetic underpinnings 58, it can be speculated that genetic variation can 
contribute to the differentiation of a cluster within this diagnosis based on cortical 
curvature.  
Our cases did not show significantly larger curvature values as compared to controls, 
but this finding probably reflects the expected heterogeneity of curvature in a clinically-
defined population of schizophrenia. In fact, in our previous sample, the group 
comprising most of the cases (89 out of 121) did not show increased curvature values. 
In the same vein, the lack of FA decrease after correction for multiple comparisons 
would be coherent with a significant FA deficit in the analysed tracts limited to a subset 
of cases.  
Heterogeneous results regarding curvature have been reported in schizophrenia, 
with increased 233,275–277 normal 234,278 and reduced 235 gyrification indexes being 
reported. This, along with our former study 259 and the present results support the 
existence of patients with and without altered cortico-cortical connectivity. Moreover, 
increased gyrification may also be found in bipolar disorder in the anterior and 
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infragenual cingulate cortices 263, suggesting that this may be a cross-diagnostic 
alteration. In agreement with this possibility, both bipolar and schizophrenia adolescent 
patients showed increased sulcal within the frontal lobe, although only in the latter this 
alteration was found also in the other lobes 279.  
In our sample, we found a similar association between curvature and FA in both FE 
and chronic patients. In our previous analysis, the cluster with larger curvature was 
contributed by 50% FE and 50% chronic patients. This suggests that the relation here 
found is not an artefact of chronicity or treatment. Moreover, in the present sample, 
neither duration nor current antipsychotic dose was significantly associated with 
curvature values. Also, in agreement with our previous report, larger curvature values 
were associated with a worse clinical outcome, which seems coherent with the poor 
treatment response showed by cases with lower FA values 135. 
We also found an inverse association between prefrontal curvature and cognitive 
deficits. This gives additional support to the possibility of finding discrete subtypes 
within schizophrenia diagnosis with or without cognitive deficits associated with frontal 
connectivity. Previous reports on the association between schizophrenia clusters and 
structural connectivity measurements did not assess cognition in the participants 
35,258,259. However, an association between FA and cognitive deficits has been reported 
in schizophrenia 280,281, which is coherent with the direction of our findings. On the other 
hand, the presence of increased frontal gamma noise power, an electrophysiological 
measurement reflecting excessive background activity in this band during task 
performance, distinguished a patients cluster with significant cognitive deficits, which 
was absent from cases without frontal noise power excess 282. Although the possibility 
that structural and functional connectivity might be associated seems logical, functional 
and anatomical networks connectivity may be dissociated 283,284, thus functional 
networks abnormalities may segregate with structural connectivity or contribute to 
distinct clusters.   
The use of tractography for the calculation of the mean FA of the analysed 
connections may raise some concerns. Several papers 285–287 have recently provided 
evidence indicating that current tractography methods produce many false positives, 
that is, fibre tracts that do not really exist. This lack of specificity would be fatal if global 
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network measures obtained from the connectome were being used 288. However, our 
analysis only focuses on some specific, well-known connections that are defined a priori, 
and the tractography method employed does include anatomical constraints designed 
to limit that problem. Also, these fibre bundles are later used to compute the mean FA 
across the spatial ROI defined by that bundle. Because of this, the effect of possible false 
positives would be very limited on the FA values, since the role of tractography in this 
study is improving the spatial localization of regions on which FA is calculated. 
This study has limitations. We could not assess cumulative antipsychotic doses. The 
sample size is still small, which precluded a clustering analysis similar to that of our 
previous study and all patients were receiving antipsychotic medication. Although 
curvature can be stable over the life-span, we cannot rule out that FA values may 
fluctuate according to clinical state or treatments received, suggesting the interest of 
longitudinally studies assessing the stability of the relation between curvature and FA 
here reported. The possible influence of cortical curvature on tractography, by means 
of its known bias towards gyral crests, cannot be discarded, but this may not have 
affected mean FA values. Among the study strengths, the study was hypothesis-driven 
and made use of two different imaging techniques and cognitive measurements. As a 
conclusion, our results suggest that deficits in both short- and long-range prefrontal 
connectivity contribute to increased cortical curvature values in schizophrenia, which 
could help in characterizing distinct subgroups within this syndrome. 
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Alterations in prefrontal connectivity in 
schizophrenia assessed using diffusion 
magnetic resonance imaging.  
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Abstract 
Spatial and biological characteristics of structural frontal disconnectivity in 
schizophrenia remain incompletely understood. Simultaneous streamline count (SC) and 
fractional anisotropy (FA) analyses may yield relevant complementary information to 
this end.  
Using 3T diffusion magnetic resonance imaging, both SC and FA were calculated at 
the tracts linking lateral and medial subregions of the prefrontal cortex (PFC) to 
cingulate, hippocampus, caudate and thalamus in 27 schizophrenia patients (14 first-
episodes) and 27 controls. Relationships of these parameters with cognition, symptoms, 
treatment doses and illness duration were assessed where significant between-groups 
differences were detected.  
Patients showed lower SC and FA in the tracts linking lateral and medial PFC to the 
thalamus (likely corresponding to anterior thalamic peduncle) and lower FA in those 
linking PFC to caudate (likely through internal capsule), right caudal anterior cingulate 
and left hippocampus (likely corresponding to hippocampal-prefrontal pathway). 
Moreover, patients showed greater SC values for the tracts linking medial PFC and left 
caudal anterior cingulate. SC and FA values for the tracts linking PFC and caudal anterior 
cingulate were positively related to motor speed, executive function, problem-solving 
and completed categories in WCST. FA for the tract linking right lateral PFC and caudate 
was directly related to positive symptoms and FA for the tract linking left medial PFC 
and left thalamus was inversely related to negative symptoms. Treatment doses were 
not associated with SC or FA values in any tract. Illness duration was negatively 
associated with SC and FA in the tracts linking PFC and subcortical areas. 
As a conclusion, widespread alterations in frontal structural connectivity of PFC can 
be found in schizophrenia, and are related to cognition, symptoms and illness duration.
5.1. Introduction 
Disconnectivity in schizophrenia is supported by analyses using diffusion magnetic 
resonance imaging (dMRI) revealing fractional anisotropy (FA) deficits in white matter 
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tracts 64,289. Available evidence support that such disconnectivity may be particularly 
evident for the prefrontal cortex (PFC) 66,261. However, two questions concerning this 
alteration remain to be clarified. First, which are the specifically affected connections of 
PFC (i.e. with which particular regions is PFC connectivity more affected). Second, 
whether connectivity deficits identified in dMRI studies are secondary to impaired 
myelination or decreased number of axons 290,291. 
In order to investigate these possibilities, dMRI offers potentially useful 
complementary connectivity descriptors. FA is generally thought to reflect myelin 
integrity in the corresponding WM tracts, therefore its deficits likely reflecting 
myelination impairments. Besides, streamline count (SC) quantifies the number of 
streamlines connecting selected pairs of regions and its value may be associated with 
the number of axons directly linking these regions 292. SC is the result of extracting the 
streamlines connecting two particular regions generated by a whole-brain tractography 
algorithm. Since the total number of generated streamlines is a fixed parameter, 
differences in SC values (for instance, between patients and controls) for a certain 
connection reflect differences in the connection strength of that connection relative to 
the total amount of connections in the brain. Thus, SC is complementary to FA, since it 
can provide information about subtle changes in the connectivity pattern that may not 
be identified using FA alone. 
In order to investigate both possibilities (decreased myelination and/or number of 
axons) and its spatial distribution, we determined both SC and FA for the most relevant 
connections of the PFC. Since PFC is directly linked to a large number of regions in the 
normal brain we chose candidate connections by selecting regions directly connected to 
PFC and also meeting these criteria: i) prior findings supporting its involvement in 
schizophrenia and ii) having a role in functions deemed to be relevant to this syndrome.   
Among the regions strongly linked to the PFC via direct connections and previously 
reported to be involved in schizophrenia are anterior cingulate 293, hippocampus 294, 
thalamus 295 and caudate 296. Besides, these regions play a role in cognitive functions 
deemed to be altered in schizophrenia, such as working memory, executive functions 
and social cognition 297,298. Given the different physiological roles of medial PFC and 
dorsolateral PFC 299, and the reported involvement of both medial 101,300 and lateral PFC 
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301,302 in schizophrenia, we studied the tracts connecting both subregions of PFC with 
the above-mentioned regions of interest.  
Therefore, the aim of this study is to analyze both the spatial distribution and 
characteristics of PFC connectivity alterations in schizophrenia. To this end, the 
differences between patients and controls in SC and FA in relevant WM tracts were 
assessed. We hypothesized that deficits in SC and/or FA should be found in patients, 
independently of their treatment and chronicity and be related to clinical symptoms 
and/or cognitive deficits. 
5.2. Subjects and Methods 
5.2.1. Patients  
Our sample included 27 schizophrenia patients (14 of them were first-episode, FE) 
and 27 age and sex-matched healthy controls (table 5.1). Participants were fully 
informed about the study and provided written informed consent.  
 
Table 5.1. Demographic and clinical data shown as mean (standard deviation). First-
episode group (n=14) is a sub-sample of the schizophrenia patients group (n=27). 
  Schizophrenia First episode  Controls  
  n=27 n=14 n=27 
Age 33.85 (9.13) 29.43 (7.94) 33.85 (10.54) 
Sex (M:F) 17:10 9:05 18:09 
Educational level (years) 13.79 (3.56) 15.50 (2.78) 15.67 (2.50) 
Illness duration (months) 88.68 (123.84) 7.31 (8.30) - 
CPZ equivalents (mg) 374.80 (193.42) 357.14 (215.82) - 
PANNS Positive 11.32 (3.60) 10.14 (2.00) - 
PANSS Negative 15.04 (5.04) 13.36 (2.95) - 
PANNS Total 47.60 (11.63) 41.00(6.18) - 
 
Inclusion criteria for patients were (i) schizophrenia diagnosis according the 
Diagnostic and Statistical Manual of Mental Disorders, 5th edition criteria; and (ii) for 
the FE patients, illness duration of less than one year. The diagnoses were made or 
confirmed by an expert clinician (V.M.). All patients were receiving stable doses of 
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atypical antipsychotic treatment at the time of MRI scans. Symptoms were scored using 
the Positive and Negative Syndrome Scale (PANSS)245.  
Exclusion criteria were: (i) intelligent quotient under 70; (ii) past or present substance 
abuse (except caffeine and nicotine); (ii) cranial trauma with loss of consciousness longer 
than one minute; (iv) for patients, any other mental or neurological diagnosis, and (v) 
for controls, any current neurological or psychiatric diagnosis or any treatment affecting 
central nervous system. 
The study complied with the ethical standards of the Helsinki Declaration and was 
approved by the ethical committee of the University Hospital of Valladolid. 
5.2.2. Cognitive assessment 
Global intelligence quotient (IQ) was assessed using a Spanish brief version of the 
Wechsler Adult Intelligence Scale WAIS-III 265 . Other cognitive assessments included the 
Spanish version of Brief Assessment in Cognition in Schizophrenia Scale (BACS) 266  and 
the Wisconsin Card Sorting Test (WCST; number of categories and percentage of 
perseverative errors). Direct scores from the subscales of the Spanish version of the 
BACS were collected, including: verbal memory (list learning), working memory (digit 
span), motor speed (token motor task), verbal fluency (FAS), attention and processing 
speed (symbol coding) and problem-solving (tower of London) 
5.2.3. Diffusion MRI acquisition and processing 
Acquisitions were carried out using a Philips Achieva 3 Tesla MRI unit (Philips 
Healthcare, Best, The Netherlands) at the MRI facility at Valladolid University, including 
T1-weighted and diffusion-weighted images. 
For the anatomical T1-weighted images, acquisition parameters were: turbo field 
echo (TFE) sequence, 256 x 256 matrix size, 1 x 1 x 1 mm3 of spatial resolution and 160 
slices covering the whole brain. 
With regard to the diffusion weighted images, the acquisition protocol parameters 
were: 61 gradient directions, one baseline volume, b-value = 1000 s/mm2, 2 × 2 × 2 mm3 
of voxel size, 128 × 128 matrix and 34 slices covering the entire brain. Total acquisition 
time was 18 minutes. 
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From the anatomical images, non-brain structures were removed in a first step using 
the brain extraction tool from FSL (http://fsl.fmrib.ox.ac.uk) 267. Next, automatic cortical 
reconstruction was performed using FreeSurfer (http://surfer.nmr.mgh.harvard.edu). 
Grey matter, white matter and CSF were also separated, and subcortical grey matter 
structures were obtained using “fast” and “first” utilities from FSL, respectively 268,269. 
These structures were combined to form a “five-tissue-type” image (5tt) using “5ttgen” 
from MRtrix (www.mrtrix.org). 
From the diffusion weighted images (DWIs), brain was then extracted using 
“dwi2mask" tool from MRtrix v3.12 270. Afterwards, employing MRtrix, orientation 
distribution functions were estimated from the diffusion data using spherical 
deconvolution 271, and anatomically-constrained tractography was carried out 272  using 
the diffusion data and the 5tt obtained from the T1-weighted anatomical images (after 
registration), setting the number of streamlines per subject at 2.000.000. 
In parallel, diffusion tensors at each voxel were estimated using a least squares 
method 273 and scalar FA volumes were computed from the tensor volumes. FA 
measures the amount of anisotropy in the diffusion tensor, that is, how much it deviates 
from a totally isotropic diffusion. 
Afterwards, connectome matrices were computed from the tractography output and 
the (registered) cortical segmentation volumes. 84x84 connectivity matrices were 
obtained using (i) FA and (ii) streamline count as connectome metrics. A diagram of the 
processing pipeline is shown in figure 5.1. 
From the connectivity matrices, further analysis was performed only in a priori 
selected pairwise connections between superior-medial prefrontal (SMPF) and rostral 
lateral prefrontal (RLPF) cortex and, on the other hand, caudal anterior cingulate cortex 
(CACC), hippocampus, thalamus and caudate (figure 5.2). Only homolateral connections 
were assessed.  
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Figure 5.1. Processing pipeline yielding streamline count and fractional anisotropy 
values.  
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Figure 5.2. Anatomical location of the areas selected for the analyses. 
 
5.2.4. Statistical analyses 
The statistical significance of between-groups differences in age, sex and years of 
education was assessed using chi-squared or t-tests. 
After testing normal distribution (using Kolmogorov-Smirnov tests) of dMRI data, the 
main hypothesis was tested by assessing the significance of between-groups differences 
in SC and FA for the tracts linking SMPF and RLPF to the selected regions using t-tests 
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for independent samples. Since we tested an a priori hypothesis, significance level was 
set at p<0.05. We also assessed the relationship between SC and FA in the tracts where 
significant between-group differences were found in the former analysis by calculating 
Pearson´s r coefficients between these values. 
The contribution of the connectivity alterations to cognitive and clinical variation was 
assessed using stepwise multivariate linear regressions with SC and FA values as 
independent variables and cognitive and PANNS scores as dependent variables. Possible 
associations between illness duration (in months), treatment dose (in milligrams of 
chlorpromazine equivalents) and SC and FA values was similarly assessed. 
Finally, we compared SC and FA values between FE patients and controls using non-
parametric tests (U-Mann Whitney) and the relationship between SC and FA data and 
symptoms and cognition in that group was assessed using Spearman’s rho coefficients.  
5.3. Results 
5.3.1. Demographic data 
No significant differences were found between patients and controls in age (t=0.00, 
df=52, p=1.00), sex (X2=0.081, df=1, p=0.776) or years of education (t=-1.378, df=21, 
p=0.183) (table 5.1). 
5.3.2. Connectivity data 
5.3.2.1. Streamline count 
SC values were normally distributed (Z<1.301, df=27, p>0.05). Significant differences 
between groups were found for SC linking the following pairs of regions: left SMPF-
CACC, with higher values in patients (t=2.795, df=52, p=0.007); right RLPF-thalamus (t=-
2.011, df=52, p=0.049) and right SMPF-thalamus (t=-2.731, df=52, p=0.009). with lower 
values in patients (table 5.2).  
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Table 5.2. SC and FA values for each pair of regions, shown as mean (sd). The 
statistically significant differences between patients and healthy controls are 
highlighted: * p < 0.05; ** p < 0.01; *** p < 0.001. 
  
Schizophrenia First-episode Controls 
n=27 n=14 n=27 
Streamline count (SC)       
Left RLPF-CACC 402.89 (442.07) 533.29 (539.54) 299.19 (223.96) 
Left SMPF-CACC 3806.96 (1551.75)** 4075.64 (1452.94)** 2756.81 (1185.21) 
Right RLPF-CACC 401.63 (332.27) 453.79 (362.44) 386.81 (249.48) 
Right SMPF-CACC  2643.37 (999.98) 2870.07 (790.67) 3029.11 (947.52) 
Left RLPF-hippocampus 36.22 (49.43) 28.21 (20.24) 59.26 (61.9) 
Left SMPF-hippocampus  94.3 (91) 116.57 (118.6) 161.37 (177.31) 
Right RLPF-hippocampus 45.04 (47.39) 39.57 (46.29) 32.33 (29.53) 
Right SMPF-hippocampus  86.22 (54.77) 92.93 (57.57) 89.93 (74.01) 
Left RLPF-thalamus 914.41 (519.49) 963.93 (601.16) 1038.37 (748.89) 
Left SMPF-thalamus 3495.41 (1733.25) 3963.64 (1942.81) 3505.96 (1354.35) 
Right RLPF-thalamus 713.41 (505.81)* 810.64 (514.23) 1054.59 (721.88) 
Right SMPF-thalamus  2512.85 (1148.75)** 2899.93 (1150.11) 3574.63 (1661.99) 
Left RLPF-caudate 3077.81 (1256.13) 3114.86 (1420.14) 3001.63 (1333.65) 
Left SMPF-caudate  3528.33 (1469.58) 3421.86 (1668.19) 3315.19 (1248.65) 
Right RLPF-caudate 2963.11 (1090.69) 3114.36 (1151.36) 2849.78 (1159.92) 
Right SMPF-caudate  4453.63 (2028.34) 4512.93 (2458.78) 4415.81 (1745.8) 
Fractional anysotropy (FA)       
Left RLPF-CACC 0.41 (0.04) 0.42 (0.03) 0.42 (0.03) 
Left SMPF-CACC 0.37 (0.05) 0.37 (0.04) 0.38 (0.04) 
Right RLPF-CACC 0.43 (0.04) 0.44 (0.04) 0.45 (0.04) 
Right SMPF-CACC  0.41 (0.04) 0.41 (0.05) 0.40 (0.04) 
Left RLPF-hippocampus 0.45 (0.03) 0.45 (0.03) 0.46 (0.04) 
Left SMPF-hippocampus  0.48 (0.04)* 0.49 (0.04) 0.50 (0.03) 
Right RLPF-hippocampus 0.45 (0.03) 0.46 (0.03) 0.46 (0.04) 
Right SMPF-hippocampus  0.49 (0.04) 0.50 (0.04) 0.49 (0.04) 
Left RLPF-thalamus 0.44 (0.02) 0.44 (0.03) 0.45 (0.03) 
Left SMPF-thalamus 0.46 (0.02)* 0.47 (0.02) 0.48 (0.03) 
Right RLPF-thalamus 0.44 (0.02) 0.45 (0.02) 0.45 (0.02) 
Right SMPF-thalamus  0.47 (0.03) 0.47 (0.03) 0.48 (0.02) 
Left RLPF-caudate 0.36 (0.03) 0.37 (0.03) 0.37 (0.03) 
Left SMPF-caudate  0.41 (0.03)* 0.42 (0.03) 0.43 (0.03) 
Right RLPF-caudate 0.36 (0.03)* 0.37 (0.03) 0.38 (0.03) 
Right SMPF-caudate  0.41 (0.02) 0.41 (0.02) 0.42 (0.03) 
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5.3.2.2. Fractional anisotropy  
FA variables were normally distributed (Z<0.484, df=27, p>0.70). FA values in tracts 
between the following pairs of regions were significantly lower in patients: right RLPF-
CACC (t=-2.280, df=52, p=0.027); right RLPF- caudate (t=-2.297, df=52, p=0.026); left 
SMPF-hippocampus (t=-2.270, df=52, p=0.027); left SMPF-thalamus (t=-2.413, df=52, 
p=0.019); left SMPF-caudate (t=-2.291, df=52, p=0.026) (table 5.2). 
5.3.3. Relation between SC and FA  
There was a significant direct association between SC values for the tracts linking right 
RLPF and thalamus and FA values for all the tracts showing significantly decreased FA 
values in the patients (0.569<r<0.446; 0.002<p<0.02; n=27).  
5.3.4. Relations of SC and FA with clinical and cognitive data 
The following significant associations were detected between variables showing 
significant between groups differences and clinical and cognitive data: i) SC between left 
SMPF and CACC and was directly related to motor speed (R2=0.295, p=0.009, β=0.543); 
ii) FA between right RLPF and CACC was directly related to problem solving (R2=0.241, 
p=0.02, β =0.491) and completed categories in WCST (R2=0.256, p=0.019, β=0.506); iii) 
FA between right RLPF and caudate was directly related to positive symptoms (R2 
=0.171, p=0.04, β =0.413); iv) FA between left SMPF and thalamus was inversely related 
to negative symptoms (R2=0.165, p=0.044, β =-0.406; figure 5.3). 
5.3.5. Effect of illness duration and treatment 
Illness duration inversely predicted SC between right SMPF and thalamus (R2=0.239, 
p=0.013, β =-0.489); FA between left SMPF and hippocampus (R2=0.199, p=0.025, β =-
0.446) and FA between left SMPF and caudate (R2=0.232, p=0.015, β =-0.481, figure 5.4). 
Treatment doses were not associated with any of dMRI values with differences between 
groups. 
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Figure 5.3. Scatterplots showing the significant associations between regional 
connectivity values and clinical scores. Black triangles = chronic patients, grey squares= 
first-episode patients. 
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Figure 5.4. Scatterplots showing the significant associations between regional 
connectivity values and illness duration. Black triangles = chronic patients, grey squares= 
first-episode patients. 
 
5.3.6. Comparison between first episode and controls 
There were no significant differences between FE patients and controls in age (U=-
140.00, p=0.178), sex (X2=0.054, df=1, p=0.541) or years of education (U=34.00, 
p=0.844). There were significant differences between FE patients and controls in SC 
between left SMPF and CACC (U=92, Z=-2.667, p=0.008), FE showing higher values. 
There were not significant FA differences between those groups.  
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5.4. Discussion 
Our data reveal a significant alteration of FA and/or SC in most of the selected 
connections between PFC and target regions relevant to schizophrenia. Alterations in FA 
were more widespread, suggesting that myelination deficits may be more prevalent in 
these connections than deficits in the number of axons, which might be limited to PFC-
thalamic tracts. In anatomical terms, this connection, probably correspond to the 
anterior thalamic peduncle, the anterior part of the thalamic radiation. Both parameters 
showed similar relationships to cognitive deficits and symptoms. 
The deficit in the number of streamlines connecting right medial and lateral PFC and 
thalamus is coherent with a decreased number of axons in the WM tracts linking these 
regions. Although we cannot fully discard that the lower SC values in the patients might 
be secondary to myelination deficits in these tracts, this seems unlikely given its normal 
FA values.  FA was instead significantly lower in the left PFC-thalamic connection, where 
it was inversely related to negative symptoms scores. Taken together, these data 
support a role in schizophrenia for a decreasing number of fibres and myelination 
deficits in tracts connecting thalamus and PFC. These regions have a common embryonic 
origin 303 , which may be coherent with neurodevelopmental theories in schizophrenia.  
Previous results agree with such a possible alteration in structural PFC-thalamic 
connectivity. Decreased FA was reported in the anterior limb of internal capsule, which 
also contains fibre tracts from medial dorsal thalamus to frontal cortex 304–306. Using 
dynamic causal modelling and FA, altered connectivity was found between the 
prefrontal cortex, thalamus and anterior cingulate in chronic patients 307. The possible 
alteration in fronto-thalamic connections is also consistent with meta-analytic data 
showing lower FA in schizophrenia patients in frontal lobe WM (including fibres 
connecting frontal, cingulate cortex and thalamus 64. A posterior meta-analysis reported 
decreased FA values in anterior thalamic radiation (including the anterior thalamic 
peduncle), cingulum, fornix, inferior longitudinal fasciculi and inferior frontal occipital 
fasciculi 31.  
The significant association in our patients between altered SC values in the PFC-
thalamic connection and other FA values found to be abnormal in the patients (with the 
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hippocampus and caudate, likely travelling through internal capsule) suggests that 
common factors may be driving both changes. 
More intriguingly, a higher SC value was found in the patients in the connection 
between left CACC and SMPF, being directly associated with motor speed. A similar 
increase was described in FE patients 308 and increased connectivity has been proposed 
to relate to psychotic symptoms and to neurodevelopmental anomalies perhaps via 
abnormal pruning 290. In this line, patients suffering from hallucinations showed higher 
FA values in the left cingulum bundle 309 and FA values in the arcuate fasciculi were 
directly correlated to hallucinations scores 310. Considered together, this suggests the 
possibility of a hampered cortico-subcortical connectivity in schizophrenia (with 
thalamus, caudate and hippocampus) along with an excess of cortico-cortical 
connections, at least with relatively near regions, such as anterior cingulate.  
In our patients, prefrontal connectivity was directly associated with cognitive 
performance. Similar associations were described in never-medicated chronic 311, 
chronic medicated 281 and adolescent-onset 312 patients. Similarly, a positive relation 
between FA in the cingulum and working memory, along with a negative relation to 
errors in the WCST has been reported 313, as well as a relationship between impaired 
fronto-temporal and cortico-subcortical connections and deficits in executive and motor 
function 308. 
FA was also associated in our cases to positive (directly) and negative (inversely) 
symptoms. Consistently with this, a positive relation between FA and positive symptoms 
was reported in FE or recent onset schizophrenia 314–316 and in chronic patients 317. 
However, other studies described no relation between diffusion parameters and 
symptoms 281,311,318–320. Regarding negative symptoms, our data are coherent with 
reported associations between higher negative symptoms and lower FA values in 
thalamic radiation, corpus callosum, inferior fronto-occipital fasciculus and inferior 
longitudinal fasciculus 35, and in the fronto-occipital fasciculus 316. These discrepancies 
may suggest that different clinical profiles might be characterized by distinct 
connectivity patterns. In this line, decreased FA in left uncinated fasciculus was reported 
in deficit schizophrenia 321. Moreover, within FE schizophrenia patients, one subgroup 
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could be characterized by widespread WM anomalies and higher negative symptoms 35, 
and patients with poor treatment response showed lower FA than good-responders 135.  
Our FE group did not show the same pattern of SC and FA differences that the chronic 
patients showed in comparison to controls. Although this lack of significance might have 
been contributed by the smaller number of FE patients, the inverse correlation between 
illness duration and SC and FA values suggests that deficits in these parameters may 
become significant in later stages of illness. This could agree with the larger FA 
reductions were reported in chronic than in FE patients 322  and the larger percent of 
WM volume loss in early phases of schizophrenia 323. Moreover, perhaps only a subset 
of FE shows FA deficit 35, which may explain in part why this was not evident in our cases. 
This heterogeneity could justify discrepancies with meta-analytic evidence in FE 
reporting FA decreased mainly in fronto-limbic connections 93, and reviews suggesting 
decreased FA and mean diffusivity in this and other tracts 324. 
The association found between connectivity and illness duration agrees with the 
results of a meta-analysis 31 and more recent data 258,325. In this context, the lack of 
association between antipsychotic doses and diffusion parameters suggests that the 
effect of illness duration upon connectivity is not a direct effect of longer exposure to 
antipsychotics. Some results suggest that antipsychotics may instead increase FA, 
perhaps through a myelinating effect 135,326.  
Our study has limitations. The sample size is relatively small and all the patients were 
medicated. Other tracts not assessed in the present study may show relevant results in 
schizophrenia. The exact meaning of SC changes is incompletely understood, and may 
be considered an indirect estimation of numbers of axons.  
As a conclusion, prefrontal connectivity may be hampered in schizophrenia and this 
may play a role in cognitive and clinical deficits. Complementary SC and FA data may 
help in elucidating the characteristics of that alteration.  
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Abstract 
Functional brain networks possess significant small-world (SW) properties. 
Genetic variation relevant to both inhibitory and excitatory transmission may 
contribute to modulate these properties. 
We hypothesized that in healthy controls, genotypic variation in Neuregulin 1 
(NRG1) related to the risk of psychosis (risk-alelles) would contribute to functional 
SW modulation of the cortical network. 
Electroencephalographic (EEG) activity during an odd-ball task was recorded in 
144 healthy controls. Then, Small-worldness index (SWn) was calculated in five 
frequency bands (i.e. theta, alpha, beta1, beta 2, and gamma) for baseline (from -300 
to the stimulus onset) and response (150 to 450 ms post-target stimulus) windows. 
The SWn modulation was defined as the difference in SWn between both windows. 
Association between SWn modulation and carrying the risk allele for three single 
nucleotide polymorphisms (SNP) of NRG1 (i.e. rs6468119, rs6994992, and rs7005606) 
was assessed. 
A significant association between three SNPs of NRG1 and the SWn modulation 
was found, specifically: NRG1 rs6468119 in alpha and beta-1 bands; NRG1 rs6994992 
in theta band; and NRG1 rs7005606 in theta and beta-1 bands. 
In conclusion, genetic variation at NRG1 may influence functional brain 
connectivity through the modulation of SWn properties of the cortical network.
6.1. Introduction 
Mental activity is likely contributed by the coordinated activity of different cortical 
regions 85,327,328. These brain networks show small-world (SW) properties, characterized 
by high local clustering and low average distance between nodes (low characteristic path 
length). SW architecture balances segregation (i.e., the ability of a network to work 
locally) and integration (i.e., the capacity to communicate separated brain areas) in 
functional brain networks. These properties can be quantified using a network 
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parameter: the small-worldness (SWn) 115,116,329, whose heritability has been proposed 
to be large 330. 
SWn of brain network properties can be studied using structural (anatomical (MRI) 
or diffusion magnetic resonance (DTI)) and functional (electroencephalography (EEG) or 
functional magnetic resonance (fMRI)) methods 331. Among the latter, temporal 
resolution of the EEG allows assessing the fast modulation of functional brain 
connectivity related to cognitive performance.  
Neural networks are contributed by a large number of factors, some susceptible of a 
genetic regulation. Among them, the excitatory/inhibitory balance may play a relevant 
role 332. On the other hand, abnormalities in SW properties of the brain networks have 
been found in the psychotic disorders 333–335, for which a high heritability is established 
46. Thus, to identify genetic contributions to network organization one possible strategy 
is to assess the influence of gene-related factors: i) contributing to neurotransmission, 
neurodevelopment and excitatory/inhibitory balance, and ii) implicated in the risk for 
psychosis.  
Genetic variation for Neuregulin 1 (NRG1) seems to comply with both conditions. 
NRG1 gene codifies a pleiotropic growth factor protein with at least fifteen different 
isoforms. All of them have an epidermal growth factor domain (EGF), which 
preferentially activates tyrosine kinase receptor ErbB4. Those receptors were principally 
located in the postsynaptic density of parvalbumin-positive interneurons 162,336. NRG1 
protein is related to central nervous system development, plasticity, myelination 337, 
migration 338 and inhibitory/excitatory balance 339,340. This protein and its interaction 
with ErbB4 could regulate glutamatergic transmission by modulating the activity of N-
methyl-d-aspartate (NMDA) 339,341,342 and α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid (AMPA) 340 receptors in the excitatory synapsis. In addition, NRG1 has a 
very relevant role in GABAergic interneurons, one of the main cells contributing to 
oscillatory activity 343,344, through the regulation of the differentiation, migration and 
activity of this type of neurons 338. Although genetic variation at NRG1 loci has not been 
consistently associated with psychotic disorders risk in genome-wide studies, other data 
support that it may play a role in the risk for schizophrenia 339,345,346. 
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Therefore, it seems of interest to assess the relation between NRG1 genetic variation 
relevant for psychosis and functional brain network organization. For this purpose, three 
NRG1 SNPs were selected due to its relation with major psychoses: rs6994992, whose T 
allele has been related to the risk of psychosis 347,348, cognitive deficits and lower brain 
activity in schizophrenia 343,348; and. rs6468119 and rs7005606, whose T alleles have 
been associated with the risk of bipolar disorder 157,349. Hence, the aim of the study was 
to assess the possible relation between genetic variations at NRG1 gene and SWn 
modulation during a cognitive task. The assessment of the association of brain network 
modulation with genetic variation in healthy population can be a first step to understand 
how genetic background influences the disconnectivity in clinical psychosis. 
6.2. Methods 
6.2.1. Participants: demographic and clinical assessment  
We recruited 144 healthy controls through newspaper announcements, all of them 
from Caucasian race. A semi-structured interview prior to the study was used to discard 
current or past psychiatric diagnoses or treatments. Exclusion criteria were: (i) comorbid 
axis-1 diagnosis; (ii) family antecedents of psychosis; (iii) psychoactive treatment; (iv) 
substance abuse; (v) history of head trauma or any disease affecting the central nervous 
system; and (vi) intelligence quotient (IQ) below 70. Socio-demographic data are shown 
in table 6.1.  
6.2.2. Electrophysiological recordings 
EEG recordings were acquired during the performance of an auditory odd-ball task. 
The task consisted on random series of 600 stimulus (duration 50 ms, rise and fall time 
5 ms, intensity 90 dB) composed by three different tones with different probabilities: (i) 
S1, 2000 Hz standard tone, probability 0.60; (ii) S2, 1000 Hz distractor tone, probability 
0.20; and (iii) S3, 500 Hz target tone, probability 0.20. The subjects were asked to press 
a buttom when they listened the target tone. During the recording, they remained 
seated, relaxed and with their eyes closed. Only attended target tones were considered 
for further analysis. 
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EEG activity was recorded using a Brain Vision electroencephalographic system (Brain 
Products, Germany), with 17 electrodes (Fp1, Fp2, F3, F4, F7, F8, C3, C4, P3, P4, O1, O2, 
T5, T6, Fz, Pz and Cz) placed following the specifications of the 10-20 international 
system (Electro-Cap International, Inc.; Eaton, OH, USA). Electrooculogram was also 
recorded to detect eye movements. Impedance was kept under 5 kΩ during EEG 
acquisition. The sampling rate was 500 Hz. 
6.2.3. Signal processing  
6.2.3.1. EEG Processing 
Each EEG recording was initially re-referenced over Cz electrode to minimize the 
effect of microsaccadic artifacts 350. Then, EEG signals were bandpass filtered between 
1 and 70 Hz. In addition, a 50 Hz notch filter was used to remove the power line artifact. 
Independent component analysis (ICA) was applied to visually discard components 
related to ocular and muscular artifacts. A segmentation into 1 s-length trials, ranging 
from -300 ms before stimulus onset to 700 ms after stimulus onset, was performed. 
Finally, an adaptive thresholding method was used to discard those epochs whose 
amplitude exceeded the threshold 351. 
6.2.3.2. Continuous wavelet transform 
Continuous wavelet transform (CWT) was used to estimate time-frequency maps, 
since it is a suitable technique to analyze non-stationary recordings 352. In this study, we 
used two different time windows: (i) the baseline window, [-300, 0] ms previous to the 
stimulus onset; and (ii) the response window, [150, 450] ms post-stimulus 351. In order 
to avoid CWT edge effects in short-time recordings, a cone of influence (COI) was 
defined for the two windows under study 353. It is noteworthy that evoked response is 
included in the response window. 
Five frequency bands were considered for subsequent analyses. They were defined 
according to the conventional EEG frequency bands: theta (θ, 4–8 Hz), alpha (α, 8–13 
Hz), beta-1 (β1, 13–19 Hz), beta-2 (β2, 19–30 Hz), and gamma (γ, 30–70 Hz). Delta 
frequency band was not analyzed, since it is associated with a wavelet duration of 
hundreds of milliseconds 351. 
- 94 -  Chapter 6 
6.2.3.3. Mean Squared Coherence Complex Network Theory 
Coherence measure assesses the functional interaction between couple of signals 
from a specific brain region 354. In this study, mean squared coherence (MSC) was used 
to quantify the spectral content between couples of EEG channels. Therefore, MSC 
between two signals is the cross function of the normalized power spectral density 
divided by the normalized power spectral density of the two signals separately 354:  
𝑀𝑆𝐶𝑋𝑌(𝑡, 𝑓) =
|𝑊𝑆𝑋𝑌(𝑡,𝑓)
2|
𝑊𝑆𝑋𝑋(𝑡,𝑓)⋅𝑊𝑆𝑌𝑌(𝑡,𝑓)
, (1) 
where WSXY is the cross-spectral density of two signals (X and Y) from the wavelet 
scalogram (which summarizes the distribution of the signal energy in the time-frequency 
plane), and WSXX and WSYY the auto-spectral density functions from the wavelet 
scalogram. Finally, MSC values were averaged in each of the spectral bands under study. 
6.2.3.4. Complex Network Theory 
To model a system as a graph, nodes may represent the dynamical units and their 
links stand for the interactions between them 355. We have used the SWn parameter, 
since it summarizes two different properties of a network: integration and segregation. 
First, cluster coefficient (ClC, a segregation measure) is computed for each node of the 
network and each frequency band: 
𝐶𝑙𝐶𝑖
𝑏 =
∑ ∑ 𝑤𝑖𝑘
𝑏 𝑤𝑖𝑙
𝑏𝑤𝑖𝑙
𝑏
𝑙≠𝑖
𝑙≠𝑘
𝑘=𝑖
∑ ∑ 𝑤𝑖𝑘
𝑏 𝑤𝑖𝑙
𝑏
𝑙≠𝑖
𝑙≠𝑘
𝑘=𝑖
, 𝑏 ∈ {𝜃, 𝛼, 𝛽1, 𝛽2, 𝛾} (2) 
where b represent the frequency band under study. And 𝑤𝑖𝑗
𝑏  the weight between two 
nodes provided by the MSC measure. Second, averaged path length (PL, an integration 
measure) was computed for each node following the following equation: 
𝑃𝐿𝑖
𝑏 =
∑ 𝑑𝑖𝑗
𝑏
𝑗≠𝑖
𝑁−1
, 𝑏 ∈ {𝜃, 𝛼, 𝛽1, 𝛽2, 𝛾} (3) 
where N is the total number of nodes of the network (17 in this case) and 𝑑𝑖𝑗
𝑏  is the 
minimum distance between nodes i and j. Then, ClC and PL values were averaged over 
all nodes in order to obtain global parameters of the network. Finally, in order to obtain 
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measures that are independent of the network size, CLC and PL were normalized 
dividing by <CLCsurrogate> and <PLsurrogate>: 
𝑃𝐿𝑛
𝑏 =
𝑃𝐿
⟨𝑃𝐿𝑠𝑢𝑟𝑟𝑜𝑔𝑎𝑡𝑒⟩
, (4) 
𝐶𝑙𝐶𝑛
𝑏 =
𝐶𝑙𝐶
⟨𝑃𝐿𝑠𝑢𝑟𝑟𝑜𝑔𝑎𝑡𝑒⟩
, (5) 
where <CLCsurrogate> and <PLsurrogate> denote weighted clustering coefficient and path 
length averaged over an ensemble of 50 surrogate random networks that were derived 
from the original 356. Therefore, SW was independent of the network size 357: 
𝑆𝑊𝑛𝑏 =
𝐶𝑙𝐶𝑛
𝑏
𝑃𝐿𝑛
𝑏  (6) 
6.2.3.5. Parameter baseline correction 
The baseline correction process is used to achieve a stimulus-independent 
characterization 351. Once the spectral parameters were computed for each temporal 1 
s-length trial, they were decomposed into the baseline and the response window 358 
Firstly, the spectral analysis provides a value for each temporal window. Secondly, the 
values of the previous parameters in the [-300, 0] ms interval were averaged to obtain 
a baseline parameter mean. Then, the baseline correction was carried out using a simple 
subtraction. For that purpose, the SWn during the baseline window for each frequency 
band under study (𝑆𝑊𝑛𝐵𝐿
𝑏  ) is subtracted from the response value (𝑆𝑊𝑛𝑅
𝑏) for each 
participant (mean of the values in the [150, 450] ms interval) obtaining the corrected 
SWn (𝑆𝑊𝑛𝑀
𝑏 ). It should be noted that negative values indicate a parameter decrease in 
the response window, while positive values represent an increase from baseline to 
response window. 
𝑆𝑊𝑛𝑀
𝑏 = < 𝑆𝑊𝑛𝑅
𝑏 − 𝑆𝑊𝑛𝐵𝐿 
𝑏 > (7) 
where < >denotes the average across trials.  
6.2.4. Genetic analyses 
We obtained from each individual approximately 10 ml of venous blood using K3-
EDTA (ethylenediaminetetraacetic acid) tubes. The samples were centrifuged with 
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Ficoll-Paque following the Trizol protocol (Invitrogen, Carlsbad, CA, USA) to obtain 
genomic DNA from white cells. The genotyping was carried out via TaqMan assays 
through real-time polymerase chain reaction (PCR) with custom-made probes and 
primers (Applied Biosystems, Foster City, CA). The final volume of reaction was 10 µl and 
the amplification program protocol used the following temperatures for 40 cycles: 94ºC 
(denaturing), 60ºC (annealing) and 72ºC (extension).  
The polymorphism distribution results were evaluated with chi-squared tests to 
analyze Hardy-Weinberg equilibrium. SNPs rs6994992 and rs7005606 showed Hardy-
Weinberg equilibrium (p=0.8248 and p=0.1312). In contrast, SNP rs6468119 does not fit 
to Hardy-Weinberg proportions (p=0.0387), which could be contributed by the smaller 
genotyping success rate in this polymorphism (75.94%). 
6.2.5. Statistics 
For each SNP, cases were dichotomized into non-risk allele carriers and risk alleles 
carriers. The distribution of SWn values was evaluated with one-sample Kolmogorov-
Smirnov tests. 
Demographic data were compared with Chi Square test or Student’s t-test when 
appropriated.  
The significance of SWn modulation on each frequency band (or 𝑆𝑊𝑛𝑀
𝑏 ) between 
carriers and non-carriers was assessed in each band of the EEG (except for delta) using 
Student’s t-test. Moreover, to assess if possible differences in SWn modulation were 
contributed by the baseline window, 𝑆𝑊𝑛𝐵𝐿
𝑏 , values were compared between risk and 
non-risk allele carriers.  
6.3. Results 
6.3.1. Socio-demographic data 
There were no significant differences between risk and non-risk allele carriers for any 
SNP in age, sex distribution and school years (table 6.1).  
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6.3.2. NRG1 SNP and SW  
SWn values for each subgroup of risk allele carriers and non-risk allele carriers were 
normally distributed according to results of Kolmogorov-Smirnov tests (range of values: 
Z values from 0.309 to 1.075 and p values from 0.198 to 1). 
There were significant differences in SWn modulation between rs6468119 carriers 
and non-carriers in alpha and beta1 frequency bands (𝑆𝑊𝑛𝑀
𝛼 .: t=-2.06, df= 106, p=0.042; 
𝑆𝑊𝑛𝑀
𝛽1
: t=-2.390, df=106; p=0.019) (table 6.1). Non-risk allele carriers (CC; n=28) 
showed a significant decrease in 𝑆𝑊𝑛𝑀
𝛼  and 𝑆𝑊𝑛𝑀
𝛽1
, while risk allele carriers (CT/TT; 
n=85) showed a slight SWn increase in these bands (table 6.1 and figure. 6.1). 𝑆𝑊𝑛𝐵𝐿
𝑏  
did not show significant differences between groups in any frequency band (table 6.2). 
We also found a significant difference in theta SWn (𝑆𝑊𝑛𝑀
𝜃 ) between rs6994992 risk 
and non-risk allele carriers. Both risk allele carriers (CT/TT; n=120) and non-carriers (CC; 
n=24) showed a positive modulation of SWn in this band, significantly larger in risk allele 
carriers (t=-2.02, df=142, p=0.046) (table 6.1 and figure. 6.1). For this allele and band, 
SWn values were significantly different at baseline in theta band (𝑆𝑊𝑛𝐵𝐿
𝜃 ) between risk 
allele carriers and non-carriers. 𝑆𝑊𝑛𝐵𝐿
𝜃   was significantly smaller in risk allele carriers 
(table 6.2).  
Finally, a significant difference in SWn modulation was observed between rs7005606 
risk and non-risk allele carriers in theta (𝑆𝑊𝑛𝑀
𝜃 ) and beta-1 (𝑆𝑊𝑛𝐵𝐿
𝜃 ) bands. Risk allele 
carriers (GT/TT; n=111) showed a significantly larger positive modulation 𝑆𝑊𝑛𝐵𝐿
𝜃  (i.e., a 
larger increase from baseline to response window) than non-carriers (GG; n= 27) (t=-
1.99, df=136, p=0.048) (table 6.1 and figure. 6.1).  
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Table 6.1. Socio-demographic data and 𝑆𝑊𝑛𝑀
𝑏  values for the cohort of subjects 
enrolled in the study. Data was divided into two groups, which were defined depending 
on the presence of NRG1 risk polymorphisms for psychoses. SWn values were calculated 
as the difference between SWn at response and baseline windows (𝑆𝑊𝑛𝑅
𝑏  -𝑆𝑊𝑛𝐵𝐿
𝑏 ). 
Positive values represent a SW increase at response. Statistically significant differences 
between risk and no-risk allele carriers are marked with an asterisk: *. p<0.05.  
   
  Non-risk allele carriers  Risk allele carriers 
  Mean (SD) Mean (SD) 
rs6468119     
N 28 85 
Age (years) 26.64 (8.57) 27.24 (8.59) 
Gender (M:F) 12:16 35:50:00 
Education (years) 15.89 (1.57) 16.89 (1.85) 
SWn-theta 0.25 (0.57) 0.42 (0.5) 
SWn-alpha -0.14 (0.36)* 0.05 (0.43) 
SWn-beta1 -0.12 (0.28)* 0.03 (0.29) 
SWn-beta2 -0.04 (0.13) 0.01 (0.17) 
SWn-gamma -0.01 (0.08) 0.01 (0.06) 
rs6994992     
N 24 120 
Age (years) 28.29 (10.9) 27.41 (8.87) 
Gender (M:F) 14:10 48:72 
Education (years) 16.69 (1.89) 16.07 (2.32) 
SWn-theta 0.14 (0.56)* 0.36 (0.48) 
SWn-alpha -0.13 (0.39) -0.02 (0.41) 
SWn-beta1 -0.06 (0.33) -0.03 (0.31) 
SWn-beta2 -0.03 (0.14) -0.02 (0.16) 
SWn-gamma -0.003 (0.07) -0.003 (0.06) 
rs7005606     
N 27 111 
Age (years) 26.44 (10.16) 27.96 (9.11) 
Gender (M:F) 12:15 43:68 
Education (years) 16.16 (1.64) 16.27 (2.44) 
SWn-theta 0.15 (0.48)* 0.36 (0.48) 
SWn-alpha -0.18 (0.34) -0.02 (0.41) 
SWn-beta1 -0.14 (0.31)* -0.01 (0.3) 
SWn-beta2 -0.06 (0.14) -0.01 (0.16) 
SWn-gamma -0.02 (0.07) 0.002 (0.06) 
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Table 6.2. 𝑆𝑊𝑛𝐵𝐿
𝜃  values in baseline window for NRG1 SNPs. The statistically 
significant differences between risk alleles carriers and non-risk allele carriers are 
marked with asterisks: * p<0.05; ** p<0.01; *** p<0.001 
 
  Non-risk allele carriers  Risk allele carriers 
  Mean (SD) Mean (SD) 
rs6468119     
Theta 1.92 (0.40) 1.91 (0.57) 
Alpha 2.68 (0.99) 2.73 (0.97) 
Beta1 2.03 (0.52) 2.02 (0.53) 
Beta2 1.49 (0.33) 1.46 (0.31) 
Gamma 1.09 (0.07) 1.09 (0.08) 
rs6994992     
Theta 2.26 (0.70)** 1.84 (0.49) 
Alpha 3.35 (1.16)*** 2.58 (1.01) 
Beta1 2.29 (0.62)* 1.98 (0.54) 
Beta2 1.53 (0.32) 1.44 (0.30) 
Gamma 1.10 (0.08) 1.09 (0.08) 
rs7005606     
Theta 1.92 (0.48) 1.90 (0.54) 
Alpha 2.66 (1.15) 2.70 (1.06) 
Beta1 1.99 (0.58) 2.03 (0.56) 
Beta2 1.43 (0.32) 1.45 (0.31) 
Gamma 1.12 (0.07) 1.09 (0.08) 
 
Moreover, risk allele carriers showed a significantly lower negative modulation in 
beta-1 band (less decrease in 𝑆𝑊𝑛𝐵𝐿
𝜃 from baseline to response) (t=-2.06, df=136, 
p=0.042) (table 6.1 and figure. 6.1). There were no significant differences at 𝑆𝑊𝑛𝐵𝐿
𝑏   for 
this allele. 
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Figure 6.1. Distribution of significant 𝑆𝑊𝑛𝑀
𝑏   modulation values (𝑆𝑊𝑛𝑅
𝑏-𝑆𝑊𝑛𝐵𝐿
𝑏 ) in 
non-risk allele carriers and risk allele carriers. 
 
6.4. Discussion 
We found a significant association between genetic variation at NRG1 and the 
modulation of SW properties of the functional cortical network during the performance 
of an odd-ball task in healthy subjects. As far as we know, no previous studies 
investigated the effect of NRG1 polymorphisms on functional brain network 
modulation. SWn modulation in the theta band, 𝑆𝑊𝑛𝑀
𝜃  was associated with two NRG1 
SNPs: rs6994992 and rs7005606. In both cases risk allele carriers presented larger 
𝑆𝑊𝑛𝑀
𝜃  (more positive SWn changes) than non-risk allele carriers. Theta oscillations are 
related to long-range synchronization in brain networks 359,360. According to our data, 
the risk allele may be associated with a larger modulation of long-range connectivity in 
response to a task. Such a larger modulation was associated with lower 𝑆𝑊𝑛𝐵𝐿
𝜃 values in 
risk allele carriers. Therefore, risk allele carriers with smaller SWn values in the baseline 
window might have to increase the SWn in this band to a larger extent than non-carriers 
during task performance.  
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NRG1 rs6994992 is located at the promotor region of the gene, inside the HAPice 
haplotype 342, being the only functional HAPice polymorphism and related to cognitive 
alterations 346. Rs6994992 has also been related to white matter integrity in healthy 
subjects 345. Thus, variation at this locus might contribute to the structural substrate of 
long-range connectivity 361. However, previous studies showed a reduced fractional 
anisotropy in anterior limb of internal capsule and anterior thalamic radiation in risk 
allele carriers 345,362. Therefore, the role of NRG1 variation on white matter integrity may 
not justify the association observed in the present study with fast regulation of cortical 
network in the theta band. 
Our findings also support an association between rs6468119 and rs7005606 and SWn 
modulation in beta 1 band, risk allele carriers showing smaller SW modulation. The same 
result was observed regarding SWn modulation in alpha band respect rs6468119. Alpha 
and beta bands may also play a role in long-range synchronization 363,364. Both SNPs are 
non-coding polymorphisms 157,349. Their specific effects are unknown, but they could be 
related to the regulation of NRG1 transcription 339,365. Either increase or decrease of the 
NRG1 is related to changes in the inhibitory/excitatory balance, supporting its possible 
contribution to connectivity supported by cerebral oscillations: an increase of NRG1-
ErbB4 signaling is related to a decrease of NMDAr activation and currents 366,367, mainly 
through the inhibition of Src kinases pathway 62. Also, hypofunction of NRG1-ErbB4 
might cause abnormal glutamatergic transmission through increasing NR2B 
phosphorylation 368. Furthermore, the NRG1 increase is associated with an impairment 
of GABA release 369 and NRG1 increase or decrease is respectively related to promotion 
or reduction of miniature excitatory postsynaptic currents in GABAergic interneurons 370 
that impair pyramidal neurons synchronization 371.  
We a priori selected SNPs on the basis of the likely risk conferred by one of their 
respective alleles for major psychosis, in which a decreased SWn has been reported. 
However, contrary to our expectations, risk alleles in healthy subjects were rather 
associated with a larger SWn modulation during a cognitive task. As previously stated, 
this may be in part justified by smaller SWn values at rest, but it also seems compatible 
with the possibility that other genetic and non-genetic factors may have a larger and 
complex influence in the network organization in schizophrenia patients.  
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Among the study limitations, larger samples are needed to adequately detect 
influences of genotype on brain networks modulation. Improved genotyping success is 
needed before our rs6468119 genotyping results could be extrapolated to the general 
population. Moreover, we measured individually the effect of every SNP, but the effect 
of genes in brain networks is more probably epistatic or additive 361. 
As a conclusion, our data are consistent with an effect of NRG1 on functional 
connectivity 372, perhaps through variation in expression of NRG1-ErbB4 pathway, which 
could contribute to GABAergic and glutamatergic imbalance. Since our results are 
significant in theta, alpha and beta-1 frequencies bands, which may support transitory, 
task-related coupling between distant areas of the brain 373, we could infer that genetic 
variation at NRG1 may influence on brain networks mostly in the modulation of long-
distance connectivity in the brain 
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Abstract 
A deficit in task-related functional connectivity modulation of the 
electroencephalographic (EEG) network has been previously described in schizophrenia. 
The use of measures of neuronal connectivity as an intermediate phenotype may allow 
identifying genetic factors involved in these deficits and therefore establishing 
underlying pathophysiological mechanisms. Genes involved in neuronal excitability and 
electric transmission and previously associated with the risk for schizophrenia may be 
adequate candidates in relation to functional connectivity alterations in schizophrenia.   
Two polymorphisms of voltage-gated ion channels CACNA1C (rs1006737) and KCNH2 
(rs3800779) were genotyped in 101 controls and 50 patients with schizophrenia. Small 
worldness index (SWn) was calculated from electroencephalography (EEG) signals 
recorded during an odd-ball task in two different temporal windows (pre-stimulus and 
response). Modulation was defined as the difference in SWn values between both 
windows. Genetic effect on SWn in the pre-stimulus window and in modulation was 
evaluated. 
The CACNA1C genotype was not associated with SW properties. KCNH2 was 
significantly associated with SWn modulation. Patients carrying the risk allele (A) 
showed a negative SWn modulation while patients not carrying the risk allele and 
controls showed a positive SWn modulation.  
Our data suggest that KCNH2 genotype contributes to the modulation efficiency of 
brain electrophysiological activity during a cognitive task in schizophrenia patients. 
Further studies with larger samples are required to confirm these results and to extend 
the knowledge of the implication of KCNH2 and CACNA1C in schizophrenia brain 
functional connectivity phenotypes.
7.1. Introduction 
Schizophrenia underpinnings remain largely unknown, which may relate to its 
complexity and heterogeneity. In this regard, endophenotypes reducing phenotypic 
complexity by means of intermediate phenotypes can contribute to shedding light on its 
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neurobiological mechanisms 374,375. Electroencephalography (EEG) is an excellent tool 
for studying neurophysiological intermediate phenotypes in schizophrenia 376. 
Oscillations in neuronal activity are known to play a crucial role in information 
processing and cortical communication 144 and are, therefore, considered not just 
biomarkers of, but essential components in neural communication and computation. 
Accordingly, data collected with EEG reflect synchronously firing neuronal assemblies 
and allow the study of functional connectivity during cognitive processes with high 
temporal resolution. Changes in brain functional connectivity have been suggested in 
the pathophysiology of schizophrenia 115–117,377 and, to a lesser extent, have also been 
detected in first degree healthy relatives of schizophrenia patients 378.  
The application of graph theory to EEG activity measures may help in refining the 
characterization of connectivity patterns in patients with schizophrenia. Brains minimize 
energy expenditure by combining highly clustered short-range local connections and 
maximizing integration of information between distant brain areas with a few long-
range connections 379,380. Such networks are named “small-world” (SW) networks and 
the Small-Worldeness (SWn) index reflect the closeness of a given network to that ideal 
structure. Higher SWn index relates to better information transmission capacity in a 
functional network 332. SWn results from dividing the global clustering coefficient (CLC) 
by characteristic path length (PL). CLC quantifies the connections of a node with their 
neighbour nodes and is interpreted as a measure of brain segregation. The characteristic 
PL is the average of all the shortest paths between each pair of nodes in the network 
and it reflects integration between distant nodes. One advantage of functional networks 
studies is the possibility of assessing its modulation with cognitive activity (i.e. the 
degree of connectivity changes associated with the cognitive demand). In one such study 
during a P300 paradigm, the functional network of schizophrenia patients was 
characterized by smaller SWn task-related modulation than healthy controls 117.  
Since schizophrenia is a genetically complex disorder with a heritability around 80% 
49, the use of intermediate phenotypes may also allow identifying disease-related 
genetic signatures 374,381. In this respect, the fact that neural oscillations are highly 
heritable traits in humans 382,383, supports the putative role of EEG as an intermediate 
phenotype in the pathway from genes to behaviour 384. As regards to resting-state EEG 
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functional connectivity, previous studies have also reported an important heritability 
across various frequency bands: 23-89% for CLC and 37-62% for PL 330,385. Despite 
evidence about genetic influences on EEG parameters, current understanding of specific 
genes or variants involved in electrophysiological phenotypes remains limited. On the 
one hand, recent genome-wide association studies (GWAS) have identified several 
candidate genes for schizophrenia, most of them converging on molecular complexes 
related to neuronal excitability and therefore also to functional connectivity processes. 
Some of those genes are related to voltage-dependent calcium channels, post-synaptic 
excitatory synapses components and gene expression regulation factors 48,386. On the 
other hand, EEG components have been significantly correlated with genes and gene 
clusters enriched for biological properties affecting neural circuitry, involved in the 
neuronal activity and/or neurodevelopment 387–389. Among these genetic candidates 
affecting neuronal excitability and electric transmission, we selected two genes in two 
voltage-gated ion channels (CACNA1C and KCNH2) as candidates to be studied in 
relation to functional connectivity alterations in schizophrenia. 
CACNA1C codifies for a pore protein (α1C) of L type voltage-gated calcium channels 
Cav1.2,  distributed throughout the brain 390 and primary mediators of neuron 
membrane polarity changes as well as of gene expression regulation 391,392. In vitro and 
conditional knockout mouse models have shown that a decreased activity of Cav1.2 
channels is related to an increased excitatory/inhibitory (E/I) ratio, to an altered 
synaptic protein composition and also to anxiety-like behavior and social behavior 
abnormalities 393,394. The critical role of Cav 1.2 in schizophrenia is highlighted by human 
genetic and imaging studies. From GWAS studies several SNPs in linkage disequilibrium 
at CACNA1C gene have been associated with neuropsychiatric disorders 48,386,395,396. 
The polymorphism rs1006737 at CACNA1C and the risk effect of the A allele has been 
replicated in different association studies and meta-analyses 397–403. In addition, the risk 
allele has also been related to: i) larger total and/or regional GM volumes both in 
patients with schizophrenia 404 and healthy subjects 63,405–407, ii) altered functional 
activity 401,408,409 and connectivity 405,408 during cognitive tasks 410,411. Accordingly, it is 
hypothesized that this polymorphism is related to variability in calcium currents and 
CACNA1C expression which in turn might affect transcriptional regulation of other 
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genes involved in neuronal signalling and excitability  401,412,413. 
KCNH2 gene encodes the pore-forming subunit of an ether-a-go-go (hERG)-family 
potassium channel, which is expressed in excitatory cells and modulates neuronal firing 
patterns 414,415. A meta-analysis has associated it with schizophrenia 416, although not 
the most recent GWAS studies 386,396. Specifically, the A allele of KCNH2 rs3800779 
polymorphism has been related to lower IQ and altered speed of cognitive processing 
and memory in both patients and healthy controls 416,417. Furthermore, it has also been 
associated with decreased hippocampal volume and increased hippocampal and 
prefrontal activation in healthy controls 416. It is noteworthy that the risk allele (A) 
seems to be involved in an increased expression of KCNH2 3.1, a primate isoform 
enriched in the brain with specific electrophysiological characteristics 416 and 
associated with alterations in dendritic spines, impaired cognition and altered 
activation in the prefrontal cortex and hippocampus in a mouse model 418.  
Accordingly, our objective was to analyze the effect of two schizophrenia risk genes 
relevant to neuronal excitability and connectivity (CACNA1C and KCNH2) on the changes 
in functional connectivity during the performance of a cognitive task (as measured with 
the EEG Small-Worldness index modulation), both in individuals with schizophrenia and 
healthy controls.  
7.2. Material and methods 
7.2.1. Sample description 
We recruited 50 Spanish Caucasian patients according to DSM-V-TR criteria diagnosis 
of schizophrenia. Diagnoses were made or confirmed by an expert clinician (V.M.). 
Twenty-five of them were first-episode patients with an illness duration shorter than 
one year.  All patients were receiving stable doses of antipsychotics. Symptoms were 
scored using the Positive and Negative symptoms scale (PANSS). Exclusion criteria 
included: medical illnesses affecting the central nervous system, substance-induced 
psychotic disorder, neurological conditions, history of head trauma with loss of 
consciousness, and IQ<70.  
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The control sample consisted of 101 Spanish Caucasian unrelated adult healthy 
individuals. They met the same exclusion criteria as patients as well as any current 
psychiatric disorder or treatment. 
All participants provided written consent after full written information. The study was 
performed in accordance with the guidelines of the institutions involved and approved 
by the local ethics committee. All procedures were carried out according to the 
Declaration of Helsinki. Demographic and clinical variables are shown in Table 7.1. 
 
Table 7.1. Sociodemographic and clinical information of patients and controls. 
Statistically significant differences were detected only in relation to patients' years of 
education (in bold, p < 0.01). 
  
Controls 
 n=101 
Patients  
n=50 
Sex (M:F) 51:50 29:21 
Age (mean and sd) 29.52 (9.83) 32.60 (9.80) 
Education (years) 15.98 (2.07) 14.21 (3.77) 
Father education (years) 13.19 (3.92) 11.72 (4.61) 
PANSS Positive - 12.92 (5.47) 
PANSSNegative - 17.72 (7.39) 
PANSS General - 25.16 (12.43) 
PANSS Total - 55.34 (22.51) 
Illness duration (months) - 80.76 (107.68) 
CPZ equivalents (mg) - 355.02 (273.49) 
 
7.2.2. Molecular analysis 
Genomic DNA was extracted from blood using standard methods. Two SNPs were 
genotyped: i) rs1006737 (A/G, intron variant, chromosome position 2236129) at 
CACNA1C gene (12p13.33); ii) rs3800779 (A/C; intron variant, chromosome position 
150974126) at KCNH2 (7q36.1). Genotyping was performed using a fluorescence-based 
allelic discrimination procedure (Applied Biosystems Taqman 5’-exonuclease assays). 
Standard conditions were used. Polymerase chain reaction plates were read on ABI 
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PRISM 7900HT instrument with SDS v2.1 software (Applied Biosystems). The genotyping 
call rate for both SNPs was higher than 99%. The accuracy of the method was tested by 
re-genotyping a 10% of the samples and confirming all the repeated genotypes. The two 
SNPs were in Hardy-Weinberg equilibrium.  
Based on the risk allele and the genotypic frequency, for the statistical analyses, both 
patients and controls were classified as risk-allele carriers (for CACNA1C: AA+AG; for 
KCNH2: AA+AC) or non-carriers (for CACNA1C: GG; for KCNH2: CC) (Table 7.2).  
 
Table 7.2. Information on SNPs included in this study. The table includes the dbSNP 
number, the genomic and gene position and the alleles of each SNP (GRCh38.p7). 
Observed genotypic and allelic frequencies are also given. 
GENE-SNP Chr 
Chr 
Position* 
Position Allelesa MAF1000Gb MAFsamplec 
Genotype Absolute Frequency. 
Controls / Patients (%) 
CACNA1C 
(rs1006737) 
12 2236129 Intronic G/A 0.302 / 0.374 0.285 
GG: 
0.57/0.50 
GA: 
0.38/0.46 
AA: 
0.05/0.04 
KCNH2 
(rs3800779) 
7 150974126 Intronic C/A 0.211 / 0.283 0.305 
CC: 
0.55/0.5 
CA: 
0.34/0.36 
AA: 
0.11/0.14 
*Chromosome position GRCh38 assembly. 
aThe less frequent allele (minor allele) is placed second. 
bMAF refers to Minor Allele Frequency observed in the 1000 Genomes project across all populations 
/ in CEU populations (Project Consortium). 
cMAF observed in the current sample. 
 
7.2.3. EEG acquisition and processing 
EEG data were recorded in the subsample previously described during a thirteen 
minutes 3-tone oddball task, which consisted of 600 random sequences of target (500 
Hz-tone, probability 0.2), distractor (1000 Hz-tone, probability 0.2), and standard (2000 
Hz-tone, probability 0.6) tones. It was recorded using a 17-channel EEG system 
(BrainVision®, Brain Products GmbH) allocated following international 10-20 system 
(Fp1, Fp2, F3, F4, F7, F8, C3, C4, P3, P4, O1, O2, T5, T6, Fz, Pz and Cz). Acquisition 
parameters: Impedance<5 kΩ, sampling frecuency=500 Hz, referenced over Cz. 
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EEG recordings were re-referenced to the average activity of all sensors in order to 
minimize the effect of microsaccadic artefacts 350. Data were filtered using a finite 
impulse response (FIR) band-pass filter (1–70 Hz, Hamming window) and a notch filter 
to remove the power line frequency interference (50 Hz, Butterworth filter).  
Artefacts were rejected and continuous EEG data were segmented into 1s-length 
trials ranging from -300 ms before target stimulus onset to 700 ms after onset. Time-
frequency representation of EEG was computed using continuous wavelet transform 
(CWT) including frequencies from 1 to 70 Hz 351,419,420. Thus, 1s-length evoked responses 
([-300 - 700] ms) were decomposed into two windows: (i) pre-stimulus ([-300 0] ms to 
target stimulus onset); and (ii) response ([150 450] ms after target stimulus onset) 351,419. 
These windows were chosen to summarize the functional modulation between pre-
stimulus and response (assumed to summarize cognitive processing). 
From each window CWT decomposition, event-related Coherence (ERC) was 
computed for each pair of electrodes 351,354,419 and its changes in ERC between resting 
and active windows allowed the assessment of task-related modulation in graph 
parameters.  
Graph parameters calculation was obtained where each electrode corresponded to 
nodes and ERC parameters to the weights of the links between vertex (edges). 
Completely filled ERC matrices were then used as adjacency matrices. From the 
matrices, two parameters were computed in each temporal window pre-stimulus (p) 
and response: i) CLC, characterize the segregation of the network 357; ii) PL, characterize 
the integration of the network, it is defined as the average shortest path length between 
all pairs of nodes in the network. CLC and PL were normalized to eliminate dependencies 
dividing CLC and PL data by random parameters following the method proposed by 356 
over an ensemble of 50 surrogate network. 
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where dij indicates the minimum distance (i.e. the inverse of ERC) between electrodes 
i and j.  
𝑆𝑊𝑛 =
𝐶𝐿𝐶
𝐶𝐿𝐶𝑟
⁄
𝑃𝐿
𝑃𝐿𝑟
⁄
  (3) 
SWn was calculated as the ratio between segregation (CLC) and integration (PL). In 
order to achieve a stimulus-independent characterization 351 and to quantify the 
dynamical changes during the evoked response (i.e: network modulation), SWn 
modulation (SWm) parameter was calculated subtracting SW at pre-stimulus (SWp) the 
SWn at the response window. Further description of EEG processing is detailed in 117. 
SWn indexes were used for the analyses as they are interpreted as good resume 
parameters characterizing the network efficiency and they have been shown to differ 
between patients and controls 117.  
7.2.4. Statistical analysis  
Data were analysed using SPSS 20.0 software. 
We compared age, sex distribution, years of education and parental education years 
between patients and controls using chi-squared or t-tests when appropriate.  
As the SWn measures were previously compared between patients and controls in a 
previous report including most of the current sample 117, this comparison was not 
included as an aim of the study. However, we did evaluate the effect of age, sex, illness 
duration, and treatment on patients’ SWn measurements and of age and sex in healthy 
subjects using Pearson correlation or Student’s t-test.  
To test the association between the genetic polymorphisms and SW measures, 
analyses of variance (ANOVA) were performed. The effect of genotype, group (patient 
or control) and their interaction (genotype x group) were tested on: i) SWn index at the 
pre-stimulus window (SWp), and ii) SWn modulation (SWm).  
To gain a better understanding of the significant detected effects, the relationship of 
the genotype and SWn parameters were tested separately in patients and healthy 
subjects with Student’s t-tests. Also, clinical differences between patients carrying the 
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risk allele and non-carriers were assessed with Student’s t-test or U-Mann Whitney tests 
when appropriate. 
7.3. Results 
There were no differences in age, sex distribution or parental education between 
patients and controls; while, as expected, years of education were significantly lower in 
patients (Table 7.1). Moreover, age, sex distribution, illness duration, and treatment did 
not have significant effects on SW measurements, therefore, these variables were not 
included as covariables in the posterior analyses. 
For CACNA1C, there was a significant effect of group on SWp (F=15.098; p<0.001) and 
SWm (F=5.623; p=0.019). Nevertheless, there were no significant effects of genotype or 
interaction for neither SWp nor SWm. Patients carrying the risk allele showed no clinical 
differences in comparison to those without the risk allele (Table 7.3).  
For KCNH2, there was a significant effect of group on SWp (F=16.190; p<0.001), with 
patients showing lower SWn modulation values than controls (mean (sd): patients 0.003 
(0.03) and controls 0.013 (0.02)). Neither genotype nor interaction effects were 
detected on SWp. As regards to SWm, there was a significant effect of group (F=6.156; 
p=0.014), genotype (F=6.19; p=0.013) and interaction (genotype*group) (F=6.209; 
p=0.014). Subsequently, a t-test revealed differences within patients, with risk-allele 
carriers showing negative values in SWm while non-carriers presented positive values 
(t=-2.84; df=48; p=0.007) (Figure 7.1 and 7.2 and Table 7.3). Patients carrying the risk 
allele did not differ in clinical variables from non-carriers (Table 7.3). Within controls, no 
differences between carriers and non-carriers were observed in SWp and SWm.  
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Table 7.3. Sociodemographic, clinical and EEG functional connectivity variables mean 
and standard deviation per group and genotype. Differences between genotypic groups 
(risk-allele carriers vs non-carriers) within patients or controls are marked in bold 
(p<0.01).  
CACNA1C   Controls AA/AG Controls GG  Patients AA/AG  Patients GG 
(rs1006737) n=43 n=58 n=25 n=25 
Sex (M:F) 23:20 28:20 17:08 12:13 
Age (mean and sd) 29.98 (9.98) 29.19 (9.79) 32.52 (9.00) 32.68 (10.72) 
PANSS Positive - - 13.11 (5.79) 12.74 (5.29) 
PANSS Negative - - 18.21 (8.00) 16.68 (6.84) 
PANSS General - - 26.11 (13.87) 24.21 (11.09) 
PANSSTotal - - 57.37 (25.11) 53.32 (20.05) 
Illness duration (months) - - 73.65 (103.69) 89.12 (114.80) 
CPZ equivalents (mg) - - 418.30 (290.29) 296.80 (248.70)  
SWn pre-stimulus 1.021 (0.024) 1.025 (0.023) 0.987 (0.068) 1.007 (0.048) 
SWn modulation 0.012 (0.025) 0.014 (0.022) 0.001 (0.026) 0.004 (0.031) 
KCNH2  Controls AA/AC Controls CC Patients AA/AC Patients CC 
(rs3800779)  n=45 n=56 n=25 n=25 
Gender (M:F) 16:29 35:21 16:09 13:12 
Age (mean and sd) 29.53 (9.61) 29.52 (10.09) 32.64 (10.5) 32.56 (9.26) 
Panns Positive - - 13.00 (5.05) 12.85 (5.96) 
Panns Negative - - 20.00 (8.55) 15.15 (5.40) 
Panss General - - 27.11 (15.20) 23.4 (9.34) 
Panss Total - - 60.17 (25.48) 51.00 (19.07) 
Illness duration (months) - - 66.31 (80.28) 91.76 (125.47) 
CPZ equivalents (mg) - - 375.91 (278.92) 335.8 (272.69) 
SWn pre-stimulus 1.03 (0.018) 1.018 (0.027) 0.993 (0.067) 1.000 (0.051) 
SWn modulation* 0.013 (0.025) 0.013 (0.022) -0.008 (0.024) 0.013 (0.028) 
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Figure 7.1. Patterns of SWn changes per group and genotype (KNCH2 rs3800779) 
from pre-stimulus to response windows. 
Figure 7.2. Distribution of SWn values at the pre-stimulus window (left) and 
modulation (right). Significant differences are marked with asterisk: * p<0.05; ** p<0.01. 
Mean and standard deviation for each group and genotype (KCNH2 rs3800779) are in 
the bottom of the figure. 
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7.4. Discussion 
In the present study, we report a significant genetic effect of KCNH2 on brain 
functional connectivity measured with EEG during an odd-ball task. However, we have 
not observed any effect of CACNA1C on this connectivity. In particular, patients carrying 
the KCNH2 rs3800779 risk allele showed an opposite pattern of SWn modulation in 
comparison with patients not carrying the risk alleles and healthy controls. Specifically, 
we found that patients carrying the A allele had negative SWn modulation, which means 
lower SWn values at response than at pre-stimulus window, contrary to the modulation 
pattern in patients not carrying the risk allele and controls.  
Contrary to what we expected, we did not find a significant effect of CACNA1C on 
brain connectivity as measured with SWn parameters (pre-stimulus or modulation). 
Nevertheless, the involvement of CACNA1C in SWn parameters cannot be completely 
excluded. First, because of the sample size and the minor allele frequency, the analyses 
have been conducted by comparing risk allele carriers versus non-carriers, which has not 
allowed testing the recessive effect of the risk allele. In this regard, a study using induced 
human neurons reported functional effects of the rs1006737 (i.e. increased Ca2+ 
current density as well as increased mRNA expression of CACNA1C) only when the risk 
allele was in homozygosis 413. Second, as suggested by previous studies, the possible 
effect of CACNA1C on connectivity could depend on the effect of other close 
polymorphisms 412,421 or on specific haplotypes 422. Third, most of the evidence on the 
effect of CACNA1C on brain activity or connectivity comes from studies based on healthy 
subjects 405,408,409. Then, there is little evidence to understand its effect in the disease 
context. To this respect, further studies are needed, also to better define the allelic 
effects as some studies that analysed the effect of CACNA1C on brain activity reported 
opposite effects; for instance the risk allele has been associated with both increased and 
decreased DLPFC activation 401,409, or even with beneficial effects on structural 
connectivity in patients 423.  
Moreover, recent data highlight other factors that can modulate the impact of 
CACNA1C in the brain. It has been observed in animal models that the effect of changes 
in CACNA1C availability seems to be dependent on the stage of neurodevelopment 424. 
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Also, it has been reported that the effect of early exposure to traumatic events on brain 
activity is mediated by the rs1006737 425. 
With respect to KCNH2, in controls, a positive SWn modulation was observed 
irrespective to the genotype, which could be interpreted as a network reorganization 
towards higher efficiency with task performance. Therefore, the opposite pattern 
observed in patients with the risk allele might be reflecting the allele-associated reduced 
ability to modulate efficiently the electrical activity during a cognitive task. It is of 
mention that there were no differences in clinical variables between patients with and 
without the risk allele. Consequently, the SWn differences observed in patients 
depending on the KCNH2 polymorphism were not driven by symptoms, treatment 
dosages or illness duration.  
We reported in our previous work 117 that SWn modulation differed between patients 
and controls. In that results, patients, as a whole, showed similar SWn modulation 
patterns than patients with the risk allele in the present report. Thus, the functional 
network alteration that we previously found might be contributed by KCNH2 genotype 
risk variant.  
The detected effect of the rs3800779 polymorphism is in line with its previously 
reported functional effects: the A allele has been associated with an increased 
expression of the KCNH2-3.1 brain isoform 416, which confers specific electrical 
properties to the neuron, like higher firing rate and faster deactivation 418. These 
properties might affect directly the spread of action potentials and consequently the 
coordination and communication between distant group of neurons. Therefore, the 
effect that we observed might be coherent with the neuronal bioelectrical properties 
associated with this polymorphism, which might influence the functional connectivity 
patterns in the patient group.  
In addition to these functional effects of the rs3800779 KCNH2, the evaluation of the 
putative effects on gene expression regulatory mechanisms represents a valuable 
resource to provide additional meaning to our association data. This can be examined 
using HaploReg 426, which is a tool that provides data on the predicted chromatin state 
of the queried SNP, their sequence conservation in mammals and their effect on 
regulatory motifs. Interestingly, this SNP is a binding site for the transcription factor 12 
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(TFC12), which is described to participate in regulating lineage-specific gene expression. 
Also, this SNP is predicted to alter a regulatory motif, with the A allele showing lower 
affinity for a transcription factor (PAX-5) that is involved in neurodevelopment. Such 
data point towards a putative molecular mechanism underlying the previously described 
impact of the rs3800779 risk allele on an increased KCNH2 expression and a higher firing 
rate and faster deactivation 418. Accordingly, despite not extensive, the accumulated 
data indicate that the risk variant in KCNH2 affects the biology of the gene in a way that 
converges on key aspects of the biology of the disorder such as neuron excitability 
alterations. Thus, the effect of gene variants might be weakly or not detected in relation 
to the susceptibility for schizophrenia but might be robust in risk-allele carrying 
populations in relation to specific intermediate phenotypes such as brain functional 
connectivity phenotypes. In this line, the results from the present study further support 
the role of genetics in the identification of groups of patients with different connectivity 
profiles, which would fit with the already suggested existence of schizophrenia 
subgroups with different biological abnormalities as an explanation of the 
heterogeneous research findings, the lack of replicability and inaccuracy of current 
clinical diagnosis 6,427.  
Our study has some limitations, principally the sample size, although Arnedo 58 
argued that the low replication rate in genetic studies is not due to small sample sizes 
but to complex genetic and phenotypic architecture. Accordingly, despite the selected 
genes and SNPs have been consistently associated with schizophrenia, the polygenic 
nature of the disorder and the minor effect of common genetic variants limit the power 
of our sample. Another limitation is the EEG frequency range selected for the study. We 
limited the functional modulation parameters to the broad band from 4 to 70 Hz in order 
to decrease the risk of type I errors and improve interpretably; however, modulation in 
each frequency band separately could yield relevant results. In summary, the 
interpretation of these results should be done with caution and further studies are 
required.  
In conclusion, our data suggest that KCNH2 genotype contributes to functional 
connectivity deficits in schizophrenia patients. We did not find an association between 
CACNA1C polymorphism and EEG SW properties; however, based on literature, we 
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cannot discard its potential effect on connectivity. Further studies with larger samples 
are required to confirm our results and to extend the knowledge of the implication of 
KCNH2 and CACNA1C and in schizophrenia electrophysiological related phenotypes. 
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Discussion  
 
In this thesis, the hypothetical existence of biological distinctive subgroups among 
patients with schizophrenia has been explored. We tested two classifying approaches as 
potential tools that could be used to disentangle the schizophrenia aetiology problem. 
We shed light on the research replication problem, that is, the inconclusive variability of 
biological abnormalities found within patients with the same diagnosis.  
As a whole, we demonstrated a large heterogeneity in both structural and functional 
connectivity among schizophrenia patients. We then showed the utility of classifying 
patients based on biological data rather than through clinical diagnosis. We propose that 
classifying methods similar to those used in this thesis are necessary to solve the lack of 
research findings replication, the biological and clinical heterogeneity. Our results 
support the need to change current psychiatric research perspective towards the 
underlying biological mechanisms with the aim of achieving better clinical validity.  
In the first article, using brain anatomy data from magnetic resonance imaging, we 
identified a subgroup of approximately 20% of schizophrenia patients who display an 
increased cortical curvature (hipergyrification) at the frontal lobe, temporal lobe, 
cingulate and insula. This subgroup was also characterised by hypometabolism in the 
caudate and thalamus, a lack of increased metabolism in the putamen (a marker of 
treatment response) and more persistent negative symptoms.  
In the second article, we observed that cortical curvature in PFC was inversely related 
to the integrity of WM fibres connecting the PFC with the anterior cingulate and 
temporal lobe, primarily in schizophrenia chronic patients. Therefore, it is plausible that 
the increased cortical curvature characterising the schizophrenia subgroup is an indirect 
marker of worse short-range structural connections. It is worth noting that patients 
without clinical improvement after follow-up had larger values of cortical curvature in 
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the superior medial prefrontal cortex and that cortical curvature was inversely 
associated with cognitive performance but not with antipsychotic treatment, illness 
duration or PANSS scores.  
In the third article, we observed significant decreases of WM integrity, that is, 
decrease FA in fibres connecting the PFC to the ACC, caudate and hippocampus in a 
group of 27 patients. The reduced integrity of short cortico-cortical WM fibres (PFC-ACC) 
was associated with poorer executive function and problem-solving. Surprisingly, better 
structural connectivity between the PFC and caudate was associated with positive 
symptoms, but negative symptoms were associated with worse connectivity between 
PFC and thalamus. Illness duration was related to worse WM connectivity between PFC 
and subcortical areas, and treatment dosages were not related to WM integrity. These 
results in both the second and third article reinforced the possible existence of a 
schizophrenia subgroup with higher cortical curvature, probably due to impaired short-
range connectivity, and reduced cognitive performance. 
Considering together the first and third articles, it can be deduced that pooling 
together patients as a homogeneous group might lead to incorrect conclusions. In the 
third article, structural abnormalities were found in schizophrenia patients as a whole. 
Importantly, using neuroanatomical data and a data-driven clustering procedure (not 
taking in consideration the diagnosis), it is evident that schizophrenia patients do not 
share the same structural connectivity abnormalities. Rather, these abnormalities are 
markedly different in the subgroup of patients identified in the first article. Thus, by 
restricting our analysis to the usual comparison of patients versus controls, we would 
have assumed that cortical connectivity abnormalities are shared by all schizophrenia 
patients, which does not seem to be the case. 
In the fourth and fifth articles, we observed the utility of selected genetic 
polymorphisms to classify individuals with or without genetic risk and studied the 
subgroup´s relation to functional connectivity. Specifically, we included genes involved 
in myelination, excitatory/inhibitory (E/I) balance and neuronal signal transduction 
contributing to neuronal networks organization. In the first approach (fourth article), we 
observed that three polymorphisms in the NRG1 gene and related to increased risk of 
psychosis exert an effect on functional networks modulation during an odd-ball task in 
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healthy controls. In the second approach (fifth article), patients and controls were 
classified depending on polymorphisms located in ether calcium or potassium channels. 
We observed an effect of KCNH2 rs3800779 polymorphisms, but not CACNA1C 
rs1006737 polymorphism, on the functional connectivity changes in patients during an 
auditive odd-ball task. KCNH2 polymorphism separated two groups of schizophrenia 
patients with significant differences in their functional connectivity modulation 
efficiency: the first group included patients carrying the risk allele, and the second group 
included patients non-carrying the risk allele (homozygous for the non-risk allele). Those 
patients who carry the risk allele (AA or AC genotype) had an opposite functional 
network modulation, measured as SWn modulation, in comparison to non-risk allele 
carriers. Thus, a group of patients with hampered functional connectivity could be 
distinguished based on genetic variants in potassium channels.  
We cannot know whether the higher cortical curvature and the potassium risk-allele 
carriers subgroups overlap. We might tentatively hypothesize that they are different 
subgroups considering other work from our team 120(not included in this thesis), in which 
we showed that functional and structural connectivity abnormalities did nor co-occur in 
the same patients. Indeed, functional connectivity has been previously observed 
between areas not structurally connected 283,428. 
Therefore, we may have identified two different subtypes of schizophrenia patients, 
respectively related to structural and functional connectivity alterations. Nevertheless, 
it is not clear yet how both connectivities are associated, since some previous results 
supported a mutual relationship 122,131,132,134, while others do not 90,133. Furthermore, we 
cannot discard the possibility that the higher cortical curvature could also be a marker 
of functional connectivity. In that sense, Nenadic and colleagues observed a widespread 
cortical thinning (which might reflect functional connectivity disruptions through, for 
example, loss of dendrites connections) characterising a subgroup of patients with 
negative symptoms 81. Additional work reported a correlation between gyrification and 
functional connectivity 429. 
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Figure 8.1. A scheme summarizing the most important findings in this thesis. 
 
8.1. Subgroups of schizophrenia patients based on structural 
connectivity 
Concerning curvature, abnormalities have been previously described in 
schizophrenia patients as a whole. Both hypergyrification in some frontal areas and 
hypogyrification in the insula, superior temporal, inferior frontal and inferior parietal 
cortex have been reported 430,431. In agreement with the subgroup that we identified, 
increased prefrontal gyrification has been found in high-risk individuals, chronic 
schizophrenia patients and their relatives 233,432,433, which indicates a possible genetic 
contribution to curvature. In fact, polygenic risk score for schizophrenia was positively 
associated with frontal gyrification in individuals at high familial risk 434 but negatively 
associated with inferior parietal curvature in healthy individuals 435. By contrast, there 
are also some reports indicating lower prefrontal gyrification in schizophrenia patients 
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436–439. The main reason behind these discrepancies is likely due to the previously 
mentioned biological heterogeneity in schizophrenia, but it could also be related in part 
to recruitment strategies and sampling selection. For example, increased curvature was 
described in first episode (FE) schizophrenia 433,440, which would correspond to our group 
of FE patients included in the subgroup presenting gyrification abnormalities. However, 
a decreased curvature has also been reported, including principally FE non-responders 
to treatment 439. Finally, another study did not report curvature differences of the ACC 
in FE schizophrenia patients 234. FE patients with no curvature abnormalities might 
correspond to those FE patients included in the subgroup of patients we reported 
without curvature abnormalities. 
Our findings demonstrated that frontal increased curvature is related to abnormal 
connectivity. This is in agreement with previous data showing that disrupted 
connectivity during development would be reflected in abnormal gyrification 248. 
Indeed, one study used gyrification index as a marker of cortico-cortical connections in 
subjects at high risk of schizophrenia, schizophrenia patients and controls 432. Moreover,  
another study, in relatives of patients with schizophrenia, suggested that frontal cortical 
curvature is directly related to short-range functional connectivity (connections 
between the medial and lateral PFC), and inversely related to long-rate functional 
connections (PFC-thalamus) during a cognitive task 429. Therefore, we can interpret 
curvature as a marker of short-range cortico-cortical connections. Thus, the subgroup 
that we identified based on curvature could be related to a higher white matter 
dysconnectivity or, alternatively, the gyrification abnormalities might be caused by 
disrupted connectivity.  
So far, we have managed to characterise a subgroup of patients with marked 
gyrification, probably related to structural cortical connectivity, metabolic disruptions 
and more severe negative symptoms. This subgroup is notably in agreement with a 
previously reported subgroup of first episode treatment-naïve patients characterised by 
widespread WM abnormalities and higher negative symptoms 35. In our case, the 
subgroup of patients with higher cortical curvature included almost 50% of first episode 
patients despite the fact that they were receiving antipsychotic treatment (the 
remaining 50% were chronic schizophrenia patients). In a similar direction, a positive 
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correlation between occipital gyrification and negative symptoms was previously 
described 437. Also, partially in accordance with our results, another previous study 
supported a subgroup of patients with higher negative symptoms and widespread 
cortical thinning 81. In this case, cortical thinning was moderate in patients with 
predominantly positive symptoms and mild in those with disorganised symptoms.  
As stated in the first article, contrary to our hypothesis, cortical thickness was not the 
most discriminant variable to classify patients based on neuroanatomical data. 
Nevertheless, decreased cortical thinning is present in the ACC, right caudal middle 
frontal, precentral and superior frontal cortex in the aforementioned patients’ subgroup 
identified (with higher cortical curvature), but not in the remaining patients with 
schizophrenia or bipolar disorder. Those areas were among the areas altered in the 
subgroup identified by Nenadic and colleagues 81. However, in our study, treatment-
resistant patients were not included. Therefore, we cannot discard the possibility that 
treatment-resistant patients with negative symptoms could be distinguished by higher 
cortical thinning. 
In contrast to our results, a subgroup of schizophrenia patients with greater WM 
impairment and longer illness duration, but no differences in negative symptom, has 
been previously reported 441. This lack of differences in negative symptoms might be 
contributed by a gender and age disequilibrium in the subgroups that they identified, 
specifically the group characterised by structural connectivity disruption had older mean 
age and included a higher proportion of males  
It is interesting to note that patients non-responders to treatment with predominant 
positive symptoms, in particular, auditory hallucinations, have shown lower gyrification 
in language areas in comparison to controls 235. Similarly, patients with delusional 
infestation showed hypogyrification in the posterior frontal lobe, parietal lobe and right 
middle temporal cortex 442. Moreover, lower cortical gyrification values could be 
associated with positive symptoms in schizophrenia 437. Therefore, it is likely that higher 
gyrification is not present in patients with predominantly positive symptoms, which is in 
agreement with our finding relating higher gyrification to negative but not to positive 
symptoms.  
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In order to validate the patient subgroup we found, it is important to rule out that 
this subgroup was merely driven by treatment and illness duration. In our case, patients 
with and without higher cortical curvature do not differ in time of illness duration or 
antipsychotics doses. Congruently, in the second article, we found that curvature and 
those clinical variables were unrelated. Moreover, the third article confirmed that 
treatment was not related to WM integrity, but illness duration was indeed inversely 
associated with FA in the connections between superior-medial prefrontal cortex and 
subcortical regions (hippocampus or caudate), but not in short-range cortico-cortical 
connections. In agreement with our findings, other works showed that gyrification was 
not correlated with treatment doses or illness duration 430. Moreover, a tendency 
towards lower gyrification with age, illness duration 431,433,437,438 and medication 433 was 
described. Considering all these findings, we may conclude that the increased curvature 
in the identified subgroup is not due to the possible influence of these confusion factors.  
It is particularly interesting that the ACC, which has been considered a core region 
altered in schizophrenia and with homogeneous data among articles 28, is one of the 
most important areas involved in the structural dysconnectivity we found in patients. 
Prefrontal connection with the ACC is possibly partially responsible for the increased PFC 
curvature we found. However, besides the described is homogeneity, we observed that 
ACC abnormalities, in curvature, thickness or area, were not present in all patients. 
Indeed, we observed a decreased left ACC cortical thickness and an increased right ACC 
cortical curvature in our subgroup of patients with hipergyrification, but not in the 
remaining schizophrenia patients. This points out that the ACC is not homogeneously 
altered in all schizophrenia patients.  
We observed that higher PFC cortical curvature was associated with worse cognition 
and that lower WM integrity of short-range connections was correlated with worse 
executive and problem-solving function. Thus, we hypothesized that our subgroup with 
marked cortical curvature would have more severe cognitive deficits. Indeed, increased 
cortical gyrification was previously associated with poorer executive function in first-
episode patients 433. This finding agrees with a subgroup of patients with severe 
cognitive deterioration (28% of all patients) who showed greater deficits in grey and 
white matter, as well as elevated negative symptoms 443. In the same direction, 
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supporting the idea that greater WM impairments are associated with cognitive 
abnormalities, a subgroup of patients identified with higher cognition impairments was 
also characterized by WM abnormalities and larger ventricles 444. On the contrary, 
patients with mild cognitive impairments showed better life functionality, less severe 
positive and negative symptoms but more depression 445, accompanied by GM deficits 
but not WM disruptions 444. 
8.2. Subgroups of schizophrenia patients based on genotype 
and functional connectivity 
In a previous report 117, we observed functional connectivity abnormalities in 
schizophrenia patients during the same odd-ball task used in this thesis. Functional 
connectivity was also assessed using SWn index, which depends on the synchrony and 
coordination of the brain activity and, therefore, close to the substrate of mental 
functions altered in schizophrenia. In that article, patients showed higher SWn values at 
the pre-stimulus window but lower SWn modulation in comparison to controls. On this 
basis, we wanted to explore the effect of genetic polymorphisms on SWn modulation 
and thus the possible existence of groups of patients based on modulation deficits.  
Firstly, we found that genetic variants associated with schizophrenia risk in NRG1 
gene were related to altered SWn values at baseline and its modulation in healthy 
participants. This means that functional connectivity efficiency is partially mediated by 
this polymorphism in the population. This makes genetics a promising tool for 
identifying possible biologically-determined subgroups of schizophrenia patients. 
Secondly, we observed that KCNH2 rs3800779 polymorphisms, but not CACNA1C 
polymorphism, was able to discriminate a subgroup of patients with abnormal global 
functional connectivity modulation (SWn modulation) during the odd-ball task.  
The KCNH2 rs3800779 polymorphisms had a significant effect on SWn modulation 
only in patients but not in controls. Thus, although we did not include patients in the 
NRG1 study, speculatively, it might be possible that the effect of NRG1 polymorphisms 
on functional connectivity could be different and even more significant in patients, and 
hence useful to differentiate subgroups too. Indeed, as the effect of single genetic 
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variants is small, polygenic scores, (scores that agglutinate information of several 
genetic variants associated with schizophrenia risk) may be the best option to explore 
the existence of subgroups based on genetics446, instead of the traditional candidate 
gene approach.  
The lack of association in our results between CACNA1C rs1006737 polymorphism 
and functional connectivity (SWn at baseline or SWn modulation) could be related to 
the wide frequency range included in the article (4 to 70 Hz). CACNA1C seems to 
contribute highly to gamma oscillations (32-64 Hz) 447, therefore, its possible effect on 
functional connectivity would be more evident in the high-frequency bands. 
As far as we know, there are no previous articles studying the relationship between 
these polymorphisms and the efficiency of global functional connectivity modulation. 
There are previous data supporting abnormal functional connectivity during the 
performance of a P300 or working memory tasks. For example, Quidé and colleagues 
observed that, while healthy controls increase their functional connections in relation 
to task performance between PFC, caudate, putamen or parietal lobe, patients did not 
448. In fact, patients showed abnormal patterns of increased connectivity between the 
ventrolateral PFC and putamen, which were inversely associated with working memory 
performance 448. Another study found that the association between functional 
connections and the P300 amplitude was opposite in first-episode patients and healthy 
controls 103. In a similar direction, alteration in both task-negative and task-positive 
networks was described in patients with schizophrenia 104. Finally, increased 
connectivity between DLPFC and hippocampus has been consistently found in patients 
and was related to better task accuracy and decreased symptomatology 104.   
Based on patient’s performance on a working memory task, a report showed that the 
group with better performance exhibited increased functional connectivity involving 
DLPFC and other areas in comparison to the remaining patients and controls 449. Indeed, 
controls with better and worse cognitive performance did not differ in functional 
connectivity 449. Therefore, it seems that patients appear to compensate for their 
disruptions in functional connectivity by increasing some connections. In other words, 
those patients who are able to compensate for their brain connection alterations may 
have better cognitive resources. By contrast, those patients with more difficulties in 
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compensating for their functional connection disruptions may show a reduced cognitive 
ability.  
On the other hand, since we evidenced in two different studies, that impaired SWn 
modulation is related to both KCNH2 rs3800779 polymorphism and cognition 117, and 
the same polymorphism has been found associated with impaired cognitive 
performance and lower intelligence quotient 416,417, it could be possible that the 
cognitive impairments associated with KCNH2 rs3800779 are mediated by the inability 
to properly modulate their functional connections (SWn modulation). Indeed, those 
patients previously described, who had a lower capacity to compensate for their 
functional connectivity deficits and showed cognitive disruptions, might overlap with 
the subgroup of patients carrying the KCNH2 risk allele and showing abnormal SWn 
modulation. While, on the contrary, those patients who were able to compensate their 
functional connections and showed better cognitive performance, might overlap with 
the patient subgroup not carrying the risk allele and showing preserved SWn 
modulation.  
In terms of graph parameters, and in agreement with our results, other studies 
supported abnormal SW properties in schizophrenia, such as lower CLC and higher PL in 
beta band resulting in lower SW values 115. In the same vein, decreased SW network 
properties in beta, alpha and gamma frequency bands were described in a well-
functioning group of patients 126. In the latter study126, the disruption was higher during 
cognitive task than in resting state, encouraging the study of subgroups of patients 
based on functional connectivity during cognitive activity, as we did. 
In line with our findings, an interesting study including schizophrenia, schizoaffective 
disorder and bipolar disorder patients, identified three trans-diagnostic subgroups of 
patients based on cognition and sensorimotor data (eye movements and 
electrophysiological measures during paired stimuli task, odd-ball task, saccade task and 
stop-signalling task) 450. The first subgroup, called biotype 1, was characterized by the 
highest cognitive impairment, worst neurophysiological reactivity to stimuli, including 
higher inhibition error rates, the lowest amplitude and the poorest target detection. 
These patients showed widespread GM deficits and the most impaired psychosocial 
functioning. The second subgroup, called biotype 2, did not show such severe 
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alterations, with mild cognitive disturbances, accentuated sensorimotor reactivity 
(including normal to higher amplitude), highest stimuli-unrelated EEG activity and 
normal target detection. This second group also presented widespread GM deficits, but 
less marked, and mild impairments on the psychosocial function. Finally, the third 
subgroup, called biotype 3, was the most similar to healthy controls. Their cognitive 
function was preserved, with modest sensorimotor disruption, discrete GM reductions, 
specifically located in anterior limb areas, and good psychosocial functioning. The first 
and second groups did not differ on clinical symptoms, but the third group had 
significative lower positive and negative symptoms scores. Interestingly, these 
characteristics, though more moderate, were found in the relatives of each group of 
patients. The authors argued that, possibly, the subgroups one and two could be more 
related to familiar genetic risk as well as related to calcium and potassium channels 
disruptions, reinforcing, in agreement with our studies, the utility to study subgroups of 
patients based on polymorphisms in these voltage-gated channels. On the other hand, 
the third subgroup may be more related to environmental hazards, epigenetics or 
spontaneous mutations.  
In a later study of the same research group 451, fMRI was used to measure resting-
state functional networks between subgroups. This study found that the three biotypes 
showed dysconnectivity in relevant networks, but with it being more predominant in 
individuals from the biotype one and two. They also observed that those functional 
resting state networks were closely related to cognitive performance, but not as closely 
related to the sensoriomotor reactivity as they had expected. In conclusion, fMRI 
connectivity and electrophysiological variables during auditory task seemed to be 
complementary rather than related.  
Taking this into account, the subgroup of patients carrying the KCNH2 risk allele might 
be consistent with the biotype one or even two in those previous reports. Risk allele 
carriers had abnormal functional connectivity modulation while biotypes one and two 
had impaired electrophysiological response to stimuli and connectivity disruptions. On 
the contrary, the biotype three, with less severe impairments, could be close to our 
subgroup of patients not carrying the risk allele who showed intact SWn modulation. In 
those previous studies, genetic information was not included but it could be speculated 
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that the biotype one and/or two might show abnormalities in neuron ion channels, such 
as those within the KCNH2 gene. It could be possible that reduced functional 
connectivity adjustment during a cognitive task is partially determined by the presence 
of risk polymorphisms in genes involved in neuronal electric signalling transduction and 
excitatory/inhibitory potentials. This support the utility of classifying patients based on 
their genes to study differences in functional connectivity within schizophrenia. 
Finally, regarding the patient subgroup we identified who carry the KCNH2 risk allele, 
it is also important to rule out that their connectivity characteristics were driven by 
clinical confounders.  First, we observed no significant differences in symptomatology 
between risk-allele carriers and non-carriers, with the only mention of a non-significant 
slight tendency towards more negative symptoms with regard to risk allele carriers. Also, 
we did not observe an effect of symptoms on SWn in our previous report 117. However, 
we cannot discard a possible relation between functional connectivity and symptoms, 
as previous articles did observe such association. For example, an altered pattern of 
functional connectivity in schizophrenia patients, measured as fast-frequency band 
imaginary coherence between PFC and occipital areas, was associated with symptoms 
in post-stimulus specific time windows105. Also, CLC and PL, yielding abnormal SW, were 
associated with negative and cognitive symptoms, although in opposite directions, 
negatively in the case of CLC and positively in the case of PL115. Sample size may explain 
the lack of significant association in our studies between symptoms and functional 
connectivity. In addition, we did not observe differences in illness duration and 
treatment between KCNH2 risk polymorphism carriers and non-carriers. Moreover, in 
our previous report, SWn values were not related to months of illness duration or 
antipsychotic doses  117. In agreement with this, a correlation between illness duration 
and treatment was not found with either CLC or PL 126. Thus, global functional 
connectivity may not be affected by dosage of treatment or illness duration and the 
different modulation in risk-allele carriers we found is probably not due to the effect of 
antipsychotics or chronicity.  
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8.3. Limitations of the study 
This thesis has some limitations that should be noted: 
• All patients included were under antipsychotic medication. Therefore, it was not 
possible to completely rule out the effects of treatment on the measured variables. 
Nevertheless, the possible relations between antipsychotic dosages and relevant 
variables were studied using regressions or correlations analyses. Also, in the first 
article, the inclusion of patients with bipolar disorder aimed to discard possible 
treatment effects on neuroanatomical variables, as the majority were also under 
antipsychotic treatment.  
• Cumulative dosages of antipsychotics could not be calculated and therefore it 
was not possible to disentangle the possible effect of long-time treatment over 
connectivity difficult.  
• In the articles included, sample sizes varied from 27 to 121 schizophrenia 
patients and from 27 to 144 healthy controls. Also, in those articles considering 
different study variables, some of the measurements were not available for all 
individuals (i.e. metabolic activity and P300 data in the first study and cognitive data in 
the second and third study).  Larger samples sizes would increase the study power and 
help in identifying connectivity alterations and subgroups of patients. Remarkably, the 
first article, which is the most important in terms of subgroup identification, had the 
largest sample size.  
• The data-driven method selected for subgroup’s identification yielded one 
specific classification result, nevertheless, the result could vary slightly depending on 
the data-driven method. In other words, the classifying result is not fixed and unique 
as it would depend on, first, the variables included and, second, the classifying method 
(i.e. other algorithms or machine learning)   
• Cognition was not included in all the articles of this thesis because it was not 
available (case of the first article), or to avoid blurring the principal aim of the studies 
(the two last articles). However, in those studies, the inclusion of cognition would have 
helped validating the patient subgroups. 
• Diffusion magnetic resonance cannot identify different processes damaging WM 
fibres. Thus, we can not determine whether the decreased fractional anisotropy 
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observed in patients was due to abnormal myelin compaction, demyelination, or 
decreases in the axons/fibres number. Moreover, dMRI cannot properly identify places 
with fibres crossing.  
• Streamlines count variable (included in the third study) was assumed to be a 
measure of the number of fibres although, actually, its exact meaning it is still unknown. 
• Electroencephalogram was recorded using 17 electrodes. Nevertheless, a larger 
number of electrodes may have improved graph-parameters calculations. 
• SW parameters were calculated at five different frequency bands in the NRG1 
study, but in a global frequency band, from 4 to 70 Hz, in the KCNH2 and CACNA study. 
Therefore, the possible effect of the selected genes may have been different depending 
on the frequency band selected. 
• Single candidate gene studies may not be the most effective method of 
disentangling the genetic effects on functional connectivity, as this is probably mediated 
by thousands of possible genetic variants. 
• This thesis did not include longitudinal analyses to observe the changes in 
connectivity and the validity of subgroups over time.
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Chapter 9 
 
 Conclusions  
9.1. Main conclusions of the study 
According to the aims, hypotheses and results, the main conclusions of this thesis are 
the following: 
i. Patients with schizophrenia diagnosis could be classified by using structural data 
obtained from magnetic resonance and a data-driven classification approach. A specific 
subgroup of patients was distinguishable from the rest of patients with schizophrenia, 
patients with bipolar disorder and healthy controls based on markedly higher mean 
cortical curvature.  
ii. The schizophrenia subgroup with higher mean cortical curvature was additionally 
characterised by decreased metabolic rates in thalamus and cingulate, a lack of the 
expected, treatment-related, increased metabolic rates in putamen and no 
improvement of negative symptoms.  
iii. Cortical curvature in the prefrontal cortex could be understood as an indirect 
measure of structural connectivity mainly in short-range connections. Higher values of 
prefrontal cortical curvature were associated with lower fractional anisotropy in 
connections between the prefrontal cortex and both anterior cingulate and superior 
temporal cortices.  
iv. Schizophrenia patients showed, in comparison to healthy controls, altered 
integrity of white matter fibres connecting prefrontal cortex with cingulate, thalamus, 
caudate and hippocampus. Importantly, higher structural impairment between 
prefrontal cortex and cingulus was associated with reduced cognitive performance in 
motor speed and problem solving, and higher structural impairments between 
prefrontal cortex and subcortical regions correlated with higher positive symptoms 
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scores and illness duration. Pharmacological treatment was not associated with 
structural connectivity in any case. 
v. Selected polymorphisms associated with schizophrenia risk and located in genes 
involved in myelinization, synaptic transmission or excitatory/inhibitory balance (NRG1, 
CACNA1C and KCHN2) were associated with differences in the modulatory efficiency of 
global functional connectivity in healthy controls and patients. 
vi. The rs6468119, rs6994992 and rs7005606 polymorphisms in NRG1 gene were 
associated with small-worldness modulation (change of global functional connectivity 
efficiency) in theta, alpha and beta 1 frequency bands in healthy controls. 
vii. The rs3800779 polymorphism located in KCHN2 gene was related to differences 
in the small-worldness modulation in the global frequency band in patients but not in 
healthy control subjects. Importantly, carrying the risk allele (A) distinguished a group 
of patients with abnormal modulation of small-world values during a working memory 
task (P300).  
viii. The rs1006737 polymorphism located in CACNA1C gene was not associated with 
small-worldness either at baseline or its modulation and could not differentiate any 
subgroup of patients.  
ix. Finally, as a general conclusion, data from structural and functional connectivity, 
as well as genetic polymorphisms proved to be useful in exploring the existence of 
specific patient subgroups within schizophrenia with different patterns of brain 
connectivity. 
9.2. Future research lines 
In the near future, we would like to continue the following research lines already 
started during my thesis: 
• To continue exploring the utility of classificatory approaches, both data-driven 
and genetic based. 
• To replicate and validate our result of a subgroup of patients characterised by 
larger curvature by using a completely different and larger sample, as well as by 
employing different data-driven approaches.  
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• To replicate and validate the genetic effect and the utility of genetic-based 
classification using NRG1, KCNH2 and CACNA1C polymorphisms on functional 
connectivity in a different and larger sample.  
• To characterise the identified subgroups in more depth by using other types of 
variables such as social cognition, childhood trauma, markers of inflammation and/or 
epigenetics. 
• To study the possible existence of other subgroups of patients characterized by 
functional connectivity abnormalities by using a data-driven approach similar to that 
applied to the structural connectivity. 
• To include a larger number of polymorphisms related to the risk of mental 
diseases and involved in key processes for brain connectivity such as myelination, 
neurotransmitter signalling, E/I balance, synapsis formation and maintenance as well as 
synaptic pruning.   
• To calculate polygenic risk scores and observe its effect over both structural and 
functional connectivity, and to analyse its power as a potential classificatory tool. 
• To include patients diagnosed with bipolar disorder and/or other psychiatric 
conditions in order to evaluate the existence of biologically valid subgroups of patients 
cross the current diagnostic boundaries. 
• To analyse EEG graph parameters in different frequency bands in order to 
observe the functional connectivity divergences at several ranges of the electrical 
spectrum. 
• To study alternative EEG tasks to measure, for example, resting state activity or 
activity associated with other cognitive processes.  
• To include additional neuroimaging techniques that would help in understanding 
the altered functions in patients; for example, fMRI to assess functional connectivity 
with a better spatial resolution, or transcranial magnetic stimulation in order to 
manipulate inhibitory capacity and observe its effects on connectivity, cognition and 
clinical variables.  
• To discard the effect of treatment including naïve patients and relatives, as well 
as other diagnostic pathologies being treated with antipsychotics. 
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• To perform longitudinal studies to observe the connectivity changes over time 
and the effects of chronicity and treatment cumulative exposure. Also, to assess the 
validity of patient subgroups over time. 
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Student contributions to each publication 
 
Chapter 3: Identification of two clusters within schizophrenia with different 
structural, functional and clinical characteristics 
During the performance of this study, I processed the MRI images, calculated all the 
MRI data: cortical curvature, thickness, area and subcortical volume; and created the 
working database. Moreover, I calculated the sociodemographic statistics and designed 
all the tables in the paper. Finally, I also participated in writing and revising the 
manuscript. 
 
Chapter 4: Biological and cognitive correlates of cortical curvature in schizophrenia 
In this publication, I assisted in the MRI acquisition, processed the MRI data to obtain 
the cortical curvature measures, extracted the appropriate data from the connectivity 
matrices, and created the working database. Furthermore, together with V. Molina and 
R. de Luis, I participated in the statistical analyses, designed the tables and figures in the 
article, and wrote the manuscript. 
 
Chapter 5: Alterations in prefrontal connectivity in schizophrenia assessed using 
diffusion magnetic resonance imaging 
To perform this work, I assisted in the MRI acquisition and data processing, extracted 
the appropriate data from the connectivity matrices previously calculated by R. de Luis, 
and created the database. Similar to previous work, V. Molina, R. de Luis and I undertook 
the statistical analyses, created the tables and figures in the article, and wrote the 
manuscript. 
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Chapter 6: Variation at NRG1 genotype related to modulation of small-world 
properties of the functional cortical network 
In the elaboration of this publication, I helped in the EEG acquisition, created the 
working database and performed the statistical analyses. I configured the tables and 
figures in the article and wrote the manuscript in collaboration with V. Molina and A. 
Palomino.  
 
Chapter 7: Analysis of KCNH2 and CACNA1C schizophrenia risk genes on EEG 
functional network modulation during an auditory odd-ball task 
During this work, I helped in the EEG acquisition and the genotyping procedure. I also 
created the working database. M. Fatjó-Vilas and I undertook the statistical analyses, 
designed the tables and figures in the article and wrote the manuscript under the 
supervision of V. Molina.  
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Spanish summary / Resumen en 
castellano 
 
A.1. Introducción 
La esquizofrenia es una enfermedad neuropsiquiátrica grave, que afecta al 
pensamiento, las emociones y el comportamiento, determinando una gran afectación 
de la calidad de vida del paciente y quienes le rodean y una disminución de la esperanza 
de vida en torno a 20 años. Por otro lado, sus costes económicos son elevadísimos: un 
estudio calculó que los costes directos e indirectos asociados a la enfermedad en España 
en el año 2002, eran alrededor de 1970 millones de euros anuales, siendo los gastos 
directos un 2,7% del presupuesto anual del sistema público de salud.  
La esquizofrenia se caracteriza por la presencia de síntomas positivos, negativos y 
cognitvos. Está presente en todo el mundo con una prevalencia e incidencia muy similar, 
entre el 0,3-0,7% y el 10,2-22,0‰ respectivamente. El inicio de la enfermedad se da 
entre los 20 y 30 años, pudiendo comenzar tras un periodo de sintomatología atenuada 
conocido como pródromo. El pronóstico varía mucho entre los pacientes, pero al menos 
la mitad son pacientes crónicos, algunos con gran incapacidad, que requieren atención 
sanitaria y farmacológica a lo largo de la vida.  
La etiopatogenia de la esquizofrenia es actualmente desconocida, las evidencias 
apuntan a que es la suma de factores genéticos y factores ambientales que conceden 
vulnerabilidad, lo que desencadena la enfermedad. A pesar del gran número de 
investigaciones científicas, el dinero y el esfuerzo invertido en entender las 
enfermedades mentales, hasta la fecha no se ha podido identificar de modo fiable una 
sola anomalía genética, cerebral, biológica o de otro tipo característica de cualquiera de 
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las formas clínicas de la psicosis. Es decir, actualmente no existe ningún fenotipo 
biológico que ayude en el diagnóstico o la predicción de respuesta al tratamiento. 
Los criterios diagnósticos vigentes actualmente llevan a que pacientes con grandes 
diferencias clínicas reciban el mismo diagnóstico y tratamiento o que, por el contrario, 
pacientes con distintos diagnósticos (esquizofrenia, trastorno bipolar, depresión mayor 
con síntomas psicóticos…) compartan síntomas, evolución, respuesta farmacológica o 
perfiles cognitivos. Esto hace que el grupo de pacientes con un mismo diagnóstico sea 
ampliamente heterogéneo. Por lo tanto, tratando a los pacientes con esquizofrenia 
como un grupo homogéneo se impide la identificación de sustratos biológicos que lo 
expliquen y diferencien de otras enfermedades mentales. De hecho, los hallazgos hasta 
la fecha indican que pacientes con diagnósticos distintos comparten tanto variaciones 
genéticas como anomalías cerebrales. Y a su vez, pacientes con el mismo diagnóstico 
pueden tener distinta variaciones genética y alteraciones cerebrales. La búsqueda de 
grupos de pacientes que compartan alteraciones biológicas comunes sin tener el cuenta 
el diagnóstico inicial puede ayudar, por un lado, a entender mejor qué ocurre en el 
cerebro de los pacientes, y ,por otro, a buscar métodos diagnósticos más cercanos a la 
etiopatogenia biológica que ayuden a mejorar los tratamientos y la calidad de vida de 
los pacientes.  
Esta tesis incluye datos procedentes de varias técnicas que estudian los procesos 
biológicos cerebrales, analizando su relación con la esquizofrenia y las posibles 
alteraciones biológicas en este trastorno. En otras palabras, mediante un análisis de las 
alteraciones cerebrales y genéticas en pacientes con esquizofrenia y en comparación 
con la población sana, se planteó definir patrones de alteración de la conectividad 
estructural y funcional independientemente del diagnóstico clínico inicial.. 
Para ello, se partió del estudio anatómico del cerebro utilizando imágenes de 
resonancia magnética (RM) que cuantifican las regiones cerebrales y la integridad de las 
conexiones estructurales. La idea inicial era la identificación  de grupos de pacientes con 
distintas alteraciones, para lo que se estudió la relación entre medidas corticales y de 
conectividad estructural y se analizó esa conectividad estructural en los pacientes. 
Posteriormente, se evaluó la relación entre variantes genéticas relacionadas con un 
aumento del riesgo de la esquizofrenia e implicadas en funciones relevantes con las 
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alteraciones de las conexiones cerebrales funcionales. Y, por último, se estudió la 
capacidad de estas variantes genéticas para identificar subgrupos de pacientes con 
distintas anomalías de la conectividad funcional.  
A.2. Hipótesis y Objetivos 
En base a la literatura actual y teniendo en cuenta la gran heterogeneidad dentro de 
la esquizofrenia, la hipótesis principal de esta tesis es la existencia de distintos 
subgrupos de pacientes con diferentes alteraciones de la conectividad estructural y 
funcional dentro de la esquizofrenia. Estos grupos podrían determinarse con métodos 
estadísticos de agrupamiento  que no tienen en cuenta los diagnósticos o en base a las 
variantes genéticas presentes en cada individuo.  
Partiendo de esta hipótesis, los objetivos de esta tesis doctoral son los que se 
relacionan a continuación:  
• Estudiar la posible existencia de grupos de pacientes dentro de la esquizofrenia, 
en función de datos de anatomía cerebral (volumen, grosor y curvatura cortical y 
volumen subcortical), junto con métodos estadísticos de clasificación. 
• Validar los subgrupos encontrados en función de otros parámetros biológicos. 
• Relacionar las alteraciones anatómicas cerebrales con alteraciones de la 
conectividad estructural basadas en el estudio de la integridad de los tractos de materia 
blanca. 
• Analizar las diferencias de conectividad estructural de regiones prefrontales 
entre pacientes y controles.  
• Evaluar si variantes genéticas relacionadas con un mayor riesgo de la 
esquizofrenia e implicadas en la transmisión sináptica y el balance excitación/inhibición, 
se relacionan con la conectividad funcional en pacientes y en controles sanos.  
• Estudiar la capacidad de esas variantes genéticas para distinguir grupos de 
pacientes con distintas alteraciones de la conectividad funcional.  
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A.3. Materiales y Métodos 
Esta tesis doctoral está formada por cinco artículos científicos, cuatro de ellos ya 
publicados y uno en proceso de revisión. Se han incluido datos de controles sanos, 
pacientes con diagnóstico de esquizofrenia y pacientes con trastorno bipolar. Los sujetos 
fueron seleccionados según criterios específicos de inclusión y exclusión. Los pacientes 
fueron diagnosticados siguiendo los criterios del DSM-IV y V, estaban bajo tratamiento 
y su sintomatología positiva y negativa se cuantificó mediante la escala Positive and 
Negative Syndrome Scale (PANSS). El tamaño muestral varía en función de cada artículo, 
desde 21 hasta 121 pacientes con esquizofrenia, desde 27 hasta 144 controles sanos y 
22 pacientes con trastorno bipolar.  
En el primer trabajo incluido en esta tesis, se analizaron las imágenes de RM (T1) de 
controles sanos y pacientes con esquizofrenia y trastorno bipolar mediante el programa 
FreeSufer. Se obtuvieron datos de volumen, grosor y curvatura cortical y volumen 
subcortical. Además, se incluyeron en los análisis estadísticos, datos 
electroencefalográficos de amplitud y latencia de la onda P300 y datos de consumo de 
glucosa cerebral adquiridos con tomografía de emisión de positrones.  
En el segundo y tercer trabajo, se utilizaron imágemes de resonancias magnéticas 
realizadas en la Unidad de Resonancia Magnética de 3 Teslas de la Universidad de 
Valladolid. Por cada sujeto se adquirieron dos secuencias: una imagen estructural T1 y 
una imagen de tensores de difusión (DTI). Además, en estos trabajos se evaluó la 
capacidad cognitiva y el coeficiente intelectual de los sujetos participantes mediante los 
siguientes test: WAIS-III, BACS y WCST. Las imágenes T1 se procesaron mediante el 
programa FreeSurfer para obtener, por un lado, datos de curvatura cortical y, por otro , 
una matriz de 84 regiones. Por otra parte, la imágenes de tensores de difusión fueron 
procesadas en colaboración con el grupo de Laboratorio de Procesado de Imagen de la 
Universidad de Valladolid, obteniendo junto a las matrices anatómicas, una matriz de 
conexiones entre cada par de regiones cerebrales (en total 84 regiones). 
En el cuarto y quinto trabajo, se obtuvieron muestras sanguíneas de los sujetos, de 
las que se aisló ADN. A partir de este ADN, se genotiparon polimorfismos de nucleótido 
único (variantes alélicas de un solo nucleótido presentes en al menos el 1% de la 
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población) relacionados con un mayor riesgo de esquizofrenia y localizados en genes 
con funciones relevantes para la mielinización, el balance excitatorio e inhibitorio y la 
transmisión sináptica. En concreto, se analizaron tres polimorfismos en el gen de la 
neuregulina 1 (NRG1) , un polimorfismo en el gen de la subunidad alfa 1C del canal de 
calcio dependiente de voltaje (CACNA1C) y otro polimorfismo localizado en un gen de 
una subunidad de un canal de potasio dependiente de voltaje, subfamilia H y miembro 
2 (KCNH2). En el proceso de genotipación se utilizaron sondas TaqManTM y 
discriminación alélica basada en fluorescencia.  
Por otro lado, a los sujetos participantes en ambos estudios se les realizó un registro 
electroencefalográfico durante una tarea auditiva de potenciales evocados (P300). Esta 
tarea consistía en la presentación aleatoria de 3 estímulos sonoros de corta duración y 
distinta probabilidad de presentación. Uno de esos tonos era un estímulo diana, cuando 
sonaba este estímulo los sujetos respondían presionando un botón. Los registros 
electroencefalográficos fueron analizados en colaboración con el grupo de Investigación 
Biomédica de la Universidad de Valladolid. El procesado se realizó siguiendo los 
siguientes pasos: i) filtrado de los registros, ii) eliminación de artefactos oculares (ICA) y 
motores, iii) transformación de la señal a tiempo-frecuencia mediante la transformada 
Wavelet, iv) segmentación de los registros (desde -300 ms hasta 700 ms tras el estímulo 
diana) y división en dos ventanas temporales: ventana pre-estímulo (desde -300 ms 
hasta el inicio del tono diana) y ventana de respuesta (desde los 150 ms hasta los 450 
ms tras el tono diana), v) cálculo de la coherencia de la señal entre cada par de 
electrodos y de las matrices de conectividad entre electrodos, y vi) cálculo de 
parámetros de red en cada ventana temporal. Finalmente, se obtuvo un parámetro de 
eficiencia de la red llamado “Small-world” (SW) que cuantifica la similitud de la red a 
una red ideal eficiente en la transmisión de información. Los valores de SW se restaron 
entre la ventana de respuesta y la de pre-estímulo para obtener el valor de la 
modulación de la red de conexiones ante el estímulo diana.  
Por último, para cada trabajo se realizó un análisis estadístico específico. 
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A.4. Resultados 
En primer lugar, se identificó un subgrupo de pacientes con esquizofrenia 
caracterizado por mayores valores de curvatura cortical respecto al resto de pacientes 
con esquizofrenia, los pacientes con trastorno bipolar y los controles sanos. Este 
subgrupo además presentaba una ligera disminución del grosor cortical, más 
alteraciones del consumo de glucosa cerebral y menor mejoría en los síntomas 
negativos.  
Posteriormente, se encontró que mayores valores de curvatura cortical en regiones 
prefrontales se relacionaban con peor integridad de las conexiones estructurales 
(menos anisotropía fraccional en los correspondientes tractos de materia blanca) entre 
la corteza prefrontal con el cíngulo anterior y la corteza prefrontal con la corteza 
temporal superior. De esta manera, la curvatura cortical prefrontal puede interpretarse 
como una medida indirecta de las conexiones estructurales a corta distancia. Además, 
esta curvatura cortical se relacionaba negativamente con las puntuaciones cognitivas y 
la mejoría clínica.  
En el siguiente trabajo se estudiaron las conexiones estructurales, el número y su 
integridad, entre regiones prefrontales, cíngulo anterior y áreas subcorticales de interés 
en pacientes con esquizofrenia. El resultado indicaba que los pacientes en su conjunto 
tenían peor integridad de muchas de estas conexiones, pero esta peor integridad no 
siempre iba acompañada de una disminución en el numero de fibras. Las conexiones 
prefrontales con el cíngulo anterior se relacionaban positivamente con la cognición, es 
decir, a mayor número de fibras y más integridad, mejor cognición. También se observó 
que el tratamiento no influía en la conectividad estructural, aunque la duración de la 
enfermedad sí parecía tener un efecto negativo, sobre todo en las conexiones 
prefrontales con áreas subcorticales. 
En la segunda parte de la tesis se evaluó la relación de las variaciones genéticas 
relacionadas con el riesgo de esquizofrenia y la capacidad de modular adecuadamente 
las conexiones cerebrales funcionales (medidas con la variable SW) durante una tarea 
cognitiva. Los polimorfismos localizados en el gen de la NRG1 influían en la modulación 
de la red cerebral en sujetos sanos. Además, incluyendo pacientes y controles, se 
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observó que el polimorfismo en el canal de calcio (CACNA1C) no tenía efecto sobre la 
modulación del SW. Sin embargo, existía un efecto significativo del polimorfismo del 
canal de potasio (KCNH2) sobre la modulación del SW. Aquellos pacientes portadores 
del alelo de riesgo para esquizofrena del polimorfismo en KCNH2 tenían una modulación 
del SW contraria al resto de pacientes y los controles. En otras palabras, los pacientes 
portadores del alelo de riesgo disminuían la eficiencia de la red de conexiones al 
responder a la tarea, mientras que los pacientes no portadores y los controles 
aumentaban la eficiencia. 
A.5. Discusión 
Los resultados de los tres primeros artículos apuntan hacia la existencia de un 
subgrupo de pacientes dentro de la esquizofrenia con más curvatura cortical, que parece 
reflejar alteraciones en la integridad de los tractos de materia blanca subyacentes. 
Además, este subgrupo se caracteriza por alteraciones del consumo cerebral de glucosa, 
más síntomas negativos y probablemente peor capacidad cognitiva. Es importante 
destacar que el tratamiento no determina las diferencias observadas en este subgrupo. 
Estos resultados parecen coherentes con los trabajos de otros autores. Así, en pacientes 
de primer episodio sin tratamiento, se observó un grupo con menor integridad de las 
conexiones estructurales y más síntomas negativos. También se ha identificado un 
posible grupo de pacientes caracterizado por más síntomas negativos y menor grosor 
cortical. En la misma línea, se han encontrado grupos de pacientes con peor capacidad 
cognitiva y alteraciones asociadas de la materia blanca.  
En la segunda parte, los resultados demuestran la utilidad de las variantes genéticas 
para identificar subgrupos de pacientes, en esta ocasión con alteraciones de la 
conectividad funcional. El polimorfismo localizado en el gen KCNH2 parece identificar 
dos grupos relacionados con esa conectividad: pacientes con menor capacidad de 
modular adecudamente sus conexiones cerebrales durante una tarea cognitiva y sujetos 
sin esa alteración. El alelo de riesgo en este polimorfismo se ha relacionado con el 
aumento de la expresión de una isoforma de la proteína que se encuentra en mayor 
proporción en el cerebro y que cambia las propiedades bioeléctricas del canal de 
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potasio. Por tanto, el efecto observado en los pacientes portadores del alelo de riesgo 
de KCNH2 podría deberse a los cambios electrofisiológicos en este canal, que afectaría 
a la coordinación de la actividad eléctrica neuronal.  
A.6. Conclusiones 
Teniendo en cuenta los objetivos e hipótesis iniciales y los resultados obtenidos, las 
conclusiones principales de esta tesis doctoral son:  
I. Los pacientes con diagnóstico de esquizofrenia pueden ser clasificados en 
subgrupos en función de sus datos anatómicos y procesos de clasificación que no tienen 
en cuenta los grupos a priori o en función de variantes genéticas.  
II. Se identificó un grupo de pacientes con esquizofrenia caracterizado por mayores 
valores de curvatura cortical, alteraciones del consumo de glucosa cerebral y falta de 
mejoría en síntomas negativos.  
III. La curvatura cortical prefrontal se relaciona con la integridad de las conexiones 
cortico-corticales principalmente de corta distancia.  
IV. Los pacientes con esquizofrenia mostraban peor integridad y cambios en el 
número de conexiones en los tractos de mielina que conectaban la corteza prefrontal 
con el cíngulo anterior, el tálamo, el hipotálamo y el núcleo caudado. La peor 
conectividad prefrontal con el cíngulo anterior, se relacionaba con peor función 
cognitiva.  
V. En sujetos sanos, los polimorfismos rs6468119, rs6994992 y rs7005606 en el gen 
de la NRG1 están asociados con la modulación de las conexiones funcionales cerebrales 
durante la realización de una tarea cognitiva. 
VI. El polimorfismo rs1006737 localizado en el gen CACNA1C, no está asociado con 
la modulación de las conexiones funcionales, ni en pacientes ni en controles. 
VII. El polimorfismo rs3800779 localizado en el gen KCHN2, se relaciona con la 
modulación de las conexiones funcionales en pacientes. En concreto, los pacientes 
portadores del alelo de riesgo disminuyen la eficiencia de sus conexiones cerebrales 
ante un estímulo, mientras que los pacientes no portadores y los controles la aumentan.  
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Estos hallazgos confirman la hipótesis de partida de esta tesis doctoral, que sugería 
que la esquizofrenia no es una enfermedad única, sino un síndrome que engloba 
pacientes con diferentes alteraciones biológicas. Esto respalda la necesidad de cambiar 
la perspectiva de investigación dentro de la salud mental, replanteando la validez de los 
diagnósticos actuales. 
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